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Abstract 
Non-clinical safety assessment is essential during the drug development process in 
the pharmaceutical industry, and involves numerous, detailed in vitro and in vivo 
toxicology tests (general, reproductive and genetic), and safety pharmacology 
studies. The testis is a common organ for adverse drug effects leading to attrition of 
potential compounds. It would, therefore, be useful to detect testicular toxicity as 
early as possible in the drug development process. Histopathology is the standard 
method for assessing testis toxicity, but a biomarker for ‘early warning’ detection of 
testicular toxicity would be far more useful in non-clinical toxicology studies. The 
aim of this thesis was to evaluate the feasibility of this approach.  
 
It is thought that proteins can leak from seminiferous tubules into testicular 
interstitial fluid following testicular damage, due to either loss of integrity of the 
blood-testis barrier (BTB) or germ cell damage. A potential biomarker protein could, 
therefore, leak out of seminiferous tubules into interstitial fluid and then into blood 
following toxicological insult to the testis. A suitable biomarker protein must be 
testis specific, abundant, and not normally be present in blood. It may also need to 
have a low molecular weight. To investigate if proteins do leak out of seminiferous 
tubules following testicular damage, three known testicular toxicants which affect 
different aspects of the testis were used; cadmium chloride causes disruption to the 
blood-testis barrier and spermatogenesis, methoxyacetic acid (MAA) specifically 
causes a loss of pachytene spermatocytes, and 1,3-dinitrobenzene (DNB) causes 
Sertoli cell vacuolation and subsequent germ cell disruption. Adult male Wistar rats 
were treated with various doses of these toxicants to give mild and moderate 
responses. Samples were collected 24 hours later. Testicular damage was 
investigated by immunohistochemistry for well-known germ cell markers (DAZL, 
VASA) and using a general antibody to seminiferous tubule proteins. The integrity of 
the BTB was evaluated using immunofluorescent co-localisation of occludin, ZO-1, 
claudin-11, N-cadherin and β-catenin, and a biotin tracer. Protein leakage was 
investigated using analysis of interstitial fluid samples by 1D gel electrophoresis and 
  ii 
staining with Coomassie-based dye or Western blotting for germ cell proteins and 
with the general antibody to seminiferous tubule proteins.  
 
Protein leakage from seminiferous tubules into interstitial fluid was observed with 
high dose cadmium chloride treatment. This was coincident with a loss of integrity of 
the BTB. No leakage was observed with MAA treatment which caused a specific 
loss of pachytene spermatocytes, or DNB which caused Sertoli cell vacuolation. 
With both treatments the BTB did not appear to be damaged suggesting that protein 
leakage occurs only following loss of integrity of the BTB. This was further 
investigated using treatments reported to specifically disrupt the BTB, namely intra-
testicular administration of glycerol or transforming growth factor-β3, with samples 
collected 48 hours later. The damage caused was very localised, although BTB 
disruption with glycerol treatment caused some protein leakage. The presence of 
germ cell proteins in interstitial fluid samples before and after the development of the 
BTB during normal development was also evaluated, although most proteins of 
interest were not expressed in germ cells of the immature testis before BTB 
formation. 
 
Finally, five potential biomarker candidate proteins (ADAM3, Calpastatin, DAZL, 
FABP9, VASA) were selected and investigated using samples from the testicular 
toxicant studies. Smaller molecular weight proteins were thought to be more likely to 
leak out of seminiferous tubules, however, VASA, a large molecular protein (76kDa) 
was shown to leak into interstitial fluid following high dose cadmium chloride 
treatment. However, FABP9 (low molecular weight) was found to be the most 
promising biomarker for loss of BTB integrity. 
 
The results suggest that a biomarker could only be detected if there is a loss of 
integrity of the BTB and severe disruption of spermatogenesis, thus conferring no 
real advantage over present histopathology-based toxicity evaluations. Therefore, an 
automated immunohistochemistry and image analysis method was investigated as a 
refined method for detection of testicular toxicity at the end of a toxicology study, 
and shown to have promise. 
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1 Introduction 
An essential part of the drug development process in the pharmaceutical industry is 
an assessment of the potential adverse effects of a new drug compound. An 
evaluation of any potential adverse effects of the drug at the pharmacological dose 
must be carried out in relation to the benefits of the drug in order for it to be 
approved for use by the relevant regulatory bodies. The safety of potential drug 
compounds is evaluated in non-clinical and clinical studies. A range of non-clinical 
studies are carried out before first administration to humans in phase I clinical trials. 
Non-clinical assessments continue throughout the development process, with certain 
studies being carried out before administration of the drug to different groups of 
people in clinical trials. For example, potential drugs cannot be tested in clinical 
trials with women of child-bearing age, without a non-clinical evaluation of the 
potential effects of the drug on fertility and fetal development. 
 
Non-clinical safety testing involves in vitro and in vivo toxicology tests (general, 
reproductive and genetic), and safety pharmacology studies. General regulatory 
toxicology studies involve administration of the potential drug compound to a range 
of animal species (usually one rodent (rat) and one non-rodent (dog)), for varying 
lengths of time, and with different doses. The toxicology of the potential drug is 
evaluated during these studies via monitoring of bodyweight and clinical 
observations, and at the end of these studies using histopathological analysis of 
tissue, and clinical chemistry. Any toxicology observed must be evaluated depending 
on the dose level (and how different it is to the pharmacological dose) and the effects 
observed. If the potential drug compound causes adverse effects at a 
pharmacologically relevant dose, depending on the risk:benefit ratio of the potential 
drug, it may not be developed further, 
 
One of the most common target organs leading to cessation of development of a drug 
is the testis (GSK internal report). Early detection of toxicity leading to cessation of 
development is essential for reducing the number of animals used, and the cost of 
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drug development. Biomarkers are becoming increasingly important in bioscience, 
particularly in toxicology, and could have a role in early detection of testicular 
damage, and translation into the clinic for monitoring testicular damage. In 
toxicology studies, as well as early detection, a profile of testicular damage could 
also be obtained throughout the period of the study to provide an idea as to how the 
damage is caused, rather than just looking at the histopathology at one point in time; 
the end of the study.  
 
The objective of this project is to investigate if sensitive biomarkers can be identified 
and measured as a means of providing an ‘early warning’ of testicular damage in 
non-clinical toxicology studies. In order to achieve this, candidate germ cell specific 
proteins will be identified, and the potential for their leakage from seminiferous 
tubules into interstitial fluid (and bloodstream) will be investigated in situations in 
which experimental damage to spermatogenesis has been induced.  
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2 Review of the Literature 
2.1 Introduction 
The objective of this thesis is to investigate the potential for identifying and 
developing biomarkers of testicular toxicity. Before this can be evaluated, knowledge 
of the testis is essential. An understanding of the safety assessment process in the 
pharmaceutical industry and why such biomarkers would be advantageous is also 
important. Both of these subjects are addressed in this chapter, as well as an 
introduction to well-studied testicular toxicants, and current methods of detection and 
previously investigated biomarkers for testicular toxicity. 
 
2.2 Development of the Testis 
In early embryonic development, the gonad is the same for males and females. The 
mesenchyme tissue from the genital ridge forms the basic structure of both male and 
female gonads (Johnson, 2007). Primordial germ cells, the precursor germ cells, 
develop from the coelemic epithelium in the hindgut mesentery (Brennan and Capel, 
2004). They migrate to the genital ridge, guided by chemotactic agents (Johnson, 
2007). Development of the testis is an active process, under the action of the Y-
chromosome derived Sry gene (reviewed in Clarkson and Harley, 2002). Sry 
expression promotes differentiation of cells derived from the coelomic epithelium, 
the precursor Sertoli cells. These cells penetrate the mesenchyme and aggregate 
around the primordial germ cells, forming testis cords (Brennan and Capel, 2004). 
Cells also migrate from the mesenophric primordia into the developing gonad. These 
cells were previously thought to be precursor peritubular myoid cells, however, this 
has recently been shown not to be the case (Cool et al., 2008). Whilst the cords are 
forming, Leydig cells, also derived from the coelomic epithelium, differentiate and 
migrate into the spaces between the seminiferous cords (Sharpe, 2006). Testosterone 
produced by these fetal Leydig cells has a role in differentiation of the Wolffian duct 
into the epididymis, vas deferens and seminal vesicles (Sharpe, 2006). Anti-
müllerian hormone, another important hormone, secreted by the developing Sertoli 
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cells, promotes regression of the Müllerian duct (in females, this would develop into 
the fallopian tubes and uterus) (Behringer et al., 1994). 
 
The testes develop below the kidneys in the embryo. The testes must descend from 
the abdomen, through the inguinal canal into the scrotum as the fetus develops. This 
occurs in response to androgens and insulin-like growth factor 3, produced by the 
fetal Leydig cells (Sharpe, 2006). Testes finally complete descent into the scrotum at 
about postnatal day 20 in the rat (Vitale et al., 1973). 
 
During postnatal and pubertal development, Sertoli cells change in morphology and 
function from the immature proliferative cells to mature non-proliferative cells 
(Sharpe et al., 2003). Differentiation and proliferation of the gonocytes also occurs, 
forming the spermatogonia that will undergo spermatogenesis. Fetal Leydig cells 
mature into adult Leydig cells accompanied by an increase in testosterone 
biosynthetic enzymes and a decrease in testosterone metabolism, resulting in 
production of five times more testosterone (Shan et al., 1996). 
 
In the rat, the onset of spermatogenesis occurs at around postnatal day 8 (Vitale et 
al., 1973). Junction protein complexes form between adjacent Sertoli cells, creating 
the blood-testis barrier, dividing the tubule into two compartments, the basal, and 
adluminal compartments separating the pre- and post-meiotic germ cells. Formation 
of the functional blood-testis barrier occurs around postnatal days 15-19 in the rat 
(Vitale et al., 1973; Russell et al., 1989). This corresponds with the time that the first 
spermatocytes form. 
 
2.3 The Adult Testis and Male Reproductive Tract 
The function of the male reproductive system is to produce and release sperm to 
allow fertilisation of an ovum leading to the production of offspring. The adult male 
reproductive system consists of two testes, each joined to its own epididymis and 
connected to the penis via the vas deferens. Germ cells develop in the testes, and then 
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travel through the epididymis (caput to cauda) where maturation, including gain of 
motility, takes place. The epididymis connects to the vas deferens (Figure 2-1), 
which converges with the seminal vesicles at the site of the ejaculatory ducts. The 
sperm then travel through the urethra, ready for ejaculation. During sexual 
intercourse, the sperm are released, as semen, into the female reproductive tract, 
where the final stages of maturation occur (capacitation). This final stage of 
maturation leaves the sperm ready for fertilisation should an ovum be present. The 
sperm are protected during their journey from the epididymides into the female tract 





Figure 2-1 Structure of the testis, seminiferous tubule and spermatozoon. Spermatogenesis 
takes place in the seminiferous tubules located in the testes. Each end of the tubules drains 
into the Rete testis which connects to the epididymis. Here the spermatids released from the 
seminiferous tubules continue to develop into functionally mature spermatozoa. The cauda 
epididymis leads to the vas deferens. from Krawetz, 2005. 
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The main parts of the male reproductive tract are found outside of the body; with the 
testes and epididymis located in the scrotum. The scrotum functions to regulate the 
temperature of the testes between 2-7oC cooler than the rest of the body, the 
temperature required for spermatogenesis (Setchell, 1970; Waites, 1970). 
 
The focus of this review is testicular toxicity. Before adverse effects on the testis can 
be considered, an understanding of the structure and function of the testis is essential. 
This section of the review will focus on providing the background understanding of 
these areas. 
 
2.3.1 The Testis 
The testis has two functions; a reproductive function, the production of sperm, and an 
endocrine function, the production of testosterone. The testis can be generally split 
into two compartments, each of which focuses on one of these functions. The 
interstitial space contains the Leydig cells, responsible for testosterone production. 
The second compartment is the seminiferous tubules, comprised of lengths of tubules 
consisting of a seminiferous epithelium and lumen. It is here that spermatogenesis 
takes place. The tubules converge at the rete testis, a network of channels, which lies 
towards one pole of the testis in the rat, close to the surface. The efferent ducts 
connect the rete testis to the epididymis. In rats, the efferent ducts are long 
convoluted ducts, and are the primary site for fluid resorption. Both compartments of 
the testis are enclosed in a thick fibrous capsule, the tunica albuginea. The capsule 
has a contractile role to aid sperm transport and a role in maintenance of pressure 
inside the testis (Setchell et al., 1994). 
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Figure 2-2 Diagrammatic representation of cross-section of seminiferous tubule structure 
showing the site of the blood-testis barrier, and the Leydig cells and blood vessels in the 
interstitial space.  
 
2.3.2 Interstitial Space  
The testicular interstitial space is the site of testicular endocrine function. The space 
between the seminiferous tubules, contains loose connective tissue with Leydig cells, 
blood vessels, lymphatics (Fawcett et al., 1973) and leukocytes (Hedger, 1997) 
(Figure 2-2). 
 
2.3.2.1 Leydig Cells 
The Leydig cells make up about 10-60% of the tissue in the interstitial space, 
depending on species (Setchell et al., 1994). Leydig cells are typically irregular in 
shape, and clustered around blood vessels (Clark, 1976). Steroid hormone synthesis 
takes place in the Leydig cells, and the dominant organelle in these cells is smooth 
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endoplasmic reticulum which has a vast surface area with binding sites for  enzymes 
for steriodogenic conversions (de Kretser and Kerr, 1994). The most important 
hormone produced by the Leydig cells is testosterone, although oestrogens, insulin 
like factor 3 (insl3), cytokines and oxytocin are also produced (Sharpe et al., 1990; 
Hall, 1994; Ivell and Bathgate, 2002).  
 
Testosterone has an important role in the testis as it controls spermatogenesis, as well 
as regulating and maintaining masculinisation and development. Testosterone 
production is regulated by the secretion of pulses of LH from the pituitary (Hall, 
1994). LH has both acute and long-term effects on the Leydig cells and testosterone 
production (Zirkin et al., 1997). Long-term effects of LH include the maintenance of 
steroidogenic enzymes, and Leydig cell volume and structure, whereas acute effects 
involve activation of signalling cascades to initiate testosterone production (Zirkin et 
al., 1997).  
 
Testosterone is synthesised from cholesterol, which is either synthesised in the 
endoplasmic reticulum or mobilised from the plasma membrane or lipid droplets 
(Rone et al., 2009). Activation of adenylate cyclase following binding of LH to its 
receptor in the Leydig cell plasma membrane causes an increase in intracellular 
cAMP. This leads to an increase in lipid synthesis, protein synthesis and protein 
phosphorylation, all of which assist with the translocation of cholesterol to the 
mitochondria (Rone et al., 2009). Delivery of cholesterol to the inner mitochondrial 
membrane is the rate-limiting step in steriodogenesis (Crivello and Jefcoate, 1980). 
Therefore regulation of testosterone synthesis must be controlled by factors involved 
in translocation of cholesterol. Cholesterol is thought to be targeted to the 
mitochondria via a combination of cholesterol-binding proteins and 
endosomes/lysomes (Rone et al., 2009). Many proteins have been studied in 
association with cholesterol translocation in steroidogenesis. Rone et al., 2009, 
reviewed current ideas regarding protein-protein interactions in cholesterol 
translocation. A range of proteins have been implicated including START domain 
proteins such as MLN64 and steroidogenic acute regulatory protein (StAR) with 
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roles in targeting cholesterol to the mitochondria, and translocator protein (TSPO) 
(previously referred to as peripheral benzodiazepine receptor (PBR)), with a role in 
importing cholesterol to the inner mitochondrial membrane. The mechanism 
proposed involves the binding of cholesterol to StAR located in the outer 
mitochondrial membrane, which promotes a conformational change in the protein 
and in the outer mitochondrial membrane. This interaction could promote clustering 
of TSPO and its associated proteins (including VDAC, DBI and PAP7), which 
connect the outer and inner mitochondrial membranes allowing transfer of 
cholesterol to the inner membrane (Rone et al., 2009). 
 
At the inner mitochondrial membrane, cholesterol associates with the P450scc (or 
CYP11A1) enzyme, and is converted to pregnenolone via a series of hydroxylation 
reactions (Hall, 1994). Pregnenolone is translocated from the mitochondria to the 
smooth endoplasmic reticulum (SER), where it binds to 3β-hydroxysteroid 
dehydrogenase (3β-HSD) and is converted to progesterone. Progesterone is then 
converted to 17α-hydroxyprogesterone, and then to androstenedione, catalysed by 
17α-hydroylase and C17-20 lyase, respectively. 17β-hydroxysteroid dehydrogenase 
promotes the conversion of androstenedione to testosterone, also in the SER (Hall, 
1994; Zirkin et al., 1997). 
 
Testosterone synthesised in the Leydig cells is secreted and transported in the blood 
and lymph or to the seminiferous tubules via the interstitial fluid. In the seminiferous 
tubules, testosterone can pass freely through the epithelium into the lumen, where it 
binds with androgen binding protein and is carried into the efferent ducts (Johnson, 
2007). Testosterone can also be converted to oestrogen (Hall, 1994). Bergh, 1982, 
suggested that Leydig cells vary in size throughout a Leydig cell cycle, thought to be 
regulated by factors secreted by Sertoli cells in a stage specific manner, however, 
Fouquet, 1987, observed no significant changes in Leydig cell size across the 
spermatogenic cycle but noted an increase in SER volume density at stages VII-VIII 
(compared to stages XI-XII) in adult rats. 
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In humans, two populations of Leydig cells exist, fetal Leydig cells, responsible for 
masculinisation and testicular development during fetal life, and adult Leydig cells, 
which become apparent at puberty. The number of fetal Leydig cells rapidly declines 
after birth, while the adult population expands at puberty (reviewed in Griswold and 
Behringer, 2009). 
 
2.3.2.2 Blood Vessels 
Supply of blood is essential to all organs, to transport oxygen and nutrients to the 
cells, and transport waste products away from the cells. In the testes, a rich 
hexagonal and pentagonal columnar network of capillaries surrounds the 
seminiferous tubules (Murakami et al., 1989). This capillary bed is derived from the 
testicular artery and drains via subalbugineal and intra-albugneal veins into the 
pampiniform plexus and into the testicular vein (Murakami et al., 1989).  
 
Two types of capillaries have been described in the rat testis. Intertubular capillaries 
or ‘Zwickelcappillaren’ are found in the triangular interstitial spaces between three 
adjacent seminiferous tubules (Kormano, 1967). These vessels are encircled by 
(Clark, 1976), and supply (Murakami et al., 1989) the Leydig cells. Larger blood 
vessels, the peritubular capillaries or ‘Quercapillaren’ run parallel along the long 
axes of the seminiferous tubules near the basement membranes, in a rope like 
structure (Kormano, 1967). These peritubular capillaries supply the seminiferous 
tubules (Murakami et al., 1989). Intertubular venules drain both types of capillaries 
(Kormano, 1967). In humans, the structure of the testicular vasculature is less 
organised, with the capillaries forming an irregular plexus around the tubules (Suzuki 
and Nagano, 1986). 
 
2.3.2.3 Lymphatics 
The testicular lymphatic system varies depending on species. Fawcett et al., 1973, 
compared the interstitial space in 14 mammalian species, and found that in rats, there 
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is a relatively small volume of Leydig cells and connective tissue, with extensive 
lymphatic sinusoids with discontinuous endothelial lining. This means that a large 
part of the interstitial cells are directly exposed to the lymph. In contrast, in humans, 
the lymphatic vessels are centrally located in the interstitial spaces with clusters of 
Leydig cells (Fawcett et al., 1973). The three-dimensional organisation of the 
lymphatics in the rat testis was considered by Clark, 1976, who reported that 
endothelial lined lymphatic sinusoids are located between lengths of adjacent 
seminiferous tubules (along the long axes), whereas open sinusoids are found in the 
triangular interstices between three adjacent tubules. A lymphatic space was noted 
around each tubule with free communication via fenestrae to the interstitial fluid 
(Clark, 1976). Clark, 1976, also reported that substances from Leydig cells and blood 
vessels must, therefore, pass through the interstitial fluid into the lymphatic fluid and 
then into the seminiferous tubules. The lymphatic sinusoids drain into lymphatic 
collecting vessels and emerge from the capsule at three points. These three lymphatic 
vessels join to form a single collecting trunk (Perezclavier and Harrison, 1978). 
 
2.3.2.4 Leukocytes 
Testicular leukocytes consist mainly of macrophages, although lymphocytes and 
mast cells are also present (Hedger, 1997). Macrophages make up about 25% of the 
cells in the interstitum in the rat (Niemi et al., 1986). The exact role of macrophages 
and other leukocytes in the testis is yet to be completely understood. Macrophages 
are located in close proximity to Leydig cells, and the complex cytoplasmic 
processes of Leydig cells have been shown to extend to adjacent macrophages 
(Miller et al., 1983; Hutson, 1992). The macrophages are thought to have a role in 
Leydig cell function with a positive effect on steriodogenesis (reviewed in Hedger, 
1997) and a potential role in Leydig cell development (Raburn et al., 1993). A 
second role for the interstitial macrophages is that they have an immunoregulatory 
role involved with maintenance of immune-privilege in the testis (reviewed in 
Hedger, 2002). Finally a third role for resident macrophages in the interstitial space 
is to increase capillary permeability (Setchell et al., 1994). 
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2.3.2.5 Interstitial Fluid 
Testicular interstitial fluid is derived from the blood plasma, and in the rat, is 
continuous with the lymphatic system (Fawcett et al., 1973). The interstitial fluid has 
an important role for transport and communication in the testis, and is similar in 
composition to plasma. The seminiferous tubules are avascular so transport of 
nutrients and hormones from the blood vessels and interstitial cells must take place 
via the interstitial fluid. Formation of interstitial fluid is balanced by removal of the 
fluid to the bloodstream via either resorption into venules or by lymphatic drainage 
(Setchell et al., 1994). Interstitial fluid is also taken up by the Sertoli cells and 
resecreted with a different composition as seminiferous tubule fluid, to transport 
factors from the Sertoli cells to the germ cells (Sharpe et al., 1996). The control of 
interstitial fluid production is, therefore, important. It is thought to be regulated by 
testosterone, as a consequence of its effects on vasomotion and blood flow. It is also 
thought that elongate spermatids may have a role in regulation of testicular fluid 
dynamics, likely to be via their effect on the Sertoli cells (Sharpe et al., 1996). 
 
2.3.3 Seminiferous Tubules 
The seminiferous tubules are the site for the second testicular function; 
spermatogenesis. Seminiferous tubules are long lengths of cylindrical tubules, 
consisting of a seminiferous epithelium made up of somatic Sertoli cells, and 
developing germ cells. A central lumen contains seminiferous tubule fluid. A 
basement membrane and layer of peritubular myoid cells surround and enclose the 
seminiferous epithelium (Figure 2-2). These function as a partial barrier between the 
interstitial space and seminiferous epithelium, and the peritubular myoid cells have 
been shown to have a contractile function, thought to promote movement of the 
seminiferous tubule fluid through the tubules or to have a role in movement and 
release of spermatids from the epithelium (Suvanto and Kormano, 1970). A second, 
and fundamentally more important barrier in the seminiferous epithelium exists 
between adjacent Sertoli cells and is termed the blood-testis barrier (BTB) (Dym and 
Fawcett, 1970).  This splits the seminiferous tubules into two compartments, the 
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basal compartment and the adluminal compartment. The site of the blood-testis 
barrier is shown in Figure 2-2. 
 
In rats, the seminiferous tubules are straight and bundled parallel to each other except 
in turning areas where they bend sharply in hairpins (Clermont and Huckins, 1961; 
Suzuki and Nagano, 1986), whereas in humans, seminiferous tubules are more 
convoluted, although they become straighter towards the collecting ducts, and are 
arranged in lobules (Gier and Marion, 1970). 
 
2.3.4 Spermatogenesis 
Spermatogenesis is the process by which spermatozoa are formed from germ cells. It 
is a complex process involving different stages of differentiation as the cells move 
towards the lumen of the seminiferous tubules for release and collection in the later 
sections of the reproductive tract. Spermatogenesis can be divided into three phases 
(Sharpe, 1994): 
 
• Proliferative Phase – production of a large numbers of cells via a series of 
mitotic divisions 
• Meiotic Phase – generation of haploid cells 
• Spermiogenic Phase – differentiation of haploid cells into the complex and 
compact structure of mature spermatozoa and release from the seminiferous 
epithelium (spermiation) 
 
2.3.4.1 Proliferative Phase 
The proliferative phase (or spermatogonial phase) involves the initial division of 
spermatogonial stem cells (termed A0 in the rat and Ad in humans) into two daughter 
cells, one of which continues the process of spermatogenesis and the other remains 
as a stem cell (Sharpe, 1994).  In rats, A0 spermatogonia undergo a series of 
sequential mitotic divisions producing four generations of A spermatogonia (termed 
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A1-A4), one generation of intermediate type spermatogonia, B spermatogonia, and 
finally, preleptotene primary spermatocytes (Figure 2-3).  
 
The number of mitotic divisions is characteristic for each species. In humans, Ad 
(dark) spermatogonia undergo two mitotic divisions, forming Ap (pale) 
spermatogonia and then type B spermatogonia, before giving rise to primary 
spermatocytes (Clermont, 1972). 
 
The proliferative phase of spermatogenesis takes places in the basal compartment of 
the seminiferous tubules. Primary spermatocytes (preleptotene-leptotene) cross the 
blood-testis barrier, and all meiotic and post meiotic germ cells reside in the 
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Figure 2-3 The Rat Spermatogenic Cycle. The spermatogenic cycle is divided into 14 stages 
in the rat, described by the complement of germ cells associated with the Sertoli cells at 
each stage. Each vertical column represents each different stage and the germ cells present 
in the seminiferous epithelium, with the lumen of the tubule to the top, and the basement 
membrane to the bottom of the diagram. Each stage lasts for a fixed period of time, shown 
underneath each column. Spermatogenesis is divided into three phases; the spermatogonial 
phase (A-spermatogonia (A1-A4), Intermediate spermatogonia (In), B-spermatogonia (B)), 
the meiotic phase (preleptotene (Pl), leptotene (L), zygotene (Z), pachytene (P), diplotene 
(D) primary spermatocytes, and secondary spermatocytes (II)), and the spermiogenic phase 
divided into the acrosomal phase, nuclear condensation/elongation phase, and cytoplasmic 
elimination and release phase (round spermatids (1-7), elongate spermatids (8-19)). from 
Sharpe, 1994 . 
 
2.3.4.2 Meiotic Phase 
Meiosis is the process of cell division by which haploid gametes are formed from 
diploid cells, and is often known as a reduction division. The prophase I phase of 
meiosis is prolonged, and produces a sequence of types of spermatocyte which can 
be identified by the nature of their nuclei. Homologous recombination takes place 
during prophase I, and is an important source of genetic variation. During the 
leptotene stage of prophase I, condensation of chromosomes occurs. Synapsis of 
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homologous chromosomes takes place during the zygotene stage. The pachytene 
stage is the longest stage of prophase; therefore pachytene spermatocytes are present 
in seminiferous tubules at most spermatogenic stages (Figure 2-3, and section 
2.3.4.4). Chromosomal crossover occurs during the pachytene stage. During the 
diplotene stage, degradation of the synaptonemal complex occurs, followed by a 
slight separation and condensation of homologous chromosomes, and some DNA 
transcription (Clermont, 1972). The first meiotic division completes through 
metaphase I (alignment of chromosomes), anaphase I (separation of homologous 
chromosomes), and telophase I (formation of daughter cells) to form two secondary 
spermatocytes. These cells are short-lived and rapidly enter the second meiotic 
division to form haploid round spermatids (Sharpe, 1994). 
 
2.3.4.3 Spermiogenic Phase 
The spermiogenic phase of spermatogenesis involves the differentiation of each 
round spermatid into a spermatozoon and its release from the seminiferous 
epithelium. This process involves remarkable remodelling of the cells.  
 
Spermiogenesis is usually divided up into stages, although the different stages do 
overlap each other (Sharpe, 1994).  Round spermatids must change shape to form 
elongate spermatids. The flagellum elongates forming a tail, which is connected to 
the mid-piece, where the cells’ mitochondria accumulate. As the spermatids 
differentiate, the acrosome develops at the tip of the sperm head (Figure 2-1).  This is 
an important part of the mature spermatozoon, as it contains lysosomal enzymes 
which are released on attachment to an ovum and allow breakdown of the zona 
pellucida to permit fertilisation. 
 
In the spermatid nucleus, condensation of the haploid chromosomes occurs. Histones 
are replaced by transition proteins, which are then replaced by protamines (Wouters-
Tyrou et al., 1998), creating compact chromatin fibres that can be packaged in 
parallel arrays in the spermatid head. Condensation of the chromosomes results in 
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transcriptionally inactive DNA. Therefore mRNA for all the proteins required during 
spermiogenesis and later stages of maturation leading to fertilisation must be 
transcribed before nuclear condensation.  
 
There is a reduction in the amount of cytoplasm in the spermatid, which is removed 
in the form of the residual body. This is later phagocytosed by the Sertoli cells, and 
drawn down through the epithelium to the base of the Sertoli cell where it is 
degraded lysosomally (Sharpe, 1994). Release of excess cytoplasm in the form of the 
residual body, marks the final stage of spermatid differentiation. Spermatids are 
released from the apex of the Sertoli cells into the tubular lumen, in a process known 
as spermiation. The released spermatozoa are washed along the seminiferous tubules 
in fluid secreted by the Sertoli cells (Johnson, 2007). Any spermatids that are not 
released are phagocytosed by the Sertoli cells (Sharpe, 1994). 
 
2.3.4.4 Organisation of Spermatogenesis 
So far, this description of spermatogenesis has not explored one of the most 
important aspects of spermatogenesis; the organisation of the germ cells at the 
different stages of development in the seminiferous epithelium.  
 
The duration of the spermatogenic cycle, or length of time between each wave of 
spermatogenesis, is constant and species specific. In the rat, the spermatogenic cycle 
is 12.5-13.3 days compared to 16 days in man (Sharpe, 1994). This is a much shorter 
time period than the duration of spermatogenesis itself (time for one A0 
spermatogonium to differentiate into a spermatozoon); 51.6-53.2 days in the rat and 
74-76 days in humans (Sharpe, 1994). The length of the spermatogenic cycle is 
clearly shorter than the duration of spermatogenesis, so successive spermatogenic 
processes must be going on at the same time. 
 
Throughout spermatogenesis, cells are progressively displaced, moving towards the 
lumen of the seminiferous tubules, as less advanced cells reach a new stage of 
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development. In a cross section of a seminiferous tubule it is, therefore, possible to 
see several germ cells at different stages of development, layered concentrically 
around the tubule. As both the spermatogenic cycle and duration of spermatogenesis 
are fixed, cells in successive cycles will always develop in parallel (Johnson, 2007). 
The spermatogenic cycle is divided up into stages dependent on the types of germ 
cells present in the seminiferous tubules at each stage. There are 14 stages in the rat, 
and 6 in humans (Figure 2-3). 
 
The second consideration for organisation of spermatogenesis in the seminiferous 
tubules is the arrangement of these spermatogenic stages along the lengths of the 
tubules. Spermatogenesis commences at different times in different areas of the 
tubules, resulting in a continuous release of spermatozoa rather than a coordinated 
release that would be present if all the spermatogonia commenced spermatogenesis at 
the same time. In the rat, the spermatogenic stages are arranged in segments along 
the length of the tubules, with consecutive stages usually adjacent to each other. In 
the human, marmoset, and a few other primates (but not all), seminiferous tubules 
have a very different organisation, with a mixed arrangement of spermatogenic 
stages, where in a cross section of a tubule, ‘wedges’ of different stages can be 
observed (Schulze and Rehder, 1984). 
 
A further consideration in the organisation of spermatogenesis in the seminiferous 
tubules is the duration of each stage. This means that along the length of a 
seminiferous tubule, sections of the tubule at each stage will be proportional to the 
duration of the stage. Therefore, in a testis section, you are more likely to see tubules 
of long duration stages than of short duration stages, because longer portions of 
tubules will be present for the former than the latter. 
 
2.3.4.5 Regulation of Spermatogenesis 
Spermatogenesis is regulated by a combination of endocrine, paracrine and autocrine 
pathways. Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH), and 
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testosterone all have a role in the control of spermatogenesis. The gonadotrophins, 
LH and FSH are secreted by the pituitary in response to hypothalamic 
gonadotrophin-releasing hormone (GnRH) (McLachlan et al., 2002). FSH binds to 
Sertoli cells in a stage-specific manner. It is thought to have effects on the Sertoli cell 
cytoskeleton, which in turn affects the ability of germ cells to bind to the Sertoli cells 
(McLachlan et al., 1995). FSH appears to support germ cell development up to the 
round spermatid stage (McLachlan et al., 1995). FSH also has a role in Sertoli cell 
proliferation during testicular development (Holdcraft and Braun, 2004). FSH 
secretion is regulated by negative feedback via the testicular hormone, inhibin B 
(Hayes et al., 2001b) and via testosterone, following aromatisation to estradiol 
(Hayes et al., 2001a). 
 
LH acts on spermatogenesis by promoting secretion of testosterone from Leydig cells 
(Sharpe, 1994).  Testosterone acts by binding to androgen receptors (ARs), 
promoting nuclear translocation and subsequent transcriptional regulatory affects. 
ARs are expressed in Leydig cells, peritubular myoid cells, and in the Sertoli cells, 
and in the latter this expression is stage-dependent being greatest at stage VII in the 
rat. Recently, the role of AR in the Sertoli cells has been investigated using Sertoli 
cell AR knockout mice. The results showed an essential role for AR-mediated affects 
on Sertoli cells for the progression of spermatocytes through meiosis I, the transition 
of round spermatids to elongate spermatids, and during the terminal stages of 
spermiogenesis (reviewed in Holdcraft and Braun, 2004). A similar approach has 
also been used to elucidate the role of AR in the peritubular myoid cells. Specific 
knockout of AR in peritubular myoid cells in mice resulted in disrupted sperm 
production, with a decrease in all types of germ cells, suggesting that androgen 
action on the peritubular myoid cells is also essential for spermatogenesis (Welsh et 
al., 2009).  
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2.3.5 The Sertoli Cell 
Sertoli cells are large irregular columnar epithelial cells in the seminiferous 
epithelium. The cells are polarised and each extends from the basement membrane to 
the lumen of the seminiferous tubule (Figure 2-1, Figure 2-2). Sertoli cells surround 
the developing germ cells, and interact with the germ cells via a range of junction 
protein complexes (Figure 2-4). Sertoli cells also form junction complexes between 
adjacent cells, forming the blood-testis barrier, which divides the tubules into the 
basal and adluminal compartments (Figure 2-4). The Sertoli cells must undergo 
many changes in conformation as the developing germ cells displace more advanced 
cells at each stage of spermatogenesis. The Sertoli cell cytoskeleton therefore has an 
important function. The cytoskeleton is made up of actin filaments, microtubules and 
intermediate filaments, all of which affect the cell shape, and location of intracellular 
organelles and intercellular junctions. A periodic cyclic reorganisation of the Sertoli 
cell cytoskeleton takes place in association with germ cell maturation (reviewed in 
Boekelheide et al., 1989). The cytoskeletal components form complex, highly 
organised structures to physically support the germ cells, and promote germ cell 
movement (Boekelheide et al., 1989). 
 
Each Sertoli cell can only support a fixed number of germ cells so the number of 
Sertoli cells is directly related to sperm counts (Monsees et al., 2000). About 1:50 
(Sertoli:germ cells) are found in adult male rats (Mruk and Cheng, 2004). Germ cells 
must remain attached to Sertoli cells throughout all stages of spermatogenesis (Mruk 
and Cheng, 2004).  Extensive interactions are present between the Sertoli cells and 
germ cells including adherens junctions, ectoplasmic specialisations, gap junctions 
and desmosome like junctions (Figure 2-4). Coordination of these interactions with 
the Sertoli cell cytoskeleton is essential for movement of germ cells across the 
seminiferous epithelium during spermatogenesis 
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Figure 2-4 Diagrammatic representation of the different stages of germ cells and their 
relative location in the seminiferous tubule, and the junction complexes formed between 
Sertoli-germ cells and Sertoli-Sertoli cells. Reproduced with permission of C.Yan Cheng, 
originally from (Mruk and Cheng, 2004). 
 
The Sertoli cells have an important role in nurturing the developing germ cells. They 
must maintain the spermatogonia, and may have a role in control of spermatogenesis 
and spermiation. They also have a role in phagocytosis of residual bodies. Due to the 
divided nature of the seminiferous tubule (basal and adluminal compartments), with 
the formation of the blood-testis barrier between adjacent cells, the Sertoli cells must 
pass nutrients and oxygen from the interstitial space to the developing germ cells, as 
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well as providing hormonal support for the germ cells. The importance of the blood-
testis barrier will be discussed in more detail in the next section. 
 
Current thinking regarding the relationship between Sertoli cells and germ cells 
suggests that although Sertoli cells are important for germ cell nurture and 
development; this is achieved by providing an appropriate environment in which the 
germ cells can undergo their endogenous programmed development. However, 
paracrine signalling must take place between the germ cells and Sertoli cells to allow 
coordination of changes to the (Sertoli-cell regulated) environment and this is 
thought to be controlled by the germ cells signalling to Sertoli cells to regulate their 
function (Sharpe, 1993). 
 
2.3.6 The Blood-Testis Barrier 
Although a barrier to the penetration of substances entering the seminiferous tubules 
had been identified previously, it was Dym and Fawcett, 1970, who reported the 
location of the barrier to be between adjacent Sertoli cells. It is formed by junctional 
complexes, on the luminal side of the preleptotene spermatocytes (Figure 2-2), 
separating the seminiferous tubule into the basal and adluminal compartments. This 
division in the seminiferous tubule creates a specialised environment for post-meiotic 
development of germ cells, as well as regulating the passage of molecules to and 
from the aduminal compartment (Mruk and Cheng, 2004). The blood-testis barrier 
has a further role in acting as an immunological barrier (Mruk and Cheng, 2004), 
ensuring that the immune system does not recognise and produce antibodies to the 
antigens on the cell surfaces of the haploid germ cells. During testicular 
development, the formation of the BTB is required for lumen formation and onset of 
fluid secretion (Vitale et al., 1973). 
 
The blood-testis barrier is unusual in its composition in comparison to the blood-
brain, blood-retina and blood-epididymal barriers which have tight junctions at the 
apical portion, followed by adherens junctions. The blood-testis barrier consists of 
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co-existing tight junctions, adherens junctions and desmosome like junctions (Yan 
and Cheng, 2005). The blood-testis barrier also has an important role in seasonal 
breeders, with cyclic degeneration and reformation of the barrier following the 




Figure 2-5 Detailed diagram of junction complexes between Sertoli cells and germ cells 
(apical ectoplasmic specialisations (ES)) and adjacent Sertoli cells at the site of the blood-
testis barrier. Reproduced with permission of C.Yan Cheng, originally from Xia et al., 2005. 
 
2.3.6.1 Tight Junctions 
Tight junctions are an example of occluding junctions. In the testis, they are areas of 
close contact between plasma membranes of neighbouring cells, composed of fibrils 
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that encircle the basal domain of each cell. These fibrils represent a row of tightly 
arranged transmembrane proteins that are sensitive to rapid changes in the lipophilic 
nature of the plasma membrane (reviewed in Mruk and Cheng, 2004).  
 
There are three groups of integral membrane proteins making up the testicular tight 
junction; occludin, claudins, and junction adhesion molecules (JAMs) (Figure 2-5). 
A further recently identified tight junction protein is coxsackievirus and adenovirus 
receptor (CAR), although its role in the blood-testis barrier has yet to be elucidated 
(Mruk and Cheng, 2004). These connect to adaptor proteins, such as zonula 
occludens family members, which in turn link to the Sertoli cell cytoskeleton. 
 
2.3.6.1.1 Occludin 
The best-studied tight junction protein is occludin (Mruk and Cheng, 2004). It was 
first described by Furuse et al., 1993. Occludin is a 65kDa transmembrane protein 
with two extracellular loops and one intracellular loop, and four transmembrane 
domains, with both N-terminal and C-terminal ends situated in the Sertoli cell 
cytoplasm (reviewed in Lui et al., 2003).  
 
The first extracellular loop of the protein is involved in cell-cell adhesion, while the 
second loop appears to be required for the formation of the tight junction barrier. 
Chung et al., 2001, showed that a synthetic peptide corresponding to 22 amino acids 
in the second loop administered to adult male rats by intra-testicular injection led to 
reversible infertility due to interference of the peptide with occludin-occludin 
interactions in the blood-testis barrier resulting in failure of the barrier and germ cell 
loss. Deletion of the occludin gene in mice (Saitou et al., 2000) produced histological 
abnormalities in the testes only in aged mice (40 to 60 weeks compared to 6 weeks), 
with seminiferous tubule atrophy and depletion and loss of germ cells observed. 
However, sexual behaviour appeared to be affected with occludin-/- males, with 
apparent normal spermatogenesis, failing to produce litters with wild-type females 
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The claudin proteins have a similar structure to occludin, with a smaller second 
extracellular loop, and smaller cytoplasmic domain. They are also smaller in size 
(20-24kDa). The superfamily of claudins consists of at least 24 members (Mruk and 
Cheng, 2004), expressed in different organs, with different C termini suggesting that 
their organ specificity might be due to their association with different cytoplasmic 
proteins.  
 
Seven of the 24 claudins have been identified in the testis, claudins 1, 3, 4, 5, 7, 8 
and 11 (reviewed in Mruk and Cheng, 2004). However, claudin 11 is the best 
studied. Gow et al., 1999, showed that ablation of claudin-11 in mice produced 
sterile claudin-11 null males with smaller testes than wild-type. Histological analysis 
of the testes showed narrowing of the seminiferous tubules, an absence of 
spermatozoa, and ill-defined lumens filled with aggregates of Sertoli cells. Other 
tight junction proteins (occludin, ZO-1) were shown to be present at the site of the 
blood-testis barrier in claudin-11 null mice suggesting that knockout of claudin-11 
does not affect recruitment of proteins to the BTB, but has an effect on establishment 
of the barrier and therefore on spermatocyte maturation, as well as a role for claudin-
11 in Sertoli cell contact with the basement membrane and long term survival of the 
Sertoli cells (Gow et al., 1999).  Their results suggested that claudin-11 is essential 
for forming the parallel organisation of the tight junction strands in a subset of tight 
junctions found in the testis and in the central-nervous system. This finding 
highlights that there are likely to be specific functions for the different members of 
the claudin family. Mazaud-Guittot et al., 2010, further investigated the testicular 
phenotype in claudin-11-/- mice. Their results showed that the Sertoli cells in claudin-
11 null mice form clusters and detach from the basement membrane. The detached 
Sertoli cells acquire a fibroblastic shape in the lumen of the tubules, which is likely 
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to be due to altered cytoplasmic gene expression. The altered Sertoli cell aggregates 
were shown to be cleared through the seminiferous tubule lumen and detected in the 
epididymis. These results suggest a role for claudin-11 in maintenance of Sertoli cell 
epithelial differentiation (Mazaud-Guittot et al., 2010). 
 
2.3.6.1.3 Junction Adhesion Molecules 
Junction adhesion molecules (JAMs) are a member of the Ig superfamily and are one 
of the most recently described components of tight junctions (Fanning et al., 1999). 
Three JAMs have been identified, JAM-A, B and C (also termed JAM-1, 2, and 3) 
with roles in the testis, and a further two (JAM-4 and JAM-L) with roles in other 
tissues (Mandell and Parkos, 2005). JAM proteins consist of an N-terminal signal 
peptide, an extracellular domain with two Ig like domains, a single membrane 
spanning domain, and a short cytoplasmic tail (Mandell and Parkos, 2005). JAMs 
have been implicated in cell adhesion and cellular polarity, via homophilic and 
heterophilic interactions (with JAM family members or with other adhesion 
molecules) (Mandell and Parkos, 2005).  
 
JAMs are thought to have a role in the regulation of tight junctions. Bazzoni et al., 
2000, showed that JAM associates with the tight junction proteins ZO-1, cingulin, 
and occludin, and may bind and shuttle occludin to the membrane where they can 
interact with junction complexes, or alternatively, may be involved in ZO-1 mediated 
recruitment of occludin to the membrane. Deletion of JAM-A, B, and C genes has 
been investigated in mouse models. As well as a role in the BTB, JAM-A has been 
shown to have a role in sperm tail formation and is essential for normal sperm 
motility (Shao et al., 2008). However, disruption of the JAM-A gene caused no effect 
on testis size, the number of sperm produced or sperm morphology (Shao et al., 
2008). Similarly, deletion of JAM-B (found at the site of the BTB), showed no 
impairment to the function of spermatozoa, with no effects observed on 
spermatogenesis or testis size (Sakaguchi et al., 2006). Gliki et al., 2004, showed that 
JAM-C has a role in Sertoli cell-spermatid interactions and is not present at the BTB. 
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Round spermatids in JAM-C-/- mice failed to polarise, suggesting a role for JAM-C in 
the differentiation of round spermatids into spermatozoa, which was shown to be due 
to its role in recruitment of a cell polarity complex to the spermatids (Gliki et al., 
2004). JAMs are also known to have a direct role in the regulation of immune cell 
transport, by modulating the migration of neutrophils and monocytes in the 
epithelium (Fanning et al., 1999; Lui et al., 2003). The roles of the JAM family 
members appear to be varied, and for some protein members, essential for 
spermatogenesis. 
 
2.3.6.1.4 Adaptor Proteins 
Adaptor proteins interact with the intracellular side of the transmembrane tight 
junction proteins and link them to the Sertoli cell cytoskeleton. Zonula occludens 1 
(ZO-1), ZO-2 and ZO-3 are examples of adaptor proteins. They are members of the 
membrane-associated guanylate kinase (MAGUK) protein family (Lapierre, 2000). 
ZO-1 is thought to have both signalling and scaffolding functions, and to directly 
interact with the C terminus of occludin and actin (Fanning et al., 1998). ZO-1 has 
also been shown to interact with α-catenin, showing a role in adherens junctions as 
well as tight junctions (reviewed in Mruk and Cheng, 2004).  
 
In the testis, ZO-1 has been localised to the site of the blood-testis barrier, and is also 
reported to be located at Sertoli cell ectoplasmic specialisations adjacent to early 
elongating spermatids (Byers et al., 1991). There are two isoforms of ZO-1, ZO-1α- 
and ZO-1α+. They have been shown to associate differently with tight junctions, with 
ZO-1α- expressed in the testis during adulthood (Balda and Anderson, 1993) and 
connecting to F-actin, and ZO-1α+ expressed during puberty, linking to G-actin 
(Pelletier et al., 1997). ZO-1 interacts with a range of proteins, including ZO-2, ZO-3 
(although this has not been identified in the testis so far), transcription factors, gap 
junction proteins, signalling molecules such as Rab, claudins, actin and cingulin, 
another adaptor protein (reviewed in Mruk and Cheng, 2004).  
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Other tight junction associated proteins include cingulin (Citi et al., 1988), which 
links to myosin, symplekin (Keon et al., 1996), and 7H6 (Zhong et al., 1993). 
 
2.3.6.2 Adherens Junctions 
Adherens junctions are a type of anchoring junction (alongside focal adherens, 
desmosomes, and hemidesmososmes). Adherens junctions form bridges between 
adjacent Sertoli cells, and Sertoli-germ cells, by binding the actin cytoskeleton of one 
cell to the other (Figure 2-4, Figure 2-5). They may also have a role in signal 
transduction. Three different types of adherens junctions exist in the testes; cadherin-
catenin complexes, nectin-afdin-ponsin complexes, and integrin-laminin complexes 
(reviewed in Mruk and Cheng, 2004).  
 
The cadherins are the best studied adherens junction proteins. Adhesion is conferred 
by calcium dependent homotypic interactions with cadherins in the adjacent cell 
membrane. Cadherins link indirectly to the actin cytoskeleton via β- or γ-catenin, 
which in turn links to α-catenin. This either connects directly with actin or via further 
proteins such as ZO-1. E-cadherin and N-cadherin, amongst other cadherins, have 
been shown to be present in the testis (Johnson et al., 2000).  
 
Adherens junctions consisting of nectin-afadin-ponsin complexes are calcium 
independent and have been shown to associate with the cadherin-catenin complexes 
(Takai and Nakanishi, 2003).  
 
Ectoplasmic specialisations (ES) are a modified type of adherens junctions found 
only in the testis. They are found between Sertoli cells, and Sertoli-germ cells, and 
have an important role in prevention of the premature release of elongate spermatids 
(reviewed in Mruk and Cheng, 2004). Espin is a component of apical and basal 
ectoplasmic specialisations, connecting to actin. 
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2.3.6.3 Gap Junctions 
Gap junctions are a type of communicating junction. Gap junctions are intracellular 
channels which allow the transport of ions and small molecules (up to 1kDa), such as 
nutrients, second messengers and metabolite precursors, between adjacent cells 
(Pointis and Segretain, 2005). They consist of six integral membrane connexins, 
which make up a connexon. Two connexons (one from each cell) then make up the 
junction complex, with connexons often found clustered together in plaques. 
Connexin proteins have four transmembrane domains with both N- and C- terminals 
in the cytoplasm. Gap junctions are found between Sertoli cells and germ cells and 
adjacent Sertoli cells, and are thought to have a role in coordination of germ cell 
movement (reviewed in Mruk and Cheng, 2004). At least 20 connexin proteins are 
present in mammalian tissues, with connexin 43 the most important gap junction 
protein in the testis. Pelletier, 1995, showed that connexin 43 is present in the blood-
testis barrier in a stage-dependent manner.  The importance of connexin 43 in the 
testis was demonstrated by Brehm et al., 2007. They created a Sertoli cell specific 
connexin 43 knockout mouse, and showed that connexin 43 was required for the 
initiation of spermatogenesis, as well as a role in regulation of Sertoli cell maturation 
and proliferation, and that its role cannot be compensated for by other connexins 
(Brehm et al., 2007). However, Li et al., 2009a, showed that RNAi knockdown of 
connexin 43 in Sertoli cells in vitro did not cause any changes in the integrity of the 
tight junctions, suggesting that connexin 43 alone is not necessary for maintenance of 
BTB integrity. 
 
2.3.6.4 Regulation of the Blood-Testis Barrier 
Developing preleptotene/leptotene spermatocytes must traverse the blood-testis 
barrier at stage VII-IX of spermatogenesis in the rat. This requires disengagement of 
the junction complexes in the BTB; however, the barrier must still remain functional 
during this process so that the microenvironment of the adluminal compartment is 
maintained.   
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Unlike other blood-tissue barriers, tight junctions, adherens junctions and 
desmosome-like junctions coexist at the site of the blood-testis barrier. Yan and 
Cheng, 2005, investigated this unusual distribution of junction proteins and their role 
in regulation of blood-testis barrier dynamics. They proposed that under normal 
physiological conditions the tight junction and adherens junction proteins are 
engaged via interaction with their adaptor proteins (ZO-1, catenins). During 
restructuring of the blood-testis barrier to facilitate germ cell movement, there is a 
disengagement of the adaptor proteins and an increase in the levels of the tight 
junction and adherens junction proteins, suggesting that disengagement of the two 
types of junction proteins allows dissociation of the tight junction proteins at the 
BTB, allowing spermatocytes across the tight junction barrier, while the adherens 
junction proteins are still associated and temporarily supersede the tight junction 
barrier function and maintain the integrity of the BTB (Yan and Cheng, 2005). 
Similarly, a dissociation of adherens junctions to allow transport of the 
spermatocytes is accompanied by a surge in tight junction proteins to reinforce the 
tight junction barrier and maintain BTB integrity (Yan and Cheng, 2005). 
 
Many signalling pathways have been implicated in restructuring of the blood-testis 
barrier. Cytokines, such as TNFα and TGF-β3 are thought to be secreted by primary 
spermatocytes and to have a role in induction of junction restructuring by causing 
accelerated endocytosis of the junction proteins and endosome-mediated 
degeneration leading to a reduction in the number of integral membrane junction 
proteins at the BTB (reviewed in Li et al., 2009b). Testosterone was also shown to 
enhance endocytosis of junction proteins at the BTB, however, it appears to promote 
recycling of the endocytosed proteins back to the cell surface rather than 
degeneration of the proteins, and could promote reassembly of the junctions during 
the restructuring process (Yan et al., 2008). IL-1α has also been shown to have a role 
in blood-testis barrier disruption, by acting on the actin cytoskeleton (reviewed in Li 
et al., 2009b). Gap junctions such as connexin 43 may also have a role in mediating 
BTB restructuring. Li et al., 2009a, suggested that a connexin 43/plakophilin-2 
protein complex has an effect on redistribution of the tight junction proteins in the 
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BTB by affecting the phosphorylation state of the tight junction proteins (a loss of 
phosphorylation is thought to be related to a decline in the protein at the BTB) (Li et 
al., 2009a). Metalloproteases, hemidesmosomes and apical ectoplasmic 
specialisations have also been implicated in the regulation of BTB dynamics 
(reviewed in Li et al., 2009b). Proteases and protease inhibitors, as well as cAMP 
and intracellular phosphoprotein content have also been shown to have a role in 
blood-testis barrier dynamics (Lui et al., 2003). 
 
2.4 The Pharmaceutical Industry 
The pharmaceutical industry is a global business involved in the discovery, 
development, manufacture and marketing of drugs. In the UK, it takes an average of 
10-12 years and £550million to develop a drug and bring it to market (Information 
and Statistics, ABPI website, http://www.abpi.org.uk/statistics/intro.asp accessed 
14th January 2010). This long and expensive process involves many different stages 
and expertise, with essential criteria to meet at each stage to continue development of 
the drug. Drug discovery starts out with a target for a disease, such as a metabolic 
pathway thought to be altered in the disease state, and involves extensive 
investigations until lead drug compounds can be selected. The drug development 
process takes the lead compounds through stages from selection of the most 
promising candidate through clinical trials to launch of the drug. This process 
involves the development of drug formulations, investigations into the therapeutic 
doses, an assessment of drug safety, as well as analysis of drug metabolism. 
Following completion of these long processes, successful drug compounds are filed 
with the relevant agency and launched onto the market.  Post-launch studies are 
carried out to ensure the drug is working as expected and to investigate any further 
manipulations that could be carried out so that the product could be re-launched with 
an alternative mechanism of dosing for example (Figure 2-6).  
 
This project is in collaboration with GlaxoSmithKline (GSK), and therefore, the 
following sections will focus on practices at GSK, although the general pattern will 
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be observed by all pharmaceutical companies. GSK was formed in 2000 through the 
merger of SmithKline Beecham and Glaxo Wellcome, and is one of the leading 
pharmaceutical companies. GSK holds an estimated 7% of the world’s 
pharmaceutical market (GSK literature). Research and Development (R&D) makes 
up a significant part of the company employing over 16,000 people, working at 24 
sites in 7 different countries. GSK R&D has a leading position in genomics/genetics 
and new drug discovery techniques.  
 
2.4.1 Safety Assessment 
Ensuring that potential drug compounds will not cause adverse effects is an essential 
part of the drug development process. All drugs must be approved by the relevant 
agency, such as the US Food and Drugs Administration (FDA), before they can be 
launched commercially.  Assessment of the safety of potential drugs is evaluated 
using non-clinical and clinical studies. Non-clinical safety testing involves in vitro 
and in vivo toxicology tests (general, reproductive and genetic), and safety 
pharmacology studies (detailed in Figure 2-6). Clinical tests involve administration 
of the potential drug compound to various groups of people in Phase I - IV trials 
(Table 2-1).  
 
At GSK, the Safety Assessment division is involved in the non-clinical development 
of drug compounds, supporting the controlled administration to humans in clinical 
trials. UK Safety Assessment is divided into five departments, Pathology, General 
Toxicology, Investigative Preclinical Toxicology (IPT), Safety Pharmacology, and 
Genetic Toxicology. 
Figure 2-6 The drug development process, illustrating the relevant milestones in research and development of a drug. The role of Safety 
Assessment during the development stage is shown in blue, with more specific details of some of the studies required at each stage shown in the 
yellow boxes. FTIH – first time in human, PoC – proof of concept. Adapted from GSK literature.  
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2.4.2 Toxicology Testing 
Non-clinical animal based toxicology studies are important in drug development for 
assessing the possible adverse effects a new potential drug compound may cause, 
prior to controlled administration to humans. Results of such studies can lead to the 
termination of development of a compound due to adverse effects or other 
limitations. Identification of problems as early in the process as possible is, therefore, 
essential.  
 
Table 2-1 Clinical Trials for assessment of safety and efficacy of potential drugs (information 
from ABPI publication – Clinical Trials – Developing New Medicines). 
Phase Character of Trial 
Phase I Administration of drug to a small number of healthy volunteers  
Phase II 
Administration to a small group of patients (100-300)  with the 
condition for which the drug has been developed 
Phase III Administration to a larger group of patients (1000-5000) 
Phase IV Post-licensing monitoring of the drug in the clinic 
 
 
General toxicology studies involve the administration of varying concentrations of 
the compound to different animal models for different time periods. These studies are 
generally designed to directly support clinical trials (detailed in Table 2-1). The 
duration of the toxicology study is usually related to the duration and scale of the 
clinical trial. Generally studies are carried out in two species, one rodent, and one 
non-rodent, using doses of the drug exceeding the therapeutic dose. It is usual to try 
to show a no observed adverse effect level (NOAEL) or dose of compound that does 
not cause any adverse effects. Ideally this should be much higher than the intended 
human therapeutic dose. The number of studies that could be carried out is endless, 
therefore, suggested study guidelines are used to provide data to support clinical 
trials, with a consideration for the 3Rs. 
 
The general drug development process, and suggested toxicology studies are shown 
in Figure 2-6. Usually a short initial study is conducted in a small number of rats, 
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prior to candidate selection, alongside genotoxicology screens and safety 
pharmacology screens. Following candidate selection, repeat dose studies are carried 
out for up to a month, to support first time in human studies (phase I). Longer repeat 
dose studies (3 – 6 months) are carried out to support the longer phase II trials, and 
proof of concept of the drug compound. At this point reproductive toxicology studies 
are also carried out if required (depending on the population group required for 
clinical trials). A female fertility study is carried out in the rat, alongside embryo-
fetal development studies in the rat and rabbit. Investigative toxicology studies are 
also initiated to investigate any specific actions or adverse effects of the drug. 
Following proof of concept of the drug, further repeat dose toxicity studies are 
carried out (6, 9, 12 months in non-rodents). Oncogenicity studies are initiated, and 
male fertility studies and pre/post natal studies are also carried out, to support phase 
III clinical trials.  
 
Species are selected for various reasons, including knowledge of the species, or their 
similarity to a human situation (for example pigs are used for dermal applications, 
and rabbits for embryo-fetal development).  Route of administration is usually the 
intended route of administration in humans. 
 
The exact toxicology studies carried out will depend upon the indication of the drug, 
how much is known about the class of drug, the route of administration, and the 
dose. An assessment of recovery of any adverse effects may be carried out, where 
animals are dosed for a set period of time, and then left for a recovery period before 
being examined for adverse effects. 
 
Data obtained in toxicology studies must be carefully evaluated. The relevance of 
any adverse effects to humans and whether they may outweigh the therapeutic use 
must be carefully considered when interpreting results.  
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2.4.3 Detection of in vivo Toxicological Damage 
Toxicity is assessed during the studies using a range of endpoints, depending on the 
exact aim of the study. Generally, all major organs are examined using 
histopathology, any observed clinical signs are recorded along with body weight 
changes and food consumption, and changes in clinical chemistry are assessed. This 
means that the organs are only examined at one point in time at the end of the study 
and may therefore not indicate if there have been any intermittent changes or whether 
there has been any damage that recovers during the study. 
 
2.4.3.1 Biomarkers in Toxicology 
Due to the increased cost and difficulty of developing drug compounds, it is 
becoming more and more important to be able to detect any potential adverse effects 
of drug compounds as early in the development process as possible. The importance 
of developing biomarkers to aid this is increasing.  
 
Biomarkers are molecular indicators used to determine exposure and response to 
toxic chemicals. Biomarkers may be genes, proteins, small molecules or metabolites 
(Hale et al., 2003) and may be simple or complex, invasive (such as histopathology) 
or non-invasive (such as body weight) (Timbrell, 1998). Biomarkers should also be 
quantitative, sensitive, specific, easily measurable, relate to the biochemical 
mechanism, and work at realistic doses (Timbrell, 1998).   
 
Common examples of biomarkers are the determination of prostate specific antigen 
for the early detection of prostate cancer (Koop, 2005), or the enzymes, aspartate 
transaminase (AST) and alanine transaminase (ALT) for the detection of 
hepatotoxicity (Timbrell, 2000). Proteomics, genomics and metabolomics are all 
being utilised for the discovery of biomarkers for toxicity (Hale et al., 2003; Suter et 
al., 2004; Koop, 2005). Biomarkers, especially genomics derived biomarkers, have 
the potential for detection early in a toxicological response, allowing indication of 
toxicity prior to major impairment. If used in drug toxicology studies, biomarkers 
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could help reduce the number of animals used, as the development of compounds 
could be terminated earlier than would otherwise be the case. This could also lead to 
a reduction in time and money spent on something that is not going to work, 
allowing the focus to change to other potential drug compounds. Biomarkers also 
have the potential to translate from non-clinical animal studies to clinical studies, to 
monitor any possible adverse effects. 
 
2.4.4 The Testis as a Target Organ 
The testes are an important target organ in non-clinical toxicology studies. They are 
the fourth most common target organ leading to attrition of potential drug 
compounds in GSK’s non-clinical toxicology studies. Due to the nature of the drug 
development process, it is necessary to identify toxicity as early as possible in order 
to reduce the number of toxicology studies required before a compound is deemed to 
be unsuccessful. Specific biomarkers for testicular toxicity could improve the 
detection of adverse testicular effects by indicating testicular damage (changes to 
spermatogenesis and germ cell damage/degeneration) in early toxicity studies, 
possibly within hours of first exposure to treatment. Biomarkers could also have a 
role in understanding the onset, progression and recovery of testicular damage in 
non-clinical toxicology studies. 
 
2.5 Testicular Toxicity 
As described above, the testes are an important target for toxicity. The rest of this 
review will focus on an evaluation of well-studied testicular toxicants, which are 
used as compounds in investigations of testicular toxicity, and on current methods for 
the detection of testicular toxicity, with a review of previously investigated 
biomarkers for testicular toxicity, and an introduction to the investigative approach to 
be used in this thesis. 
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2.5.1 Testicular Toxicants 
Well-studied testicular toxicants can be used as tools for investigation of testicular 
toxicity as well as in the elucidation of how different areas of the testis function (for 
example selective depletion of the Leydig cells could be useful in investigating the 
function and effects of the Leydig cells in vivo). Table 2-2 shows a range of cell 
specific toxicants which affect the male reproductive tract. One area of the testis that 
has not been well-characterised using specific testicular toxicants is the peritubular 
myoid cells, and little is known about their response to toxicological insult. A 
selection of well-known testicular toxicants will be discussed in more detail below, 
the Sertoli cell toxicants, dinitrobenzene, hexanedione, phthalate esters and cadmium 
chloride, the germ cell toxicant, methoxyacetic acid, and the Leydig cell toxicant, 
ethane dimethanesulphonate.  
 
Table 2-2 Cell specific toxicants of the male reproductive tract. Adapted from Creasy, 2001 
Target Cell Toxicant Effect 
Ethane 
dimethanesulphonate 
Leydig cell necrosis with secondary germ cell 
death and depletion and atrophy of 
secondary sex organs Leydig Cells 
Lansoprazole 
Inhibition of testosterone synthesis with 
secondary Leydig cell tumour induction 
Phthalate esters,  
2,5-hexanedione,  
1,3-dinitrobenzene 
Sertoli cell vacuoles with secondary germ 
cell death and exfoliation 
Sertoli Cells 
Cadmium chloride 
Disruption to tight junctions in blood-testis 
barrier, with a subsequent increase in fluid 
pressure and tissue ischaemia and necrosis 
Spermatogonia Busulfan, bleomycin 
Spermatogonial cell death with secondary 




Spermatocyte death with secondary 




Spermatid death with secondary depletion of 
postspermatid germ cells 
Elongated spermatids 
Boric acid, dibromoacetic 
acid 
Retention and phagocytosis of step 19 
spermatids, abnormalities in released sperm 
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2.5.1.1 Sertoli Cell Toxicants 
Sertoli cells are an important target for toxicants. Each Sertoli cell can only support a 
fixed number of germ cells so the number of Sertoli cells is directly related to sperm 
production, and due to the function of Sertoli cells, alterations may lead to impaired 
spermatogenesis, germ cell loss and infertility (Monsees et al., 2000). Toxicants can 
act on Sertoli cells in many different ways to induce testicular damage, including 
targeting germ cell-Sertoli cell interactions, disruption of the Sertoli cell 
cytoskeleton, disruption of Sertoli cell-Sertoli cell interactions at the site of the 
blood-testis barrier, alterations to receptors or second messengers, and alterations to 
nutrient supply (reviewed in Monsees et al., 2000). 
 
The Sertoli cell toxicants, dinitrobenzene, hexanedione, phthalate esters and 
cadmium chloride will be discussed here. Each toxicant has a different mechanism of 
action. Further Sertoli cell toxicants include nitrobenzene (NB) (Allenby et al., 
1990), carbendazim (Nakai et al., 1995), and cisplatin (Sawhney et al., 2005). 
 
2.5.1.1.1 Dinitrobenzene 
Dinitrobenzene is an organic aromatic compound, used in dye synthesis, manufacture 
of explosives, pesticides, and in the plastics industry (Reeve and Miller, 2002; 
McEuen et al., 1995). There are three isomers of dinitrobenzene, 1,2 (ortho)-
dinitrobenzene, 1,3 (meta)-dinitrobenzene, and 1,4 (para)-dinitrobenzene. Studies 
reported in Blackburn et al., 1988, showed that 1,2-dintirobenzene had no toxic 
effects on rats, but that 1,3-dinitrobenzene and 1,4-dinitrobenzene both caused 
cyanosis and enlarged spleens. As well as these effects, 1,3-dinitrobenzene (referred 
to as DNB) was also shown to have an effect on the testis, suggesting a different 
mechanism of action for its testicular toxicity versus its effects on cyanosis and 
effects seen on the spleen (Blackburn et al., 1988). These results support previous 
studies reported by Watanabe et al., 1976, which showed that all three dinitrobenzene 
isomers (although 1,2-dintirobenzene to a lesser extent) cause methaemoglobinemia. 
This is the probable cause of the cyanosis reported by Blackburn et al., 1988. DNB 
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has been reported to be toxic to humans, following exposure through skin (Ishihara et 
al., 1976). 
 
Linder et al., 1986, showed that high doses of DNB administered to male rats leads 
to infertility within 10 weeks due to diminished sperm quantity and quality, although 
following a 10 day recovery period, rapid regeneration of spermatogenesis was 
found, with complete recovery after 5 months. Single dose treatment of DNB led to 
degeneration of pachytene spermatocytes and round spermatids at stages VII-XII, 
with recovery of some seminiferous tubules between 16-72 days post-treatment, and 
full recovery 175 days post treatment (Hess et al., 1988). Blackburn et al., 1988, also 
reported damage to spermatocytes and spermatids, but observed this following 
vacuolation and retraction of Sertoli cells at stages VIII-XI following a single dose of 
DNB, suggesting a direct effect on the Sertoli cells. A further study carried out by 
Linder et al., 1988, with a single dose of DNB administered to adult Sprague-Dawley 
rats reported a decrease in testis weight, a decrease in number of testicular sperm 4 
days after treatment and abnormal spermatozoa in the epididymis and a reduced 
number of motile sperm 16 days after treatment, reduced fertility 34 days after 
treatment, but some recovery after 175 days (Linder et al., 1988).  
 
The testicular toxicity of DNB is thought to be due to a metabolite(s) of DNB. 1-
nitroso-3-nitrobenzene (NNB) (or metabolites of this) is thought to be the toxic 
species following a reduction of one aromatic nitro group to form the amine (Cave 
and Foster, 1990). 
 
The depletion of pachytene spermatocytes and round spermatids is thought to be due 
to apoptosis of the cells in a stage specific manner (Strandgaard and Miller, 1998; 
Muguruma et al., 2005). Strandgaard and Miller, 1998, reported that this apoptosis 
could be due to DNB acting on mitochondria in the Sertoli cells or the germ cells. 
This was further defined as an effect on the mitochondrial apoptosis pathway 
involving Bax and Bcl-2 rather than the Fas/Fas ligand pathway (Muguruma et al., 
2005). 
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Reeve and Miller, 2002, reported that DNB acts on seminiferous tubule 
mitochondria, causing its effects by either oxidative stress through redox cycling of 
DNB to its nitroxyl anion radical, or by formation of NNB, as previously described 
above. NNB could bind to aldehyde dehyrogenase in the mitochondria and inhibit the 
reduction of NAD and oxidation of aldehydes (Reeve and Miller, 2002). The 
inhibition of aldehyde dehydrogenase has been shown to cause a reduction in cell 
number in a hepatoblastoma cell line, probably by forming protein adducts (Clemens 
et al., 2002). This suggests that DNB could be causing apoptosis of germ cells via its 
metabolism to NNB, which binds to aldehyde dehydrogenase in the mitochondria 
and leads to stimulation of the Bax/Bcl-2 pathway of apoptosis. DNB has also been 
shown to activate MAPK and JNK pathways (Lee et al., 2009). 
 
2.5.1.1.2 Hexanedione 
n-Hexane is an organic solvent used widely in industry, and is a constituent of 
gasoline (Ikeda and Kasahara, 1986). n-Hexane is metabolised to the γ-diketone, 2,5-
hexanedione (HD) via P450 dependent hydroxylation and oxidation. HD combines 
with primary amines to form 2,5-dimethylpyrroles. 2,5-hexanedione has been shown 
to be toxic to both the nervous system and the testes, although each toxicity is caused 
by a separate mechanism (Boekelheide, 1987).  
 
In the testis, HD exposure causes a reduction in ST fluid formation, followed by 
stage-specific Sertoli cell vacuolation and sloughing and loss of germ cells, leading 
to an altered spermatogenic cycle (Chapin et al., 1983). Boekelheide, 1988, reported 
adverse effects following administration of low dose HD for 2 weeks, with Sertoli 
cell vacuolation observed after 4 weeks and focal germ cell loss at 7 weeks.  The 
mechanism of action of HD has been well-studied (reviewed in Boekelheide et al., 
2003). The tubulin hypothesis was proposed by Boekelheide (Boekelheide, 1987) 
suggesting that HD alters microtubule assembly kinetics, which produces a change in 
the number and length of Sertoli cell microtubules which compromises Sertoli cell 
function, and in turn leads to disruption of germ cell maturation and testicular 
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atrophy. HD was shown to induce altered α-tubulin which fixes the tubulin 
heterodimers that make up microtubules into a pro-assembly conformation (Sioussat 
and Boekelheide, 1989). HD was also shown to have an effect on microtubule 
transport via its cross linking activity, and an altered distribution of microtubule 
associated motor proteins (such as dynein and kinesin) (reviewed in Boekelheide et 
al., 2003). The effect seen on the germ cells following HD treatment is thought to be 
due to the Sertoli cells sending an apoptosis signal to the germ cells they can no 
longer support following microtubule disruption.  
 
Testicular effects of HD have been shown to be irreversible. The reasons for this are 
unknown, as the accumulated pyroles in the testis, and the Sertoli cell microtubule 
alterations do return to normal. Boekelheide, 1988, reported no increase in testis 
weight after a 17 week recovery period (12 cycles of the seminiferous epithelium), 
following low dose exposure for 2 weeks. Partial restoration of germ cell production 
was observed in 2/5 animals, with germ-cell depleted seminiferous tubules devoid of 
differentiating germ cells but containing spermatogonia (Boekelheide, 1987). 
 
2.5.1.1.3 Phthalate Esters 
Esters of phthalic acid are widely used as plasticisers (added to plastics to increase 
their flexibility). Several esters, including di(n-butyl) phthalate (DBP), dipentyl 
phthalate (DPP), di(2-ethylhexyl) phthalate (DEHP) and dihexyl phthalate (DHP) 
have been shown to have effects on male reproduction. In immature rats, this has 
been shown to be a direct effect on Sertoli cells causing Sertoli cell vacuolation and 
sloughing of spermatids and spermatocytes (Gray and Gangolli, 1986). The toxic 
effect of phthalates is due to metabolism or hydrolysis by esterases to phthalate 
monoesters (Li and Heindel, 1998).  
 
Mature animals are less sensitive than immature animals to the adverse effects of 
phthalates, an effect thought to be due to differences in metabolism rather than in the 
Sertoli cells themselves. Species specific effects have also been observed, probably 
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for the same reason. Phthalates may alter energy metabolism by acting on the 
mitochondria (Creasy et al., 1987). The stage specificity of effects seen in adult 
testes also prompted investigation into the effects of phthalates on FSH. Phthalates 
are thought to decrease FSH binding and therefore reduce subsequent cAMP 
accumulation, which could be a further part of the mechanism responsible for their 
testicular toxicity (reviewed in Li and Heindel, 1998). 
 
Over the past 30 years, many different mechanisms have been investigated in relation 
to phthalate induced testicular toxicity. These include compromise of zinc-dependent 
enzymatic activities, changes in hormonal status, altered metabolic function, 
disruption of Sertoli cell-germ cell interactions, and alterations in membrane 
dependent signalling (reviewed in Boekelheide et al., 2000). 
 
Cater et al., 1977, investigated the effect of DBP treatment on zinc metabolism. They 
reported an increase in urinary zinc levels, due to changes in the uptake and turnover 
rate in the testis, probably caused by MBP or a metabolite of DBP acting as a non-
specific chelator of divalent cations, leading to an increase in excretion and adverse 
effects in developing tissues (Cater et al., 1977). Foster et al., 1982, also looked at 
the effect of DBP treatment on zinc in rats. They observed a change in localisation of 
zinc, with a loss from the Golgi apparatus in the spermatids 6 hours after treatment, 
and a decrease in smooth endoplasmic reticulum localisation after 24 hours. They 
also reported a larger number of lipid bodies in the Sertoli and Leydig cells following 
DBP exposure, and Sertoli cell vacuolation (Foster et al., 1982). 
 
2.5.1.1.4 Cadmium Chloride 
Cadmium is a heavy metal, naturally found in trace amounts in water and air, and 
used industrially in a wide range of items such as pigments, alloys, electrical wire, 
plastics, rechargeable batteries, ceramic glazes and semiconductors (reviewed in 
Robards and Worsfold, 1991). Human exposure is from the industrial environment, 
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and via food, air, and water, although acute intoxication is rare (Robards and 
Worsfold, 1991). 
 
Cadmium has been shown to be toxic to a range of organs including the kidney, 
prostate, liver, pancreas, ovary and testis. Cadmium toxicity in the testis was first 
shown by Alsberg and Schwartze, 1919, who observed blue testes following 
cadmium treatment (reviewed in Li and Heindel, 1998). Parizek and Zahor, 1956, 
observed severe damage to all testicular tissue 24-48 hours after administration of 
cadmium chloride to rats, with oedema of the interstitum and capillary stasis 2-4hrs 
after administration, regressive changes in the seminiferous epithelium after 4-6 
hours and extensive haemorrhaging after 8 hours. Cadmium has been shown to cause 
toxic effects to the testes when administered to animals by sc or ip injection, but not 
when administered orally, suggesting that the route of administration is important. 
The effect of cadmium salts on the testis have been described in many species, and 
consist of disruption to the blood-testis barrier, germ cell loss, testicular oedema, 
haemorrhage, necrosis and sterility (reviewed in Siu et al., 2009).  
 
Initial investigations into the mechanism of action of cadmium on the testes 
suggested that it increased vascular permeability. Aoki and Hoffer, 1978, reported 
formation of pores in testicular capillaries and venules leading to endothelial injuries, 
which promote interstitial oedema and haemorrhage, modifications in blood flow, 
and ischaemia.  However, further investigations suggested that cadmium causes a 
loss of integrity of the blood-testis barrier, which leads to an increase in fluid 
pressure and tissue ischaemia and necrosis. Janecki et al., 1992, suggested that the 
tight junctions between Sertoli cells in an in vitro two-compartment culture system 
were disrupted following treatment with cadmium chloride. Hew et al., 1993a, 
showed that there was no apparent effect on the vasculature following a single low 
dose of cadmium chloride to male rats, but a stage specific failure of spermiation was 
observed, suggesting an effect on the Sertoli cells. The group went on to show that a 
single low dose of cadmium chloride resulted in stage-specific disruption of tight 
junction associated microfilament bundles at the basal region of the Sertoli cells, 
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providing further evidence for a direct effect of cadmium on the Sertoli cell tight 
junctions (Hew et al., 1993b). 
 
Siu et al., 2009, reviewed current ideas about the mechanism of action of cadmium 
salts on the testis mediated by signalling pathways. The Cd2+ ion has similarities with 
Ca2+ and Zn2+ ions, and could substitute for them in crucial physiological processes 
resulting in activation or inhibition of signalling pathways (Figure 2-7). Siu et al., 
2009, proposed a three phase system, starting with entry of Cd2+ ions into the Sertoli 
cells (or germ cells) via mechanisms such as diffusion, Ca2+ channels, the Cd2+/Zn2+ 
channel, or Cd transporter ZIP8. Inside the cells, cadmium induces the synthesis and 
release of cytokines such as TGF-β3 which, via interaction with their receptors, 
activates the stress activated p38 MAPK signalling pathway. This pathway can 
disrupt the integral membrane proteins that make up the blood-testis barrier. The p38 
MAPK pathway may also stimulate the production of proteases which leads to 
degradation of the integral membrane proteins (such as occludin, and cadherins) 
either via a direct effect of the proteases or via acceleration of clathrin-mediated 
endocytosis. Disruption of the Sertoli-Sertoli cell and Sertoli-germ cell junctions 
results in germ cell loss. Finally, in the last phase, to limit proteolysis, there is an 
activation of the c-JNK signalling pathway, which stimulates protease inhibitors 
(such as α2-macroglobulin) to initiate recovery of the seminiferous epithelium (Siu et 
al., 2009).  
 
Although the mechanism proposed by Siu et al., 2009, gives an insight into the 
mechanism of cadmium toxicity in the testis, the pathways have not been fully 
elucidated. Investigations using chemicals such as antioxidants (Kara et al., 2007; 
Manna et al., 2008; Acharya et al., 2008; Fouad et al., 2009) and calmodulin 
inhibitors (Martin et al., 2007) to prevent cadmium induced toxicity have suggested a 
role for oxidative stress in causing testicular damage, perhaps due to substitution of 
Ca2+ and Zn2+ ions in physiological processes. Further investigations into these 
effects, and the signalling pathways suggested by Siu et al., 2009, are required to 
unravel the exact mechanism/s involved in cadmium induced testicular damage. 
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Figure 2-7 Proposed mechanism of action of cadmium salts on the testis mediated by 
signalling pathways via a three-phase system. Phase I: Cd ions enter Sertoli cells and/or 
germ cells via different mechanisms (step 1). Once inside the cells, Cd induces synthesis 
and release of cytokines which interact with their receptors and activate the stress activated 
p38 MAPK pathway (step 2) and can selectively disrupt the BTB. The production of 
proteases (possibly mediated by p38 MAPK) is also induced (step 3). Phase II: Disruption of 
the BTB via degradation of integral membrane junction proteins by proteases and/or the 
acceleration of clathrin mediated endocytosis which leads to germ cell loss (step 4). Phase 
III: Activation of the c-JNK signalling pathway stimulates production of protease inhibitors to 
initiate recovery of the seminiferous epithelium (step 5). from Siu et al., 2009. 
 
2.5.1.2 Germ Cell Toxicants 
Compared to the vast number of Sertoli cell toxicants studied, only relatively few 
germ cell specific toxicants have been described. The most commonly used is 
probably methoxyacetic acid which has a direct effect on the pachytene 
spermatocytes and will be discussed below. Further ways of inducing germ cell 
specific damage include x-irradiation (Haines et al., 2002). Mild scrotal heating can 
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also be used as a tool to cause disruption of the germ cells (Chowdhury and 
Steinberger, 1964). 
 
2.5.1.2.1 Methoxyacetic Acid 
Glycol ethers are used in a wide variety of products including inks, dyes, varnishes 
and as anti-icing agents in jet fuels. Ethylene glycol monomethyl ether (EGME) or 2-
methoxyethanol (2-ME) is a commonly used glycol ether that has been shown to 
have toxic effects.  
 
Metabolism of EGME is required for it to exert its toxic effect. EGME undergoes 
oxidative metabolism via alcohol dehydrogenase and aldehyde dehydrogenase to 
methoxyacetic acid (MAA) (Miller et al., 1982; Foster et al., 1984; Moss et al., 
1985). EGME or MAA toxicity affects tissues with rapidly dividing cells and high 
energy metabolism, such as the testis, thymus and fetus. 
 
EGME was shown to cause stage-specific cell death in the testis, affecting early and 
late stage pachytene spermatocytes (Creasy et al., 1985). A decrease in testis weight 
following repeated doses, flaccid consistency of the testes, and degeneration of the 
seminiferous epithelium was reported by Miller et al., 1982. Bartlett et al., 1988, 
showed a loss of pachytene and late zygotene spermatocytes 3 days following 
administration of MAA, at all stages except stage VII, shown by extracellular spaces 
at the site of the spermatocytes or collapsed epithelium, and a reduction in testicular 
weight, following a dose of 650mg/kg. Bartlett et al., 1988, also reported 
perturbation of Sertoli cells following the loss of a germ cell layer. 
 
Moss et al., 1985, and Timbrell, 2000, suggest that the toxicity caused by MAA 
treatment is due to an effect on lactate production. Tirado et al., 2003, reported that 
the abnormal spermatogenesis caused by MAA treatment is due to a direct effect on 
the Sertoli cells (which may be in combination with a direct effect on germ cell 
activity), although they were not able to determine the mechanisms involved. Bagchi 
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and Waxman, 2008, reviewed the mechanisms of MAA induced spermatocyte 
apoptosis in relation to changes in gene expression and signalling pathways. They 
suggested that oxidative stress factors, protein kinases and nuclear receptors are all 
affected by MAA (Bagchi and Waxman, 2008). MAA induced apoptosis correlates 
with an increase in pro-apoptotic factors Bax and Bak compared to the pro-survival 
factor Bcl-W, triggering release of cytochrome C from mitochondria, leading to 
activation of caspases 9 and 3 which then leads to degradation of spermatocyte DNA. 
This process is thought to be induced by a disruption of the reduced:oxidised 
glutathione ratio due to oxidative stress (reviewed in Bagchi and Waxman, 2008) 
(illustrated in Figure 2-8).  Bagchi et al., 2009, investigated the effect of MAA on 
androgen signalling, reporting that MAA potentiates the transcriptional activity of 
androgen receptor, and that it can regulate various intracellular pathways related to 
androgen synthesis. Wade et al., 2008, reported that MAA-induced cell death 
appeared to be associated with hyperacetylation of core histones H3 and H4 in the 
cells, following inhibition of HDAC, and activation of HAT, although the relation of 
this to apoptosis has not been elucidated. More recently, Tonkin et al., 2009, looked 
at the functional classification of gene expression changes following EGME or 2-
ethoxyethanol (2-EE) treatment. They observed changes in the expression of genes 
related to protein kinase activity, the cell cycle, meiosis, protein transport and 
endocytosis. More specifically, increases in the expression of the transcription factor 
Wt1, and the actin binding protein, cortactin were reported (Tonkin et al., 2009). 
Cortactin is normally localised to the ectoplasmic specialisations and is involved in 
regulation of the actin cytoskeleton and endocytosis. Following EGME treatment, 
cortactin was localised to the spermatocytes suggesting a possible link between 
abnormal cortactin regulation and abnormal localisation and regulation of the 
tyrosine kinases that phosphorylate cortactin (Tonkin et al., 2009). 
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Figure 2-8 Schematic for proposed mechanism for MAA-induced apoptosis in 
spermatocytes. EGME is transported into the spermatocyte and oxidised to MAA, promoting 
an increase in protein kinase activation, nuclear receptor trans-activation and oxidative 
stress. Oxidative stress induces a disruption of the reduced:oxidised glutathione ratio, 
causing an increase in the apoptotic factors Bax and Bak, leading to the release of 
cytochrome c from the mitochondria. This activates caspase 9, and caspase 3 leading to 
apoptosis of the spermatocyte. from Bagchi and Waxman, 2008. 
 
2.5.1.3 Leydig Cell Toxicants 
Again, few Leydig cell toxicants have been described. The commonly used Leydig 
cell specific toxicant is ethane dimethylsulphonate. 
 
2.5.1.3.1 Ethane Dimethanesulphonate 
Ethane dimethanesulphonate (EDS) acts specifically on Leydig cells. Molenaar et al., 
1985, showed a decrease in plasma testosterone levels 16 hours after EDS treatment 
of adult rats, with a further decrease between 16-48 hours post-treatment indicating a 
total loss of Leydig cell function. After 72 hours post-treatment, no Leydig cells were 
detected in the testicular interstitum, and effects on spermatogenesis and spermiation 
were observed 1 week after exposure, probably due to testosterone deprivation 
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(Molenaar et al., 1985). Repeat dosing of EDS over 6 weeks led to similar effects as 
the single dose treatment, then restoration to control levels of testosterone, 
suggesting that the effects on Leydig cells were reversible and that the regenerating 
Leydig cells are resistant to the effects of EDS (Morris, 1985). This effect could be 
due to the regenerating cells not being functionally mature so the target for EDS is 
not present (Morris, 1985).  
 
The effects of EDS are both species specific (no effect on mouse Leydig cells) and 
age- specific (immature Leydig cells are not affected). The likely mechanism of EDS 
action is via apoptosis of Leydig cells, which has been shown both in vivo and in 
vitro, and could be due to depletion of glutathione due to EDS binding to glutathione 
(Morris et al., 1997). 
 
2.5.2 Detection of Testicular Toxicity 
Testicular toxicity can be detected by a variety of methods, each differing in their 
ease of use and sensitivity. These detection methods are important for analysis of 
male reproductive function in non-clinical toxicology testing as well as in studies 
investigating the effects of the well-known toxicants or proposed testicular toxicants.  
 
2.5.2.1 Reproductive Organ Weights 
The weights of the reproductive organs, including testes, epididymides, and prostate 
can be easily measured at the end of a toxicology study. Changes in weight following 
administration of a toxicant could indicate an effect on the organ. Morrissey et al., 
1988, found that reproductive organ weights were likely to detect moderate 
reproductive toxicants in small groups of animals. An increase in organ weight 
following treatment would suggest an increase in fluid content in the tissue, whereas 
a decrease in organ weight would suggest decreased spermatogenesis (or decreased 
sperm content in the epididymides) (Creasy, 2003).  However, following severe 
damage to seminiferous tubules, an increase in interstitial fluid volume can occur, 
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which can to some extent counterbalance any decrease in testicular weight following 
germ cell loss (Sharpe, 1988), although such an effect is most likely to be transitory 
and to lead eventually to a reduction in testis weight. A decrease in testis weight is 
still the most straightforward indicator of general testis damage. 
 
2.5.2.2 Fertility 
Assessment of male fertility carried out by administering the potential drug 
compound to the male throughout spermatogenesis and during mating with the 
female, provides an evaluation of effects on male reproductive function. This method 
is not very sensitive for the detection of specific and mild changes to 
spermatogenesis. Endpoints for these studies include: mating ratio, pregnancy ratio, 
pre- and post-implantation loss, litter size, the number of live and dead pups, sex 
ratio and offspring survival. These endpoints are relatively insensitive. For example, 
successful production of healthy offspring could be achieved even though damage to 
spermatogenesis has been caused, due to males releasing many more sperm than is 
required for fertilisation, so even a reduction in sperm production could still result in 
successful fertility (Amann, 1986). Fertility is, however, an important consideration 
in the evaluation of male reproductive toxicity, as it provides an evaluation of many 




Histopathology is the microscopic examination of tissues following their fixation and 
sectioning. It is an invasive technique but provides the chance to locate the exact 
area(s) of damage in a tissue. In the testis, the stages of spermatogenesis can be 
assessed to identify specific treatment effects such as missing germ cell layers or 
types, retained spermatids, multinucleated or apoptotic germ cells, and sloughing of 
germ cells into the lumen (Creasy, 2003). Histopathological examination of the testis 
has been described in the ICH guidelines (Safety Guideline S5(R2)) as the most 
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sensitive method for detection of drug effects on spermatogenesis. The importance of 
histopathology in the detection of testicular toxicity can also be gauged by the 
specific recommendations described by the regulatory authorities (summarised in 
Creasy, 2003) to maximise and improve detection of testicular toxicity.  
Histopathology is, however, time consuming and subjective, and also has the 
potential to miss adverse effects on the testis if only a limited number of tubules are 
evaluated (Suter et al., 1998a). 
 
2.5.2.4 Sperm Analysis 
ICH guidelines suggest that sperm analysis (sperm counts, motility and morphology) 
can be used as an optional way to confirm findings and further characterise effects 
observed with histopathological analysis, but are considered more relevant to fertility 
tests (ICH Safety Guideline S5(R2)). Sperm analysis is a non-invasive method of 
detection of testicular damage in many species, and can be used in both clinical and 
non-clinical studies. Many parameters such as sperm concentration, motility, vitality, 
and morphology, and homogenisation-resistant testicular spermatids and 
spermatozoa from the epididymis can be measured (Piffer et al., 2009). Sperm 
analysis provides a rapid, inexpensive and quantitative method for analysis of 
testicular damage in humans (Wyrobek et al., 1984). There are many variables in the 
analysis of sperm parameters, with different protocols set up in different laboratories. 
Guidelines on standardising the procedures have been discussed (Seed et al., 1996) in 
order to allow comparison of data from different sites. Sperm abnormalities, 
however, are unlikely to provide an early indication of testicular damage. Disruption 
leading to sperm abnormalities will have likely occurred at a much earlier time point 
in the spermatogenic cycle. Sperm analysis also provides no information on the 
genetic integrity of the sperm, an important consideration for reproduction (Rockett 
and Kim, 2005). 
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2.5.2.5 Hormones 
The second function of the testis is the production of hormones and reproduction is 
controlled by the gonadotrophins (LH and FSH). Analysis of plasma hormone levels 
(LH, FSH, testosterone, Insl3 and inhibin B (refer to section 2.5.2.7.2)) could be used 
to evaluate testicular damage in combination with the techniques described above (as 
used in Piffer et al., 2009; Allenby et al., 1991). This method is, however, not 
commonly used in non-clinical toxicology studies, perhaps due to the  invasive 
method of measuring hormone levels with repeated blood sampling required 
(Butterworth et al., 1995), and the inability to detect initial toxicant effects (such as 
those caused by HD treatment on Sertoli cells) (Chapin et al., 1982). 
 
2.5.2.6 Flow Cytometry 
Flow cytometry has been recently investigated as an invasive technique for use in the 
assessment of testicular damage. Suter et al., 1998b, investigated the sensitivity of 
the technique in comparison to histopathology following MAA treatment. Three 
parameter flow cytometry was carried out on enzymatically digested portions of 
testes. Their results suggested that there was no difference in sensitivity of detection 
of testicular damage caused by MAA treatment between flow cytometry and 
histopathology, and that flow cytometry could have advantages in the detection of 
testicular toxicity as it is quick, objective, and easy to carry out and requires only a 
small amount of tissue (Suter et al., 1998b). Oliveira et al., 2006, investigated the 
effect of cadmium chloride treatment on the testis using flow cytometry with fixed 
tissue samples. Significant alterations in the germ cell percentages were noted 
following cadmium chloride exposure (Oliveira et al., 2006). Flow cytometry would, 
however, need to be thoroughly investigated as a technique for detection of toxicity 
before it could be used in regulatory toxicology tests.  
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2.5.2.7 Potential for Biomarkers for Testicular Toxicity 
Current techniques for evaluation of testicular toxicity such as sperm analysis and 
histopathology all have limitations. Biomarkers would be useful for the detection of 
testicular toxicity for early evaluation of male reproductive damage in toxicology 
studies, also for use as a high throughput procedure using a small amount of 
compound in early stages of drug development (discovery phase) (Yamamoto et al., 
2005), and for longitudinal monitoring of testicular damage (Stewart and Turner, 
2005). Successful biomarkers may also have a role in detection of testicular damage 
in clinical trials and in the clinic in general. Good biomarkers should be easily 
measured, and be robust, sensitive, quick and precise (Rockett and Kim, 2005). 
 
At the moment, reliable markers of testicular damage are few and all are invasive, 
requiring blood or tissue samples (Timbrell, 1998). However, the unique nature of 
many of the proteins in the testis (testis specific proteins and testis specific isoforms) 
makes the testis a good source of potential biomarkers. Chemically-induced testicular 
damage can alter levels of proteins, the expression of which is regulated, directly or 
indirectly through the testis (Rockett and Kim, 2005). A small number of proteins 
have been previously investigated as potential biomarkers for testicular toxicity and 
will be discussed below; creatine, inhibin, lactate dehydrogenase-C4, and androgen 
binding protein. Other markers such as transferrin (Ber et al., 1990) and sperm 
surface protein SP22 have been shown to change in concentration in correlation with 
fertility (Rockett and Kim, 2005). 
 
2.5.2.7.1 Creatine 
Creatine is synthesised from arginine and glycine precursors in a two step reaction. 
This process is usually carried out in the liver and pancreas, but also occurs in the 
Sertoli cells (Moore et al., 1998). In the testis, creatine is thought to be further 
processed in the germ cells (Moore et al., 1998).  
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Creatine has been investigated as a non-invasive biomarker for testicular toxicity. 
Gray et al., 1990, showed an increase in levels of creatine in urine 48 hours 
following administration of cadmium chloride to adult male rats, and an increase in 
plasma creatine levels 24 hours following treatment. They also showed that these 
increases were due to the effect of cadmium chloride on the testis, rather than any 
other organ. However, they found that a loss of body weight could be contributing to 
the increased creatine levels rather than, specifically, the testicular damage (Gray et 
al., 1990). Draper and Timbrell, 1998, also observed increases in urinary creatine 
levels following cadmium chloride treatment, even at low doses where no pathology 
was observed. Moore et al., 1992, went on to further investigate the effects of 
specific testicular toxicants on urinary creatine levels. Treatment with MAA to 
disrupt the spermatocytes, and DNB or di-n-pentyl phthalate (DPP) to target the 
Sertoli cells, led to an increase in urinary creatine levels 24 hours after treatment 
(Moore et al., 1992). Treatment to affect the Leydig cells with EDS, however, had no 
effect on urinary creatine levels 24 hours after administration (Moore et al., 1992). 
All the studies described investigated creatine levels following a single dose of 
toxicant. Butterworth et al., 1995, went on to investigate the role for creatine in 
detection of chronic testicular damage by repeated dosing of EGME, and reported 
increased urinary creatine following repeated exposure. 
 
Creatine is found in large amounts in muscle as well as the testis. Draper et al., 1994, 
investigated changes in urinary creatine concentration following administration of a 
specific muscle toxicant (2,3,5,6-tetramethyl p-phenylenediamine) to male rats, and 
noted an increase in urinary creatine following high dose treatment. However, they 
also reported testicular damage at this dose and suggest that this is the cause of the 
increased urinary creatine (Draper et al., 1994). Creatine levels in the urine have also 
been shown to increase following liver and heart damage (Gray et al., 1990). 
Timbrell et al., 1995, investigated using a combination of biomarkers, urinary taurine 
and creatine to enable distinction between increased urinary creatine due to testicular 
damage and liver damage. They proposed that the absence of changes in urinary 
taurine levels, in conjunction with an increase in urinary creatine would indicate 
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testicular damage, but a change in the levels of urinary taurine and an increase in 
urinary creatine would indicate liver damage (Timbrell et al., 1995). 
 
2.5.2.7.2 Inhibin B 
Inhibin B is a dimeric glycoprotein, made up of an α and a βB subunit connected by a 
disulphide bond. The role of inhibin B in the male has recently been reinvestigated 
following the development of a two-site ELISA immunoassay to measure the 
concentrations of biologically active inhibin B, rather than the previously used 
‘Monash assay’ which recognised only the α subunit of inhibin and therefore 
detected free α subunit forms as well as dimeric inhibin B (Anderson and Sharpe, 
2000; Stewart and Turner, 2005). 
 
Inhibin B has a role in regulation of FSH secretion via a negative feedback 
mechanism, with the ability to inhibit FSH but not LH production (Anawalt et al., 
1996; Illingworth et al., 1996). Some investigations also suggest that inhibin is 
produced in the Leydig cells, although this is thought to have little impact on 
circulating concentrations of inhibin B (Anderson et al., 1998; Andersson et al., 
1998). Other studies also suggest that the inhibin B βB subunit could be produced in 
germ cells, although the mechanism for how the two inhibin B subunits would 
dimerise if produced in different cell types has not been proposed (Andersson et al., 
1998). 
 
Systemic concentrations of immunoreactive inhibin, especially inhibin B, have been 
broadly linked to spermatogenic status (reviewed by Stewart and Turner, 2005) as 
well as providing insight into changes in Sertoli cell function (Sharpe et al., 1988). 
Changes in the levels of inhibin B have been measured in a range of studies 
investigating human sperm concentration, and suggest a positive correlation between 
the two parameters, with a decrease in blood inhibin B levels in men with severe 
abnormalities of spermatogenesis (reviewed in Anderson and Sharpe, 2000). It has 
been suggested that this correlation is due to the role for inhibin B in the quantitative 
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feedback of the number of spermatozoa being released from the seminiferous 
epithelium, with phagocytosis of residual bodies by Sertoli cells contributing to 
inhibin B formation. This may also explain the proposed localisation of the βB 
subunit to the germ cells (Anderson and Sharpe, 2000).  
 
However, the sensitivity of changes in inhibin B following less marked effects on 
spermatogenesis is not clear, and does not appear to be as sensitive as histopathology 
(Stewart and Turner, 2005). An international collaborative project was set up to 
further investigate changes in inhibin following administration of different toxicants 
to rats, and the potential for inhibin B as a biomarker for testicular damage (Stewart 
and Turner, 2005), however the results have yet to be published. 
 
2.5.2.7.3 Lactate Dehydrogenase-C4 
Lactate dehydrogenase isozyme C4 (LDH-C4 or LDH-X) is specific to the testis and 
spermatozoa (Blanco and Zinkham, 1963; Zinkham et al., 1964), and is synthesised 
in a stage- and species- specific manner (Lalwani et al., 1996; Burgos et al., 1979). 
LDH-C4 has a role in glycolysis, in the NADH dependent reduction of pyruvate to 
lactate, in anaerobic conditions. Odet et al., 2008, disrupted the Ldhc gene in mice to 
investigate its role in the testis. Their results found Ldhc-/- males to be infertile, 
thought to be due to a progressive reduction in the motility of the spermatozoa, or 
due to defects in capacitation, all likely to be due to compromised ATP production 
due to the disruption to glycolysis (Odet et al., 2008). 
 
Changes in the levels of plasma LDH-C4 have been utilised diagnostically for 
detection of testicular damage (Timbrell, 2000). LDH-C4 has been investigated as a 
marker for post-meiotic germ cell activity, with consistent positive correlations 
between LDH-C4 concentration in seminal plasma and sperm count observed 
(Gerezdeburgos et al., 1979; Orlando et al., 1988). However, some disagreement 
exists in the reported correlation of LDH-C4 levels and sperm motility 
(Gerezdeburgos et al., 1979; Orlando et al., 1988).  LDH-C4 has also been 
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investigated in the development of new contraceptives, with evaluation of potential 
inhibitors of this specific isoform (Wong et al., 1997). Increased LDH-C4 plasma 
levels were observed following treatment with EGME and DNB (Reader et al., 
1991). A slight increase in serum LDH-C4 levels was observed following high dose 
cadmium chloride treatment of rats (Draper and Timbrell, 1998), however the 
increase was not observed with lower doses, even though histopathological damage 
had occurred. This could be due to interference of the cadmium ions in the assay 
used (Draper and Timbrell, 1998). 
 
2.5.2.7.4 Androgen Binding Protein 
Androgen binding protein (ABP) is secreted bi-directionally from Sertoli cells. ABP 
levels in interstitial fluid in rats change during sexual maturation and have been 
shown to be increased in adulthood following treatments causing both stage- and 
germ cell- specific spermatogenic impairment, suggesting that serum and interstitial 
fluid ABP levels could be useful for in vivo monitoring of Sertoli cells (Sharpe and 
Bartlett, 1987). Suter et al., 1998a, reported an increase in testicular ABP levels 
following high dose DNB treatment of rats to induce Sertoli cell damage. Reader et 
al., 1991, also reported increased levels of plasma ABP levels, following germ cell or 
Sertoli cell damage (via treatment with either EGME or DNB). However, they 
suggest that the increased ABP levels may not reflect Sertoli cell damage, but may be 
due to disruption of spermatogenesis secondarily altering ABP secretion (Reader et 
al., 1991). 
 
2.5.2.7.5 New Approach 
A good biomarker should be easily measured, robust, sensitive, quick, and precise 
(Rockett and Kim, 2005). All the previously investigated biomarkers for testicular 
toxicity have limitations and have not been accepted for widespread use in the 
pharmaceutical industry. Therefore a new approach to finding biomarkers for 
testicular damage has been undertaken. 
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Sharpe, 1992, suggested that if you can identify proteins with key roles in 
spermatogenesis that find their way into the bloodstream, you could measure changes 
in their levels which might then give insight into disruption to particular steps in 
spermatogenesis. Following on from this, Turner et al., 1996, showed preliminary 
evidence that disruption of spermatogenesis by heat treatment, increased the number 
and amounts of seminiferous tubule-derived proteins in testicular interstitial fluid, 
and suggested that such proteins therefore have potential to be markers of disruption 
to spermatogenesis. 
 
2.6 Aims of This Thesis 
The main aims of this project were:  
 
1. To investigate whether germ-cell specific proteins leak out of seminiferous 
tubules into interstitial fluid following toxicological insult, and if this 
principle could be applied to toxicants with unknown mechanisms of action. 
 
2. To identify protein biomarkers that have the potential to signal an adverse 
change to spermatogenesis after toxic insult (or damage to the testes). 
 
3. If parts 1 and 2 are successful, to develop a highly sensitive assay for 
detection of low levels of the protein biomarker in peripheral blood. This 
could be achieved using a technique such as fluorescent amplification 
catalysed by T7 polymerase technique (FACTT) (Zhang et al., 2006). 
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3 General Materials and Methods 
3.1 Animal Work 
Male Wistar rats were used for all studies (Harlan UK). Animals were maintained in 
our own animal facility, according to UK Home Office guidelines. Animals were 
housed in cages with a total of 6 adults/cage in a controlled environment. The rats 
had access ad libitum to water and a soy-free breeding diet (SDS, Dundee, UK). 
Where possible, young adult rats aged around 70-75 days, weighing approximately 
300g, were used. 
 
The 3Rs (reduction, refinement, and replacement of the use of animals in research) 
were considered when planning animal studies. The number of animals used was 
restricted to the smallest number possible to obtain reliable and accurate results. 
 
3.2 Necropsy 
Animals were killed according to UK Home Office guidelines using a rising 
concentration of carbon dioxide, followed by breaking of the neck. The bodyweights 
of the animals were recorded at necropsy. 
 
3.3 Treatments 
3.3.1 Cadmium chloride 
Cadmium chloride (Sigma-Aldrich, Dorset, UK) was made up in 0.9% saline, at the 
required dose. The following doses were investigated; control (0mg/kg), 0.2, 1, 1.75, 
and 3 mg/kg. These doses were selected to show a dose response effect based on 
published literature (Hew et al., 1993b; Wong et al., 2004) and preliminary 
investigations (Section 5.2.1). Treatments were administered to adult male Wistar 
rats by i.p. injection at a concentration of 1mL/kg bodyweight. Tissue samples were 
collected approximately 24 hours after administration.  
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3.3.2 Methoxyacetic Acid 
Methoxyacetic acid (MAA) (Fluka, Sigma-Aldrich, Dorset, UK) solutions were first 
adjusted for pH with concentrated sodium hydroxide to obtain a pH between the 
range pH 7.0-7.4, which is acceptable for dosing by oral gavage. Solutions were 
made up to the required volume with 0.9% saline. The following doses were 
investigated; control (0mg/kg), 200mg/kg, and 650mg/kg. These doses were selected 
based on a moderate effect previously seen at histopathological examination of the 
seminiferous epithelium with 650mg/kg MAA (Bartlett et al., 1988) and a mild effect 
previously observed with 200mg/kg MAA (Tirado et al., 2003; Wade et al., 2008). 
Treatments were administered to adult male rats by oral gavage at a concentration of 
2mL/kg. Tissue samples were collected approximately 24 hours after administration. 
 
3.3.3 1,3-dinitrobenzene 
1,3-dinitrobenzene (DNB) (Sigma-Aldrich) solutions were prepared for dosing by 
oral gavage. In order to dissolve the solid, a small amount of DMSO (1.5%) (Sigma-
Aldrich) was heated in a water bath, to aid dissolution. Solutions were made up to the 
required volume with corn oil. Solutions were vortexed to ensure complete mixing. 
The following doses were investigated; control (0mg/kg), 25mg/kg, and 50mg/kg. 
Doses were selected based on results published by Blackburn et al., 1988, where 
50mg/kg DNB caused widespread damage to the seminiferous epithelium 24 hours 
after administration and 25mg/kg DNB caused mild damage. Treatments were 
administered to adult male rats by oral gavage at a concentration of 5mL/kg. Tissue 
samples were collected approximately 24 hours after administration. 
 
3.3.4 Glycerol 
A 15% glycerol solution was prepared by diluting glycerol (Fisher Scientific, 
Leicestershire, UK) with 0.9% saline. Glycerol treatments were administered by 
intra-testicular injection.  
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Rats were anaesthetised with isoflurane (in combination with air) in an anaesthesia 
box.  Once under anaesthesia, rats were transferred to a mask for continued exposure 
to isoflurane during administration of the treatment. The inner (non-hairy) side of the 
scrotum was exposed by gently pushing the testes down tight into the bottom of the 
scrotum. 350µL 15% glycerol was slowly injected into the centre of the right testis 
using a 25G needle (based on methods investigated by Igdoura and Wiebe, 1994). 
350µL 0.9% saline was slowly injected into the centre of the left testis using a 25G 
needle to act as a concurrent control. Animals were kept under observation while 
recovering from anaesthesia, and tissue samples were collected approximately 48 
hours after administration. 
 
3.3.5 Transforming Growth Factor-β3 
Transforming growth factor-β3 (TGF-β3) (Calbiochem, Merck, Nottingham, UK) 
was reconstituted in 4mM HCl with 0.1% BSA (Sigma-Aldrich) according to the 
manufacturer’s instructions.  Reconstituted TGF-β3 was diluted to 1ng/µL in PBS. A 
control solution of 4mM HCl with 0.1% BSA diluted 1:10 in PBS was also prepared. 
TGF-β3 treatments were administered by intra-testicular injection, as in section 
3.3.4, except that 200µL 1ng/µL TGF-β3 was injected at two sites in the right testis, 
100µL/site. 200µL vehicle control solution was injected into two sites of the left 
testis (100µL/site). Administration of TGF-β3 treatment was based on the method 
published by Xia et al., 2006. 
 
3.3.6 Biotin Tracer 
EZ-link sulfo-NHS-LC-biotin (Pierce Bioscience, IL, USA) is a biotin conjugate. It 
can be used as a tracer to show whether the BTB is functioning, due to its’ unique 
water soluble and membrane impermeable properties (manufacturers’ literature, 
Tarulli et al., 2008). A 10mg/mL solution of the biotin tracer was prepared in 0.01M 
CaCl2 in PBS. The solution was vortexed thoroughly to ensure the tracer was fully 
suspended. With adult rats, about 200μL of biotin tracer was injected by intra-
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testicular injection into exposed testes of freshly-killed animals. Testes were then 
dissected out and left at room temperature for 30 minutes. With smaller testes from 
younger animals (day 10, 15, 18, 25), the testes were dissected out of the animals, 
and placed in a small volume of tracer solution for 30 minutes. Following incubation, 
testes were placed in Bouins fixative for the appropriate time (section 3.4.2.1). 
 
3.4 Sample Collection 
3.4.1 Peripheral Vein Blood 
Immediately following necropsy, peripheral blood was collected by opening the 
chest cavity, and collecting blood from the heart using a syringe and a heparinised 
needle. Blood samples were kept on ice, and then centrifuged at 8000rpm for 15 
minutes at 4oC to separate cells from plasma. The plasma supernatant was pipetted 
into a clean tube and stored at -20oC. 
 
3.4.2 Preparation of Whole Testis Samples 
3.4.2.1 Fixed Tissue 
Testes were dissected out of freshly killed adult rats. All fat and connective tissue 
was removed from the outside of the testis. The testes were placed in Bouin’s 
fixative (Triangle Biomedical Sciences, Lancashire, UK) for 3 hours. After this time, 
the testes were cut into 4 sections, and left to fix for a further 3 hours. After a total of 
6 hours fixation, testes were placed in 70% ethanol (Fisher Scientific, Leicestershire, 
UK). Fixed testes were passed to the Histology support service for embedding in 
paraffin wax, using an automated Leica TP1050 processor (Leica Microsystems, 
Buckinghamshire, UK) and standard techniques. Testes collected from younger 
animals (day 10, 15, and 18) were fixed for a total of 4 hours, and left whole. For day 
25 animals, testes were fixed for 6 hours and cut in half after 3 hours of fixation. 
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3.4.2.1.1 Sectioning of Fixed Tissue 
Paraffin wax blocks embedded with fixed tissue were cooled on ice for at least 15 
minutes. 5µm tissue sections were cut from the paraffin wax blocks using a manual 
rotary microtome (Leica RM2135). Sections were floated onto a water bath (45oC) 
and mounted onto SuperFrost® glass slides (Menzel-Gläser, part of Thermo-
Scientific, MA. USA).  Slides were incubated at 50oC overnight to complete the 
mounting process.  
 
3.4.2.2 Snap-Frozen Tissue 
Testes were dissected out of freshly killed rats. The capsule was removed from the 
testis, and remaining tissue squashed on aluminium foil and frozen in dry ice. 
Samples were stored at -80oC. 
 
3.4.3 Collection of Interstitial Fluid 
Interstitial fluid was collected based on the method validated by Sharpe and Cooper, 
1983. Testes were dissected out of freshly killed rats. Any remaining fat or 
connective tissue was trimmed, and the capsule carefully cut at the opposite end to 
the Rete testis, ensuring that no damage occurred to the underlying tubules. Testes 
were placed on ice, in pre-weighed 25mL Falcon tubes (1.5mL eppendorf tubes were 
used for smaller testes) containing 5μL protease inhibitor (Complete protease 
inhibitor, Roche, West Sussex, UK) at the bottom, with the cut end of the capsule 
facing downwards (Figure 3-1). Testes and tubes were weighed. Samples were left in 
the fridge (4oC) overnight to allow interstitial fluid to drip out of the testes. Testes 
were then removed from the tubes, leaving as much fluid as possible in the tube. 
Interstitial fluid (IF) weights were taken. IF was removed to a 1.5mL eppendorf tube 
where appropriate, and centrifuged at 8,000rpm at 4oC for 15 minutes. The 
supernatant was removed to a clean tube, and stored at -20oC. 
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Figure 3-1 Collection of Interstitial Fluid. Each testis was placed in a tube with the capsule 
cut at the end opposite to the Rete testis and left overnight for the interstitial fluid to collect in 
the bottom of the tube. 
 
3.4.4 Isolation of Seminiferous Tubules 
Seminiferous tubules (STs) were isolated from freshly dissected testes. The capsule 
was removed from the testis. A few drops of PBS were added to aid dissection. 
Using a dissecting microscope, where necessary, each end of the testis was carefully 
pulled in opposite directions, exposing lengths of STs. The tubules were isolated, by 
securing each end of the section of tubule with forceps, and gently but firmly pulling 
upwards. Isolated tubules were collected, homogenised with RIPA buffer (section 
3.12.7) containing protease inhibitor, and left to stand on ice.  Then, the 
homogenised tubules were centrifuged at 13,200rpm at 4oC for 10 minutes to remove 
any debris. The supernatant was removed to a clean tube and stored at -20oC. 
 
3.4.4.1 Isolation of Staged Seminiferous Tubules 
Seminiferous tubules isolated as described above (section 3.4.4) were staged into 3 
groups – I-V, VI-VIII, IX-XIV, under the dissecting microscope according to the 
pattern seen in the tubules (Figure 3-2), based on the method described by Parvinen 
and Vanhaper, 1972. Lengths of the same stage group were cut and pooled before 
homogenisation in RIPA buffer (as section 3.4.4). 
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Figure 3-2 Staging Seminiferous Tubules. Tubules were dissected into three stage groups 




Immunohistochemistry was carried out on fixed tissue with a range of different 
antibodies (Table 3-1). The labelled streptavidin-biotin (LSAB) method was used. 
This is an indirect method of immunohistochemistry which amplifies the signal by 
using an unlabelled primary antibody, followed by a biotinylated secondary antibody 
and then a streptavidin-peroxidase conjugate (Figure 3-3).  
 
Negative method control slides were used for each immunohistochemistry run, and 
incubated with normal serum instead of primary antibody. Positive control tissue 
(known to stain well for the selected antibody) was used when available to show 
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Figure 3-3 Schematic Diagram of LSAB immunohistochemistry. The primary antibody 
binds to the antigen on the tissue surface. A biotinylated secondary antibody raised to the 
species of the primary antibody binds to the complex. A streptavidin-HRP conjugate binds to 
the biotin on the secondary antibody. The HRP can then be detected using the chromagen 
DAB. Adapted from Dako Handbook for Immunochemical Staining. 
 
3.5.1 Dewaxing and Rehydration of Tissue Sections 
The first step in an immunohistochemistry run involves removal of wax from the 
fixed tissue sections. Slides were immersed in xylene for 4 minutes, and then placed 
in a fresh xylene bath for a further 4 minutes. This was followed by rehydration of 
the tissue by placing slides in 2 baths of absolute ethanol for 20 seconds in each, then 
95% and 70% ethanol baths for 20 seconds each. Slides were finally placed in water.  
 
3.5.2 Antigen Retrieval  
Antigen retrieval or heat-induced epitope retrieval (HIER) was used for 
immunohistochemistry runs with certain antibodies (Table 3-1).  This process is used 
to improve the immunoreactivity of antigens by breaking protein cross-links formed 
during the fixation process.  
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Buffer (either 0.01M citrate pH 6.0 buffer or 0.05M glycine pH 3.5 buffer) was 
heated to boiling in a pressure cooker. Slides in racks were then immersed in the 
buffer and the pressure cooker set to the highest pressure setting. Slides were heated 
for 5 minutes, then left to cool in the buffer for 20 minutes. 
 
3.5.3 Wash Buffer 
Tris buffered saline (TBS) was used to wash slides between each step. Typically 
slides were immersed in TBS twice, each for 5 minutes. 
 
3.5.4 Blocking Steps 
Two main blocking steps were carried out on all immunohistochemistry runs; a 
methanol/peroxide block, and a normal serum block. A streptavidin/biotin blocking 
step was included to reduce background staining for some antibody protocols. 
Blocking steps were carried out in a humidity chamber. 
 
3.5.4.1 Methanol/Peroxide Block 
Slides were incubated in a mixture of methanol (Fisher Scientific, ThermoFisher 
Scientific, MA, USA) and 3% hydrogen peroxide (VWR International, 
Leicestershire, UK) for 30 minutes. This blocking step was carried out to block 
endogenous peroxidase activity in the tissue in order to reduce background staining 
that could be caused by endogenous peroxidase reacting with the chromagen 
detection in the final step of the process. 
 
3.5.4.2 Serum Block 
In order to prevent non-specific binding of primary and secondary antibodies, a 
normal serum block with a low concentration of BSA was carried out. Slides were 
incubated with normal serum (Autogen Bioclear, Wiltshire, UK) with 5% BSA 
(Sigma) in TBS, for 30 minutes. 
Chapter 3     General Materials and Methods 69 
3.5.4.3 Streptavidin-Biotin Block 
In order to reduce background with some antibody runs, a streptavidin-biotin 
blocking step was carried out.  The Streptavidin/biotin blocking kit from Vector 
Laboratories (Peterborough, UK) was used. A drop of streptavidin solution was 
placed on each section for 15 minutes, to block any endogenous biotin or biotin-
binding proteins in the tissue. Sections were washed, and then incubated with a drop 
of biotin solution for 15 minutes. This step is important in order to ensure all the 
biotin binding sites on the streptavidin molecules were occupied. 
 
3.5.5 Primary Antibodies 
Titre runs were carried out to work out the optimal concentration for each primary 
antibody. Antibodies were diluted to the required concentration (Table 3-1) in 
normal serum/5% BSA/TBS. Slides were incubated with primary antibody in a 
humidity chamber overnight at 4oC. Appropriate negative control slides incubated 
without primary antibody were used. 
 

















Calpastatin 1:1000 Rabbit Citrate pH6 No Sigma 
DAZL 1:500 Mouse Citrate pH6 No Serotec2 
FABP9 1:10,000 Goat Citrate pH6 No 
R&D 
Systems3 
STCM 1:500 Rabbit none No 
N/A (see 
4.3.1) 
VASA 1:200 Rabbit Citrate pH6 No Abcam4 
 
1Chemicon International, now part of Millipore, Herts, UK 
2Serotec, Oxford, UK 
3R&D Systems, Abingdon, UK 
4Abcam, Cambridge, UK 
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3.5.6 Secondary Antibodies 
Following overnight incubation with primary antibodies, biotinylated secondary 
antibodies were added. Secondary antibodies were chosen to be specific against the 
species in which the primary antibody was raised, and to be raised in the same 
species as the normal blocking serum used (Table 3-2). Biotinylated secondary 
antibodies were diluted 1:500 in normal blocking serum (5% BSA/TBS), and left on 
slides for 30 minutes. 
 
Table 3-2 Secondary Antibodies used for immunohistochemistry. 
Anti-species Species raised Conjugate Supplier 
Goat Rabbit Biotin Vector Laboratories 
Mouse Rabbit Biotin Dako 
Rabbit Swine Biotin Dako 
 
3.5.7 Chromagen Detection 
Biotinylated secondary antibodies were detected using a streptavidin-horseradish 
peroxidase (HRP) conjugate. Streptavidin-HRP (Vector Laboratories, Peterborough, 
UK) was diluted 1:500 in TBS and applied to slides for 30 minutes. 
 
The chromagen, 3,3’-diaminobenzidinetrahydrochloride (DAB) was then used to 
produce brown staining that could be visualised. DAB acts as an electron donor to 
the HRP, a process during which it becomes oxidised and produces the brown 
product, allowing visualisation of the location of the original tissue antigen. 
 
DAB+ chromagen (Dako, Cambridgeshire, UK) was diluted in DAB+ substrate 
buffer, 1 drop:1mL as detailed in manufacturer’s instructions, and placed on each 
slide until the staining had developed to the required intensity. The reaction was 
stopped by immersing slides in TBS. 
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3.5.8 Counterstaining, Dehydration and Mounting 
Tissue sections were counterstained with haematoxylin nuclear stain. Slides were 
immersed in Harris’ haematoxylin (Triangle Biomedical Sciences, Lancashire, UK) 
for 3-5 minutes (depending on whether antigen retrieval had been carried out), 
washed in water then rinsed in acid alcohol for 10 seconds. Slides were immersed in 
Scots Tap Water for 30 seconds then dehydrated by immersion through a series of 
increasing concentrations of alcohol solutions. Slides were placed in baths of 70%, 
85%, and 95% ethanol for 20 seconds each, then two absolute ethanol baths for 20 
seconds each. Finally slides were placed in xylene to replace the ethanol, in two 
separate baths for 4 minutes each. 
 
Stained tissue was fixed to the slide by mounting suitable sized coverslips with 
Pertex. Slides were left to air dry. 
 
3.5.9 Analysis of Stained Slides 
Fixed stained slides were visualised using light microscopes. Micrographs of each 
slide were taken using a Provis Microscope (Olympus Optical, London, UK), fitted 
with a Canon DS126131 camera, and Canon EOS image capture software (Canon, 
Surrey, UK). 
 
3.5.10 Detection of Apoptosis by TUNEL Immunohistochemistry 
The terminal deoxynucleotidyl transferase-mediated (TdT) dUTP nick end labelling 
(TUNEL) method was used for looking at apoptosis in tissue sections. This is an    
in-situ method for detection of DNA fragmentation, by end-labelling of double 
stranded DNA breaks. The terminal transferase enzyme labels dsDNA breaks with 
digoxigenin (DIG)-dUTPs. The DIG-dUTPS are then detected with an anti-DIG 
antibody and then the general immunohistochemistry method is followed from the 
secondary antibody stage. 
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Following the methanol/peroxidase blocking step, slides were incubated with TdT 
and dig-11-dUTPs diluted in reaction buffer (all Roche, West Sussex, UK) at 37oC in 
a humidity chamber for 30 minutes. Washes were performed in PBS, and then slides 
were incubated with normal rabbit serum for 10 minutes. Primary sheep-anti-DIG 
was diluted 1:50 in normal serum and placed on slides for 90 minutes. Following 
incubation with the secondary antibody, biotinylated rabbit anti-sheep (Vector 
Laboratories) at 1:500 in normal serum, TBS was used for washing steps. The 
protocol was completed using the Streptavidin-HRP and DAB detection system, as 
detailed above (section 3.5.7), followed by counterstaining and mounting (section 
3.5.8). 
 
3.6 Double Immunofluorescent Detection 
Immunofluorescence was used to show the localisation (and co-localisation) of two 
antigens in the same tissue sections. This process uses the same basic principle as 
standard immunohistochemistry (section 3.5) but with fluorescent conjugated 
streptavidin or fluorescent amplification detection systems (tyramide). 
 
This section details antibodies and tertiary reagents used for double 
immunofluorescent detection, as well as details on combined antibody protocols. 
Antigen retrieval and blocking steps were carried out as above (sections 3.5.2 and 
3.5.4). 
 
3.6.1 Wash Buffer 
Phosphate buffered saline (PBS) was used to wash slides between each step. 
Typically slides were immersed in two baths of PBS, for 5 minutes each. 
 
3.6.2 Primary Antibodies 
As with basic DAB immunohistochemistry, titre runs were carried out to establish 
the optimal concentration for each primary antibody. Antibodies were diluted to the 
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required concentration (Table 3-3) in normal goat serum/5% BSA/PBS. Slides were 
incubated with primary antibody in a humidity chamber overnight at 4oC. 
Appropriate negative and method control slides were included in each run. 
 
3.6.3 Secondary Antibodies and Detection Systems 
Two different detection systems were used for immunofluorescent runs. The first 
method used biotinylated secondary antibodies (diluted in normal serum) and 
fluorescent labelled streptavidin conjugates (diluted in PBS) in the same way as the 
streptavidin-HRP detection system.  
 
The second fluorescent detection method used the Tyramide Signal AmplificationTM 
(TSA) system (PerkinElmer, MA, USA). This system is a quicker and more sensitive 
alternative to the fluorescently labelled streptavidin method. It works in a similar 
way, with HRP conjugated secondary antibodies used, followed by binding of 
flurophore labelled tyramide. Peroxidase labelled secondary antibodies were diluted 
in normal goat serum and incubated on slides for 1 hour. Tyramide-cyanine 3 or 
tyramide-fluroscein (PerkinElmer) was diluted 1:50 in TSA kit buffer, and incubated 
on slides for 10 minutes. 
 
3.6.4 Counterstaining and Mounting 
Dapi (Molecular Probes, Invitrogen, Paisley, UK) was used as a nuclear counterstain 
for immunofluorescent runs. Dapi was diluted 1:1000 in PBS and placed on slides 
for 10 minutes, keeping the slides in the dark as much as possible. 
 
Slides were mounted with appropriate sized coverslips using PermaFluorTM aqueous 
mounting medium (ThermoScientific), and left in the dark at 4oC overnight to set. 
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3.6.5  Double Antibody Protocols 
In order to carry out double immunofluorescent antibody protocols, the species that 
the primary antibodies are raised in must be considered. Ideally both antibodies 
should be raised in different species. However, two antibodies raised in the same 
species can be used with some modifications to the basic immunofluorescent 
protocol. Peroxidase labelled secondary antibody Fab fragments were used instead of 
whole IgG secondary antibodies. Fab fragments are much smaller than whole IgGs 
with only one binding site, allowing better antigen recognition and reduction in 
background signal. Slides were incubated with secondary antibody Fab fragments 
diluted in normal serum for 30 minutes.  
 
A second antigen retrieval step was also carried out in situations where two same 
species primary antibodies were used. This step was carried out following tyramide 
detection of the first primary antibody. Slides were placed in boiling 0.01M citrate 
buffer (pH6) and heated in a microwave on full power for 2.5 minutes. Slides were 
then left to rest before continuing the protocol with a second serum blocking step, 
followed by incubation of the second primary antibody. Details of the protocols for 
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Table 3-3 Double Immunofluorescent Protocol Information  
All primary antibodies from Zymed, now part of Invitrogen, except anti- β-catenin, from BD 















































































3.6.6  Confocal Microscopy 
Immunofluorescent slides were imaged using a Zeiss LSM510 Meta Confocal 
Microscope (Carl Zeiss Ltd, Hertfordshire, UK) and Zen software (Carl Zeiss Ltd).  
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3.6.7 Identification of Biotin Tracer 
The biotin tracer (section 3.3.6) was detected using a direct immunofluorescent 
technique. Occludin was also stained for, to show the site of the blood-testis barrier, 
using a modified double immunofluorescent protocol.  
 
Antigen retrieval (0.01M citrate, pH6) and blocking steps were carried out as 
detailed above (sections 3.5.2 and 3.5.4). Biotin tracer was detected by incubating 
slides with Streptavidin-488 diluted 1:200 in PBS for 1 hour.  A second blocking step 
with normal goat serum was carried out for 30 minutes before addition of the 
occludin antibody. Detection of occludin was carried out using goat anti-mouse 
peroxidase and tyramide-Cy3 as detailed above (section 3.6.3). Slides were 
counterstained with Dapi and mounted with PermaFluorTM. 
 
3.7 Protein Assay 
The total concentrations of protein present in IF and homogenised ST samples were 
determined using the BioRad DC Assay kit (Bio-Rad, Herts, UK).  This is a 
colourimetric assay based on the Lowry protein assay, and uses a two step process. 
The first step involves the reaction between protein in the sample and copper in an 
alkaline solution. The second step involves the reduction of Folin reagent by the 
copper-treated protein. The reduced species have a characteristic blue colour which 
can be measured at a wavelength of 650-750nm, and compared to a protein standard 
curve to give the concentration of the sample protein.  
 
Samples were first diluted in RIPA buffer containing complete protease inhibitor 
(Roche, West Sussex, UK) (a 1:50 dilution was sufficient for most samples). The 
Microplate Assay protocol was followed, according to the Manufacturers’ guidelines. 
Plates were read at 690nm after developing the assay for 30 minutes. A BSA 
standard curve (diluted in RIPA buffer) was run on every plate to allow protein 
quantification.  
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3.8 Separation of Proteins by Gel Electrophoresis  
Invitrogen’s NuPAGE® System (Invitrogen, Paisley, UK) was used to separate 
proteins in IF and homogenised ST samples by size. The system utilises the 
traditional method of protein separation using polyacrylamide gels and 
electrophoresis with specially optimised buffers and pre-cast gels which allow 
increased gel stability, protein stability and consistent sharp band resolution. 
 
3.8.1 Sample Preparation 
In general, samples were prepared for loading 15µg protein in a total volume of 
20µL. The required volume of sample was added to 5µL NuPAGE® 4x LDS Sample 
buffer (Invitrogen) and 2µL NuPAGE® 10x Reducing Agent (Invitrogen) to ensure 
complete reduction of proteins. Deionised water was added to make up the volume to 
20µL. Samples were heated at 70oC for 10 minutes to denature the proteins, and 
briefly centrifuged to collect the sample at the bottom of the tube, prior to loading 
onto the gel. 
 
3.8.2 Gel Electrophoresis 
Proteins were separated using 12% acrylamide 1mm NuPAGE® Novex bis-tris gels 
(Invitrogen). These gels allow denaturing gel electrophoresis, at a lower pH than 
conventional SDS-PAGE gels (Manufacturers literature). NuPAGE® SDS MOPS 
buffer (Invitrogen) was used as the running buffer, with NuPAGE® Antioxidant 
(Invitrogen) added to the cathode buffer chamber to prevent reduced proteins 
reoxidising during electrophoresis (Invitrogen literature). The SeeBlue Plus2 Pre-
Stained Standard (Invitrogen) was run alongside samples on all gels, as a size 
marker. This standard contains 10 proteins, two with contrasting colours for easy 
band identification.  
 
Gels were run at a constant voltage of 200V, for approximately 40 minutes or until 
the loading dye had reached the bottom of the gel. 
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3.9 Staining Gels for Total Protein 
In order to look at all the proteins separated by gel electrophoresis, GelCode Blue 
Stain Reagent (Pierce, Thermo Scientific) was used. Traditionally proteins can be 
visualised on a gel using Coomassie Brilliant Blue Dye.  GelCode Blue Stain 
Reagent is a Coomassie based gel stain, which utilises the properties of the 
Coomassie G-250 dye for protein staining on acrylamide gels (manufacturers’ 
literature) and allows quantification of stained protein bands.  
 
Gels were first pre-fixed with 50% methanol and 7% acetic acid for 15 minutes, due 
to running the gels in MOPS buffer. The gels were thoroughly washed, and then 
25mL GelCode Blue Stain Reagent added, and incubated on a rocker at room 
temperature for 1 hour. Protein bands could be clearly seen to develop during the 
staining process. Gels were washed with ultrapure water for 1-2 hours to allow the 
stain to develop further, and remove any excess stain reagent. 
 
3.9.1 Quantification of Protein Bands  
GelCode Blue stained gels were scanned using ImageScanner III (GE Healthcare, 
Buckinghamshire, UK) and ImageMaster 2D Platinum software (GE Healthcare). 
Scanned images were saved as tif files for analysis with ImageQuantTM TL software 
(GE Healthcare). Using the 1D Gel Analysis function of this software, protein bands 
of interest were manually selected in each lane by drawing boxes around them 
(Figure 3-4). The centre and edges of bands were automatically identified by the 
software using the pixel profile of the scanned gel (Figure 3-4).  Band selection was 
manually adjusted to ensure only the band of interest had been selected in each box, 
and the rolling ball method of background detection chosen. This method allows a 
quantification of the total protein in each selected band based on the pixels, so that 
each band can be compared. A linear relationship between protein concentration and 
band intensity, calculated by this method, was shown to be accurate by running BSA 
standards on a gel, and quantifying the bands (Figure 3-5). 
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Figure 3-5 Validation of ImageQuantTM TL Band Analysis Technique. 
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In order to run all samples for comparison on gels, more than one gel had to be used. 
To allow a comparison of band profiles from two (or more) different gels, control 
homogenised ST samples were run on every gel, and bands normalised to the 
concurrent band in the ST sample (by expressing band profile values as a percentage 
of ST band profile value). Statistical analysis of results was carried out using a one 
way analysis of variance with a Tukey post-test, using GraphPad Prism software. 
 
3.10 Western Blotting 
Western blotting was used to look at specific proteins separated by gel 
electrophoresis.  Proteins were transferred onto an Immobilon-FL PVDF membrane 
(Millipore, Herts, UK) for fluorescent detection, using a Hoefer TE22 transfer 
chamber (Amersham Biosciences, GE Healthcare, Buckinghamshire, UK). A 
‘sandwich’ (Figure 3-6) was set up with gel and membrane in between layers of 
blotting paper, and sponges, surrounded by the blotting cassette. Individual 
components were equilibrated in transfer buffer before assembling the cassette. 
NuPAGE® transfer buffer (Invitrogen, Paisley, UK) (supplemented with NuPAGE® 
antioxidant (0.01%) and methanol (10%) according to manufacturers’ instructions) 
was used for Western blotting. Up to four cassettes were placed in the transfer 
chamber, and transfer run for approximately 4 hours at 40V.  
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Figure 3-6 Western Blot Transfer Chamber showing ‘sandwich’ setup. Next to the cathode is 
a piece of sponge (S), 3x pieces of blotting paper (P), gel (G), membrane (M), 3x pieces of 
blotting paper (P), and a final piece of sponge (S) next to the anode. 
 
Following transfer of the proteins to the Immobilon membrane, the membrane was 
blocked for 1 hour using one of two blocking buffers: 
• Odyssey blocking buffer (Li-cor Biosciences, Cambridge, UK) diluted with 
PBS (1:1) 
• Dried skimmed milk powder (20% w/v) in TBS+0.05% Tween-20 (Sigma) 
 
Primary antibody was diluted to the required concentration (Table 3-4) in the same 
buffer, and incubated with the membrane overnight at 4oC. Membranes were then 
washed using either PBS+0.1% Tween or TBS+0.05% Tween, depending on the 
blocking buffer used, then incubated at room temperature with fluorescent secondary 
antibodies diluted to 1:10,000 in blocking buffer for 1 hour (Table 3-5) The 
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Table 3-4 Primary Antibodies used for Western Blotting. 







Calpastatin 1:1000 Sigma Rabbit 
DAZL 1:1000 Serotec Mouse 
FABP9 1:5000 R&D Systems Goat 
STCM 1:1000 N/A Rabbit 
VASA 1:1000 Abcam Rabbit 
 
 
Table 3-5 Secondary Antibodies used for Western Blotting. 
Antibody Supplier Detection 
Donkey anti-goat Molecular Probes 680nm 
Goat anti-mouse Molecular Probes 680nm 
Goat anti-rabbit Rockland, USA 800nm 
 
 
Membranes were analysed using the Odyssey Infrared Imaging System (Li-cor 
Biosciences). Blots were scanned, and viewed using the Odyssey Software (Li-cor 
Biosciences). Any bands identified on the blots were quantified by drawing boxes 
around the bands and measuring the intensity of the fluorescence (Figure 3-7).  
 
As with 1D gels, in order to run all samples for comparison on Western blots, more 
than one blot had to be used. To allow a comparison of band intensities from two (or 
more) different blots, control homogenised ST samples were run on every blot, and 
bands normalised to the concurrent band in the ST sample (by expressing band 
intensities as a percentage of ST band intensity). Statistical analysis of results was 
carried out using a one way analysis of variance with a Tukey post-test, using 
GraphPad Prism software. 
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Figure 3-7 Western Blot Analysis using the Odyssey Infrared Imaging System and Odyssey 
Software. The intensity of each band was measured by drawing a box around it. 
 
3.11 TaqMan® Q-PCR 
3.11.1 RNA Preparation 
3.11.1.1 RNA Extraction 
RNA extraction was carried out using the Promega SV Total RNA Isolation kit 
(Promega, WI, USA). This kit uses a spin column assembly containing a silica 
membrane, to which the RNA, precipitated with ethanol, binds. Simple wash steps 
allow removal of proteins, salts and cell debris, while incubating with DNase I 
ensures the removal of contaminating genomic DNA. 
 
Tissue was first homogenised in RNA lysis buffer (supplied with kit, Promega) using 
a tissue lyser (Qiagen, West Sussex, UK) and steel balls. The process was optimised 
to use 60-75mg frozen tissue, where possible (some testes from younger animals 
were below this range) in 450µL of lysis buffer, lysing for 1 minute at a frequency of 
20 (1/s) in a deep well plate. RNA was isolated from the tissue lysates according to 
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the manufacturer’s instructions, following the spin protocol, and performing two 
isolations per tissue lysate (resulting in 2 RNA samples/tissue sample).  
 
Isolated RNA was analysed for integrity and quantity, and stored at -80oC. 
 
3.11.1.2 Analysis of RNA 
3.11.1.2.1 RNA Integrity 
The integrity of the RNA extracted from the testis samples was assessed using the 
Agilent 2100 Bioanalyser. This technique uses the ‘lab-on-a-chip’ technology to 
separate RNA by size, and using fluorescent detection with capillary electrophoresis. 
The Agilent RNA 6000 Nano kit (Agilent Technologies, Berkshire, UK) was used to 
prepare the chips (kit protocol followed). RNA samples were diluted 2:5 in DNase, 
RNase, and protease free water (5-PRIME, VWR International) before loading onto 
the chip. Results were assessed by analysing the gel/electrophoreograms produced 
and looking for the presence of only two peaks/bands representing 18S and 28S RNA 
(Figure 3-8).  
 
The integrity of all isolated RNA samples was deemed to be suitable to continue with 
the PCR. 
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Figure 3-8 Example of read-out from Agilent 2100 Bioanalyser. RNA integrity results can be 
displayed as: (a) gel layout showing two clear bands for 18S and 28S RNA. Green band is 
marker band to allow alignment of all samples. (b) electrophoreogram layout showing two 
clear peaks for 18S and 28S RNA and a small marker peak. 
 
 
3.11.1.2.2 RNA Quantity 
The quantity of RNA extracted from the testis samples was evaluated using the ND-
1000 Nanodrop (Labtech, East Sussex, UK). This is a spectrophotometer method 
which allows accurate quantification of a small volume of sample (2µL). 
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3.11.2 cDNA Preparation 
cDNA was prepared using the Invitrogen Superscript TM First-Strand Synthesis 
System for RT-PCR kit (Invitrogen, Paisley, UK) to synthesise cDNA from total 
RNA using random hexamers. This is a non-specific priming method for 
synthesising DNA. Reverse transcriptase (RT) positive and negative cDNA samples 
were synthesised from each RNA sample. RT minus samples were included to rule 
out any amplification of the genes of interest due to genomic DNA.  
 
The volume required of each RNA sample was calculated, based on the assumption 
that 1µg RNA is converted to 1µg cDNA using the kit. A total of 3µg RNA was 
required for each RT+ and RT- samples, a total of 6µg RNA per sample. RNA 
samples that were too dilute for the kit protocol were spun down in a vacuum 
centrifuge, and then resuspended in the required volume of RNase/DNase free water. 
cDNA was synthesised according to the manufacturer’s instructions supplied with 
the kit. cDNA was diluted to the required concentration of 0.01µg/µL, and stored at 
-20oC. 
 
3.11.3 TaqMan® Q-PCR 
TaqMan® is the trademark name of the PCR-based, fluorogenic 5'-nuclease assay, 
which allows for the real time quantification of DNA. The assay uses a fluorogenic 
probe to enable the detection of a specific PCR product as it accumulates during PCR 
(Figure 3-9). A fluorescent reporter dye is incorporated on the 5' end, and a quencher 
on the 3' end of the probe. When the probe is intact, the proximity of the reporter dye 
to the quencher dye results in suppression of the reporter fluorescence. During PCR, 
if the target of interest is present, the probe specifically anneals between the forward 
and reverse primer sites. The 5’ to 3’ exonuclease activity of Taq polymerase cleaves 
the probe, increasing the proximity between the reporter and the quencher, causing 
an increase in fluorescence signal. The fluorescence at each PCR amplification cycle 
is recorded, allowing quantification of the accumulating PCR product. 
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Figure 3-9 TaqMan® Q-PCR process.  Forward and reverse primers bind to target 
sequence. Probe with reporter (R) and quencher (Q) dyes bind to DNA sequence between 
primers.  5’-3’ exonuclease activity of Taq polymerase cleaves probe as it extends the primer 
sequences. Degradation of probe separates R and Q dyes causing an increase in 
fluorescence. Taq polymerase continues extension of PCR product. Amount of PCR product 
synthesised is proportional to the increase in fluorescence from the degraded probes. 
Adapted from Applied Biosystems website. 
 
3.11.3.1 Primer and Probe design 
Primers and probes were designed to eight genes of interest (3βHSD, β-catenin, 
claudin-11, FABP9, JAM-A, N-cadherin. occludin, ZO-1) using the Primer Express® 
software (Applied Biosystems, Roche). Rat sequences for the required genes were 
obtained, and entered into the software. TAMRA dye labelled probes were designed 
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for as many genes as possible, using the Applied Biosystems criteria. For genes, 
where no suitable primers and probes could be found (usually due to high G/C 
content in the probe), MGB probes were designed (Table 3-6). These probes are 
shorter than traditional probes with a non-fluorescent quencher and a minor groove 
binder at the 3’ end. This increases the melting temperature of the probe, therefore 
allowing a shorter probe to be used, as well as increasing the difference in Tm 
between matched and mismatched probes. (Applied Biosystems literature). Primers 
and probes were tested using control cDNA before starting the main TaqMan® study. 
 
Table 3-6 Primer and probe sequences for genes of interest and control genes. The Applied 
Biosystems kit was used for GAPDH. All other primers and probes were designed using 
Primer Express software, and supplied by Applied Biosystems. 





















































GAPDH Applied Biosystems kit VIC-MGB  
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Three housekeeping genes were selected to be used as controls. GAPDH and 18S are 
classic control genes used for PCR. SPAG5 was chosen as a previously validated 
testis specific control gene (Laura Robbins, GSK). 
 
3.11.3.2 TaqMan® Q-PCR Reaction 
TaqMan® reactions were carried out using clear 96-well plates (MicroAmp, Applied 
Biosystems). A “reverse plate” template was used. The plate layout was designed 
with all 11 genes on each plate, as well as an inter-plate control well, containing 
control cDNA and primers/probes for 18S (Table 3-7). Primers and probes were 
diluted to 10µM and 5µM, respectively, and mixed with RNase/DNase free water so 
that the required concentration (200nM) of each was reached in a total volume of 
25μL, allowing 5μL primer/probe mixture to be loaded into each well. The PlateMate 
Plus (Matrix, ThermoScientific, Cheshire, UK) machine was used to stamp out all 
plates with 5μL primer/probe mix in each well, according to the plate layout. Plates 
were temporarily sealed with the ABgene ALPS-300 Plate Sealer (ThermoScientific) 
(106oC) and stored at -20oC until required. 
 
Master mixes were prepared containing RNase/DNase free water, TaqMan® master 
mix (Applied Biosciences, Roche), and cDNA template (5uL 0.01μg/μL). 20μL of 
each mastermix was pipetted into each well of the stamped out plates using the 
Biomek FX (Beckman Coulter, High Wycombe, UK) automated machine. 
Mastermixes were pipetted along each row of the plates, allowing each cDNA 
template and gene combination, in duplicate. Plates were then sealed at 160oC using 
the ABgene plate sealer and centrifuged at 1000rpm for 1 minute. Lids were placed 
on each plate, and the plates run overnight on ABI7900HT TaqMan® machines 
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Table 3-7 “Reverse Plate” Layout for TaqMan® Q-PCR. Grid represents each 96-well plate, 
stamped out with primers and probes for each of the 11 genes of interest down each column 
from 1-11. Well A12 contained primers and probes for 18S run with the same cDNA on each 
plate as an inter-plate control. Each cDNA sample was pipetted across a row on a plate. 
 
 
3.11.3.3 TaqMan® Q-PCR Cycling Parameters  
Amplification was performed according to the following program: 50˚C UNG 
activation step, a 95˚C AmpliTaq Gold enzyme activation, and 40 cycles of 95˚C 






Figure 3-10 TaqMan® cycling parameters 
 
3.11.3.4 Standard curves 
Rat genomic DNA (Clontech Laboratories, CA, USA) standards were made and run 
on the TaqMan® plates in triplicate alongside cDNA templates. Following the primer 
and probe test, cDNA standards were made up to run with β-catenin primers and 
probes as these did not work with genomic DNA. 
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3.11.3.5 TaqMan® Q-PCR Analysis of Results 
Data analysis was performed using the threshold cycle (Ct) (the cycle at which 
amplification of the gene reaches exponential phase) (Figure 3-11). Using the 
TaqMan® SDS 2.2.2 software, a Ct value was selected to satisfy all genes. Each plate 
was checked, to ensure the selected value was suitable for all samples. Some samples 
were repeated due to insufficient results. Standard curves were produced from the 
genomic DNA (and cDNA for β-catenin) Ct values, and used to calculate copy 
numbers of each gene in each sample. The mean of the technical replicates of the 
samples from the TaqMan® plates was calculated, and RT- values subtracted from 
RT+ values to account for genomic DNA contamination. The mean of the values 
from each RNA extraction/tissue sample was then calculated to give a value for each 
tissue sample. 
 
Some variability was observed with the data points, and those chosen to be out of the 
range of the data or those RT+ reactions that did not appear to work were excluded 
from the analysis. Results were analysed using log transformation and plotting mean 
values with SEM. Statistical analysis was carried out using one way ANOVA, 
followed by a Tukey post-test, using GraphPad prism software. 
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Figure 3-11 Screen-shot of SDS 2.2.2 Software for Analysis of TaqMan® Results. On the 
right hand side is the amplification plot. Different coloured lines denote the amplification 
curves of different samples. The threshold is shown by a red horizontal line, and the Ct is the 
cycle at which this line is crossed. A diagram of the 96 well plate is displayed in the top left 
hand corner of the screen. Below that is the TaqMan® data itself. 
 
 
3.12 Commonly Used Buffers and Reagents 
3.12.1 Tris Buffered Saline (10x working concentration) 
605g Tris  
876g NaCl  
pH was adjusted to 7.4 using HCl (at least 300mL required) 
make up to 10L with deionised water 
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3.12.2 Phosphate Buffered Saline 
Dissolve PBS tablets (Sigma-Aldrich) 1 in 20mL deionised water 
 
3.12.3 Citrate Buffer (0.1M) 
42.02g citric acid 
1900mL distilled water 
Adjust to pH6.0 with concentrated NaOH 
Make up to 2L 
 
3.12.4 Glycine Buffer (0.5M) 
75.07g glycine 
1900mL distilled water 
Adjust to pH3.5 using concentrated HCl 
Make up to 2L 
Add 2g EDTA 
 
3.12.5 Scots Tap water 
10g potassium hydrogen carbonate 
100g magnesium sulphate 
5L tap water 
 
3.12.6 Acid Alcohol 
70% ethanol 
1% concentrated HCl 
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3.12.7 RIPA Buffer (5x working concentration) 
750mM NaCl 
250mM TrisHCl pH7.4 
25mM EDTA 
5% sodium deoxycholate 
0.5% SDS 
 
3.12.8 Homogenisation buffer 
For 5mL 
3.5mL deionised water 
0.5mL 10x Complete protease inhibitor 
1.0mL 5x RIPA buffer 
 
3.12.9 TUNEL Reaction buffer 
30mM TrisHCl pH7.2 
140mM Na Cacodylate 
1.5mM CoCl 
 
3.12.10 Bouin’s Fixative 
Prepared by Triangle Biomedical Sciences (Lancashire, UK) 
1L 40% formaldehyde 
200mL glacial acetic acid 
4L saturated picric acid 
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4 Normal Testis and Investigative Tools used in this 
Thesis 
4.1 Introduction 
Throughout this thesis various testicular toxicants with differing target areas have 
been used. Before tissues collected from animals given these treatments can be 
evaluated, it is important to understand the tissue, and how it responds in different 
experimental conditions. This chapter aims to introduce the different approaches, 
techniques and tools used in this thesis with vehicle control samples in order to 
understand the ‘normal’ situation. 
 
The aim of this project is to evaluate the potential for biomarkers for testicular 
toxicity.  Previous work (Turner et al., 1996) suggested that proteins may leak from 
seminiferous tubules into the interstitum under toxicological insult to the testis. This 
could be due to either loss of integrity of the blood-testis barrier, or germ-cell 
damage.  In order to investigate this, adult male Wistar rats were treated with 
testicular toxicants with differing targets of action. Analysis of germ cell damage, 
blood-testis barrier integrity, and an evaluation of proteins in interstitial fluid 
samples were carried out on samples collected from the treated animals.  
 
As well as the challenge of working with a complex tissue, in order to evaluate 
potential biomarkers, it is necessary to consider a large number of proteins. Three 
approaches were taken to investigate potential biomarkers; a general antibody to 
seminiferous tubule proteins was used to look at a range of proteins, 1D Coomassie 
gel analysis was used to assess total proteins in samples, and specific proteins were 
selected from an Affymetrix Genechip® Screen carried out at GSK as potential 
biomarkers for testis toxicity. 
 
This chapter introduces these three approaches as well as detailing methods used for 
evaluation of blood-testis barrier integrity. 
Chapter 4     Normal Testis and Investigative Tools 96 
4.2 Methods 
4.2.1 Samples 
Studies were set up to investigate known testicular toxicants. A group of vehicle 
control treated animals were used for comparison with each study. The results in this 
chapter all used fixed testes or interstitial fluid samples from vehicle control treated 
animals for these studies. Isolated and staged seminiferous tubules (refer to section 
3.4.4.1) were also used in this chapter. 
 
4.2.2 Immunohistochemistry and Immunofluorescence 
Immunohistochemistry with antibodies to the proteins of interest (DAZL, VASA, 
ADAM3, Calpastatin, FABP9), and a general antibody raised to seminiferous tubule 
conditioned medium, was carried out to investigate the localisation of proteins in the 
testis. The DAB protocol described in section 3.5 was used. 
 
Immunofluorescence was used to investigate the blood-testis barrier proteins, ZO-1, 
occludin, claudin-11, N-cadherin, and β-catenin. Immunofluorescent detection was 
also used to detect the biotin tracer. Detailed protocols are described in chapter 3. 
 
4.2.3 Coomassie Stained Gels and Western Blotting 
Proteins in IF and ST samples were separated using 1D gels. Coomassie stain was 
used to look at total protein, and Western blotting with the STCM antibody, and an 
antibody to FABP9 were carried out following the methods described in sections 3.9 
and 3.10. 
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4.3 Results 
4.3.1 Antibody raised to Seminiferous Tubule Conditioned Medium  
An antibody raised to seminiferous tubule conditioned medium (STCM) was 
prepared by a previous PhD student (Katie Turner, Turner, 1996). Seminiferous 
tubules were isolated from adult rats and cultured. Conditioned medium was 
collected and pooled from 4 rats, before being lyophilised, reconstituted and 
emulsified. Two rabbits were injected with the resulting immunogen at five different 
intradermal sites, followed by booster injections nine weeks later, and collection of 
blood samples after a further 3 weeks. The IgG fraction was prepared from the serum 
by affinity chromatography producing the polyvalent antiserum to STCM (Turner, 
1996; Turner et al., 1996). 
 
The antibody detects a range of seminiferous tubule derived proteins as shown in 
Figure 4-1, although the exact identity of these proteins is unknown. The antibody 
was used in immunohistochemistry and Western blotting to investigate general 
changes in the proteins present in control and treated testis samples, in initial 
investigations into the protein leakage hypothesis.   
Figure 4-1 Antibody raised to seminiferous tubule conditioned medium. a, b) Immunohistochemistry with antibody to STCM (brown) on control 
testis sections, counterstained with haematoxylin (blue). A variety of undefined proteins are detected and show stage- and germ cell- dependent 
expression. sg- spermatogonia, sc- spermatocytes, lsc- leptotene spermatocytes, psc- pachytene spermatocytes, rst- round spermatids, est- 
elongate spermatids, sz- spermatozoa, rb- residual bodies (please refer to Figure 2-3 for further information about the spermatogenic cycle). 
Scale bar represents 100µm. c) Panel from Western blot with antibody to STCM and control interstitial fluid (IF) and control seminiferous tubules 
(ST) to illustrate the variety of proteins the antibody detects. The box indicates expected sizes of specific proteins investigated later in this chapter 
(molecular weights suggested in antibody manufacturers literature). 
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Figure 4-1 illustrates the results obtained when the STCM antibody was used for 
immunohistochemistry on control testis sections (a, b), and Western blotting with 
interstitial fluid and seminiferous tubule samples from control animals (c). 
Immunohistochemistry shows the range of proteins detected at different locations in 
the seminiferous tubules. Stage specific differences in the staining patterns can be 
seen in both panels a and b, with intense staining in the elongate spermatids and 
weaker staining in the round spermatids. Panels a and b also illustrate the 
organisation of spermatogenesis in the seminiferous tubules (refer to Section 2.3.4.4 
and Figure 2-3). Western blotting also shows the range of proteins detected by the 
STCM antibody with many protein bands present in the seminiferous tubule sample 
(Figure 4-1c), and a smaller number of these proteins detected in the interstitial fluid 
sample. The sizes of some proteins of interest, discussed later in this chapter and 
chapter 7 are also indicated in Figure 4-1c to illustrate the range of sizes of proteins 
investigated and their relation to the protein bands seen with the STCM antibody (the 
labels do not necessarily mean that the bands observed are the proteins indicated). 
 
4.3.2 Seminiferous Tubule Proteins at Different Stages of 
Spermatogenesis 
As shown in Figure 4-1a and b, different proteins are present in each tubule 
depending on the stage of spermatogenesis. To investigate whether the stage of 
spermatogenesis might have an affect on the proteins leaking out of STs into IF, STs 
were dissected out of untreated testes, and staged using light microscopy. Stages I-V, 
VI-VIII and IX-XIV can be easily identified depending on the transillumination 
pattern seen in the tubules (Figure 4-2).  Staged tubules were homogenised and run 
on a Western blot with the STCM antibody (Figure 4-3). 
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Figure 4-2 Staging Seminiferous Tubules. Tubules were dissected into three stage groups 
(stages I-V, VI-VIII and IX-XIV) according to the transillumination pattern seen in the tubule.  
 
 
The Western blot again highlights the range of proteins detected by the STCM 
antibody. Two separate samples for each group of stages were run on the blot for 
comparison. The blot also illustrates the variability that naturally occurs between 
different samples, as well as the variability involved with experimental techniques. 
For these reasons it is important to run more than one sample from each group so that 
account can be taken of this variation and the chance of spurious findings minimised.  
 
The Western blot in Figure 4-3a does not appear to show any major differences in the 
proteins detected between each stage group. A selection of bands were quantified 
from the Western blot, to allow an objective comparison of the different groups with 
the mean for each group plotted on graphs (Figure 4-3b). The graphs agreed with the 
observation that there are no major differences in the intensity of the protein bands 
across the stage groups, although there was a trend for a greater intensity of protein 
bands at 51kDa, 39kDa, and 27kDa in size with the VI-VIII staged group compared 
to the other two staged groups.  
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Figure 4-3 a) Western Blot with antibody to STCM, showing staged seminiferous tubules 
and control unstaged STs. Arrows indicate examples of protein bands quantified. b) Graphs 
showing quantification of 51kDa, 45kDa, 39kDa, 27kDa, 25kDa and 15kDa bands (mean 
with SEM) with values taken from samples run on one blot (n=2 samples/staged group).  
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These graphs illustrate how useful it is to be able to quantify the protein bands and 
calculate averages to compare across groups. Throughout this thesis, at least two 
samples for each group have been run on Western blots in order to carry out 
statistical analyses and comparisons between groups.  
 
In order to further investigate the proteins present in STs, staged STs were also run 
on a 1D gel and stained with a Coomassie dye based stain to look at total protein 
content (Figure 4-4). As with the Western blot (Figure 4-3) there do not appear to be 
any obvious differences in the proteins present in each staged group.  
 
A variety of protein bands were quantified (Figure 4-4b). The graphed results agreed 
with the observations and suggested there were no differences between the staged 
groups.  
 
Both Western blots with the general STCM antibody and Coomassie stained gels 
have been used throughout this thesis for the analysis of IF and ST samples. Both 
techniques have a role in the identification and comparison of proteins. The STCM 
antibody detects a range of seminiferous tubule derived proteins and can also be used 
with immunohistochemistry to look at the localisation of the proteins in testis 
sections. In comparison, the Coomassie gels detect proteins present in the samples, 
regardless of origin. However, only 1D gels have been used and so proteins of 
similar sizes may be masked in one band. Coomassie gels could still be useful for 




Chapter 4     Normal Testis and Investigative Tools 103 
 
Figure 4-4 Coomassie stained gel showing staged STs and unstaged STs. Arrows indicate 
examples of protein bands quantified. b) Graphs showing quantification of indicated bands 
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4.3.3 Specific Protein Investigations  
The primary aim of this thesis was to evaluate the potential use of biomarkers for 
testicular toxicity. Therefore, as well as looking generally at the proteins present in 
control and treated samples, specific candidate biomarker proteins were also 
investigated. This section of work, including the background to selecting specific 
proteins, is described thoroughly in chapter 7. Some of these proteins are mentioned 
in earlier chapters with toxicant treatments, and so it is important to understand how 
they are expressed in control testicular tissue. 
 
Immunohistochemistry for five germ cell proteins is shown in Figure 4-5. The 
proteins investigated were: 
• A disintegrin and metalloprotease domain3 (ADAM3) 
• Calpastatin 
• DAZL 
• Fatty acid binding protein 9 (FABP9) 
• VASA 
 
The immunohistochemical staining clearly shows the localisation of each protein, 
and stage specific expression. ADAM3 was expressed in round and elongate 
spermatids (Figure 4-5a). Staining for calpastatin was also in round spermatids 
(Figure 4-5b). DAZL was localised to pachytene spermatocytes and residual bodies 
towards the lumen of the tubules (Figure 4-5c) and VASA was localised to both 
spermatocytes and spermatids (Figure 4-5e). Staining for FABP9 was not as distinct 
as the four other proteins, but suggested localisation of FABP9 to spermatocytes and 
spermatids (Figure 4-5d). 
 
As well as immunohistochemical analysis to investigate the localisation of the 
proteins in testicular sections, analysis of the specific proteins in interstitial fluid and 
seminiferous tubule samples was carried out using Western blotting with the specific 
antibodies to the proteins. An example of a Western blot for FABP9 with 
seminiferous tubules is shown in Figure 4-5f. One clear band can be seen in the 
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sample, about 15kDa in size (the expected size for FABP9), showing the specificity 
of the antibody to detect the protein in seminiferous tubule samples.  The expected 
molecular weights of the five proteins of interest are shown in Figure 4-1c. 
 
 
Figure 4-5 Testis sections from control adult rats, immunostained (brown) to show a) 
ADAM3, b) Calpastatin, c) DAZL, d) FABP9 and e) VASA, all counterstained with 
haematoxylin (blue). Scale bars represent 100µm. f) Panel from Western blot with FABP9 
and seminiferous tubule extract (ST).The FABP9 band is indicated by an arrow (15kDa). 
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4.3.4 Blood-Testis Barrier Investigations 
In order to investigate the hypothesis that proteins may leak from seminiferous 
tubules into interstitial fluid due to loss of integrity of the blood-testis barrier (BTB) 
or germ cell damage, the integrity of the BTB was evaluated following toxicant 
treatments. 
 
This section serves to show the presence of the BTB in control testis sections, an 
appreciation of which is necessary before the state of the barrier following toxicant 
treatment can be evaluated. 
 
The BTB is made up of a range of different interacting proteins forming tight 
junctions and adherens junctions (described in section 2.3.6). Studies published in 
the literature regularly use immunofluorescent techniques to evaluate the integrity of 
the BTB in testis sections. Following on from this, double immunofluorescence co-
staining with tight junction proteins, occludin and ZO-1, and claudin-11 and ZO-1, 
and adherens junction proteins, N-cadherin and β-catenin, were carried out to 
evaluate the BTB in the toxicant studies. These proteins were chosen as they have 
been widely used in the literature (Wong et al., 2004; Wong et al., 2005; Yan and 
Cheng, 2005; Li et al., 2006; Xia et al., 2006; Wong et al., 2007; Kopera et al., 2009) 
and provide combinations of junction and accessory proteins, which should co-
localise at the site of the BTB.  
 
A second immunofluorescent technique for evaluating the integrity of the BTB, 
using fluorescent detection of a biotin tracer injected into the testes, was also carried 
out (sections 3.3.6 and 3.6.7). The site of the BTB was illustrated in these studies by 
immunofluorescent detection of occludin.  
 
4.3.4.1 Tight Junctions 
The blood-testis barrier forms between post-natal days 15-19 in the rat (Vitale et al., 
1973; Russell et al., 1989). Figure 4-6 illustrates the presence of both ZO-1 and 
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occludin at the site of the BTB in day 25 tubules, whereas at day 15, only ZO-1 the 




Figure 4-6 Immunofluorescence staining for a, d) ZO-1 (green), b, e) occludin (red) and c, f) 
merged image with Dapi nuclear counterstain (blue), with testis sections from rats aged 15 
(a, b, c) or 25 (d, e, f) days. Scale bar represents 50µm. 
 
Evaluation of the integrity of the tight junctions in the blood-testis barrier is widely 
carried out by looking at the co-localisation of a junction and an adaptor protein. 
Two different co-localisation studies have been used to investigate the tight junctions 
in the BTB in this thesis; occludin and ZO-1, and claudin-11 and ZO-1. Figure 4-7 
shows immunofluorescent co-localisation of these two protein combinations in 
control tissue sections. 
 
Occludin and ZO-1 clearly co-localise at the site of the BTB in tubules shown in 
Figure 4-7a-c. Unfortunately there is a lot of red background in these pictures; this is 
due to non-specific binding of the tyramide (used in the detection of occludin) to the 
interstitum. Figure 4-7d-f shows a similar pattern, although the absence of occludin 
Chapter 4     Normal Testis and Investigative Tools 108 
from one seminiferous tubule can be noted. As described in chapter 2, a gross 
restructuring of the BTB during stages VII-IX must take place to allow the 
spermatocytes to pass through the barrier and continue their developmental path 
moving towards the lumen of the tubule. This restructuring is thought to involve an 
engagement/disengagement mechanism with the adherens and tight junction protein 
complexes (described in section 2.3.6.4, Yan and Cheng, 2005). It has been reported 
in one study that occludin cannot be identified in stage VIII tubules (Li et al., 2006). 
Despite co-localisation of occludin and ZO-1 being one of the most widely used 
ways of showing the presence of the BTB, this is the only reference to the absence of 
occludin at stage VIII. This observation does, however, fit with the proposed 
mechanisms of BTB restructuring at stages VII-IX. The tubule in Figure 4-7f appears 
to be at stage VIII, so this could explain why occludin is not observed in this tubule. 
The stage of the tubule may, therefore be an important consideration when evaluating 
the integrity of the BTB through co-localisation of occludin and ZO-1. 
 
Localisation of a further tight junction protein, claudin-11, which also has ZO-1 as an 
adaptor protein (section 2.3.6.1), was also assessed to ensure results obtained with 
occludin/ZO-1 provide a true representation of damage to the BTB and not just to 
occludin in the tight junctions. Figure 4-7 panels g-i show the co-localisation of 
claudin-11 and ZO-1 at the site of the BTB. When looking at these figures, it is 
important to remember that the BTB is a 3D structure. The position of the proteins 
clearly changes as you adjust the z-plane of the image taken through the slide, 
showing how the proteins move up and down linking the Sertoli cells. The best 
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Figure 4-7 Immunofluorescence staining for a, d) ZO-1 (green), b, e) occludin (red) and c, f) 
ZO-1/occludin merged image, g, j) ZO-1 (green), h, k) claudin-11 (red), i. l) ZO-1/claudin-11 
merged image with Dapi nuclear counterstain (blue), on testis sections from control adult 
rats. Scale bar represents 50µm. 
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The tubules in Figure 4-7 panels j-l, do not show co-localisation of claudin-11 and 
ZO-1 as clearly as panels g-i. This illustrates the variability of the results obtained. 
Particularly with this double immunofluorescent protocol, staining was very patchy 
in some sections, making it hard to evaluate the junction proteins. The tubule on the 
right hand side of the figure (panels j-l) shows the presence of both claudin-11 and 
ZO-1, although little co-localisation. This could be due to the 3D nature of the 
structure, and ZO-1 could be localised just below the claudin-11 in the z-plane. It 
could also be due to the problems of patchy staining observed with this protocol. The 
second tubule on the left hand side (panels j-l) appears to show the absence of 
claudin-11 at the site of the BTB. Again this could be due to the method difficulties. 
Alternatively, it could be due to the same reason as for the absence of occludin 
observed in the tubule in panels d-f. This tubule also appears to be stage VIII, and 
claudin-11 could be reduced/absent from the BTB during restructuring in the same 
way that occludin is. 
 
4.3.4.2 Adherens Junctions 
As described in chapter 2 (section 2.3.6.2), adherens junctions are another 
component of the BTB. Co-localisation of an adherens junction protein, N-cadherin, 
and an adaptor protein, β-catenin, was investigated to allow an evaluation of other 
factors affecting the BTB, rather than just an evaluation of the tight junctions. 
 
Figure 4-8 shows the natural localisation of these two proteins in seminiferous 
tubules. N-cadherin can be clearly seen at the site of the BTB (Figure 4-8c). As well 
as forming Sertoli cell-Sertoli cell junctions, adherens junction proteins can also 
form Sertoli cell-germ cell connections. In panels c and d, the N-cadherin can be 
seen extending around the germ cells as well as the clear line of the BTB. The 
localisation of β-catenin can also be clearly seen in panels b and d. β-catenin appears 
to be localised to the nuclei of the germ cells. Although these two proteins do not co-
localise, they are both involved in formation of adherens junctions, and their 
localisation provides a further evaluation of the integrity of the BTB. 
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Figure 4-8 Immunofluorescence staining for a) Dapi counterstain (blue), b) β-catenin 
(green), c) N-cadherin (red) and d) β-catenin/N-cadherin merged image on a testis section 
from a control adult rat. Scale bar represents 50µm. 
 
4.3.4.3 Biotin Tracer 
The second technique used for evaluation of the integrity of the BTB involved 
fluorescent detection of a biotin tracer that was injected into the testes before 
fixation.  This method provides a technique for evaluation of the function of the 
BTB, which complements evaluation of the integrity of the structure of the BTB 
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described above. The site of the BTB was also illustrated in these studies by 
immunofluorescent detection of occludin. The biotin tracer (EZ-link sulfo-NHS-LC-
biotin (Pierce Bioscience, IL, USA)) is an ester of biotin, which is water soluble, but 
cannot penetrate cell membranes due to a charged sulphonate group. If the BTB is 
functional, the biotin tracer should be detected in the interstitum and seminiferous 
tubules up to the site of the BTB. If the functional integrity of the BTB has been lost, 
the biotin tracer should penetrate the barrier and be detected inside of the tubules 
(Tarulli et al., 2008).  
 
Figure 4-9 shows images from control testes, which were injected with the biotin 
tracer. These panels illustrate the variation that can be seen with this technique in 
control tissue, supporting the need for large n numbers, and analysis of control tissue. 
Panel a clearly shows that the biotin tracer is restricted to the interstitum. 
Unfortunately the tyramide detection system used for detection of occludin, also 
binds to non-specific proteins in the interstitum, creating red background and turning 
the green detection of the biotin tracer yellow (panel a). Panels c and d also show a 
clear distribution of the biotin tracer in the interstitum. It can also be seen 
surrounding germ cells on the interstitial side of the BTB, particularly in panel c. 
 
Figure 4-9b, f and g also show the biotin tracer in the interstitum. However, in these 
pictures, the tracer appears to have penetrated into the tubules, even though the BTB 
is still intact (shown by the presence of occludin). The pattern observed suggested 
that the tracer is moving into the tubules between Sertoli cells. The pattern does not 
suggest total loss of integrity of the BTB, and is perhaps caused by looking at an area 
of the testis close to the injection site, so a larger volume of tracer was present, or 
due to leaving the testis incubating with the injected tracer for slightly longer than 
other testes. Alternatively, this observation could be due to hydrolysis of the biotin 
tracer. Although the tracer solution was freshly made before sample collection, it is 
possible that the hydrolysis of the tracer occurred before it was injected into some of 
the tissue samples collected later during the collection period, and this could have 
affected the permeability of the tracer. Again, this illustrates the importance of 
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evaluating the variation in control tissue before drawing conclusions with results 
from treated animals. 
 
 
Figure 4-9 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain, on testis sections from control adult rats. Scale bar represents 50µm. 
 
4.4 Discussion 
The aim of this chapter was to introduce the techniques, tools and approaches used to 
investigate the potential use of biomarkers for testicular toxicity, as well as providing 
a reference for the natural variation seen with the experimental methods in testes 
from control rats. It is important to understand this variation before an objective 
evaluation of tissue from treated animals can be carried out.  
 
Three approaches have been used to investigate potential biomarkers and the 
hypothesis that germ cell derived proteins may leak from seminiferous tubules into 
interstitial fluid due to loss of integrity of the blood-testis barrier or as a direct result 
of germ cell damage following toxicological insult to the testis. A general antibody 
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to seminiferous tubule derived proteins (STCM antibody) was used to evaluate 
changes in a range of seminiferous tubule derived proteins. 1D gels stained with a 
Coomassie dye based stain were used to assess total protein content in samples, and 
specific biomarker candidate proteins were also investigated.  
 
An antibody raised to seminiferous tubule conditioned medium (STCM) was 
prepared by a previous PhD student (Katie Turner, Turner, 1996), and used to 
investigate changes in proteins in samples from heat treated testes in her studies. The 
antibody has been used in these studies in a similar way to investigate differences in 
proteins present in samples from control and toxicant-treated animals. As shown in 
Figure 4-1, the antibody was used to detect a range of proteins in testis sections by 
immunohistochemistry, with stage specific staining, and intense staining in the 
elongate spermatids and weaker staining in the round spermatids. Although the 
proteins are undefined, immunohistochemistry with the antibody to STCM can be 
used to obtain an idea of any changes to the seminiferous tubules following toxicant 
treatment. Western blotting with a homogenised seminiferous tubule sample and 
interstitial fluid sample also showed a range of proteins of different sizes. Western 
blotting with the STCM antibody can be used in investigations into leakage of 
proteins from STs into IF following toxicant treatment by providing an assessment of 
a range of seminiferous tubule derived proteins in interstitial fluid samples. 
 
Immunohistochemistry with the antibody to STCM showed that different proteins are 
present in STs at different stages of spermatogenesis. The stage of spermatogenesis 
might have an affect on the proteins leaking out of STs into IF, so this was 
investigated by dissecting seminiferous tubules from untreated testes, and staging 
them into three groups (I-V, VI-VIII, IX-XIV) using transillumination. Homogenised 
staged tubules were run on a Western blot with the antibody to STCM to compare the 
proteins present. Some sample variability was observed which could be due to 
natural variability, but no obvious differences in the proteins were observed between 
the different staged groups. Quantification of some of the proteins bands did, 
however, suggest an increase in the concentration of three proteins (51kDa, 39kDa 
Chapter 4     Normal Testis and Investigative Tools 115 
and 27kDa) with the VI-VIII group. These results showed that it is essential to run at 
least two samples/group on Western blots to allow for sample variability and also 
that it is useful to quantify bands on Western blots and calculate averages across 
different groups 
 
The differences in proteins observed with the staged STs and Western blot with the 
STCM antibody were further investigated by running the samples on a 1D gel and 
staining with a Coomassie dye based stain to assess the total protein content of the 
samples. Many more protein bands were observed than with the STCM antibody, and 
quantification of a range of proteins suggested that there are no differences in the 
concentrations of the proteins across the different staged groups.  
 
The staged ST investigations introduced the techniques used to evaluate the proteins 
in IF and ST samples in the toxicant studies. Western blotting with the STCM 
antibody has a role in evaluating a range of different ST-derived proteins, and can 
also be used for immunohistochemistry to look at the localisation of the proteins in 
testis sections. Coomassie stained gels have a complementary role, in that they can 
be used to detect proteins in the sample, regardless of origin. However, it is 
important to note, that only 1D gels have been used, and so proteins of similar sizes 
may be masked in one band. Coomassie gels could still be useful for detecting 
proteins that change across groups but aren’t detected with the STCM antibody in the 
evaluation of leakage of proteins from STs into IF. 
 
The third approach taken to investigate the potential for biomarkers for testicular 
toxicity was the selection of potential biomarker candidate proteins, from an 
Affymetrix Genechip® Screen carried out at GSK. The specific protein investigations 
and reasons for selection of the proteins are discussed in chapter 7, but the techniques 
for investigating them are introduced here. Specific antibodies to the proteins of 
interest (ADAM3, calpastatin, DAZL, FABP9, and VASA) were used with 
immunohistochemistry to assess the localisation of the proteins, and later on to 
evaluate any changes following toxicant treatment. The results presented in Figure 
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4-5 show the specificity of the antibodies when used for immunohistochemistry with 
testis sections from control rats. The localisation and stage-specificity of each protein 
can be identified, although the staining for FABP9 was not as distinct as the other 
four proteins. The specific antibodies were also used for Western blotting with IF 
and ST samples. Figure 4-5f shows an example of a blot with the FABP9 antibody 
showing the detection of the protein in a ST sample by the presence of one clear 
band at the expected size of the FABP9 protein (15kDa).  
 
Finally, in order to investigate the hypothesis that proteins may leak from 
seminiferous tubules into interstitial fluid following toxicological damage, and 
whether such leakage is due to loss of integrity of the blood-testis barrier or direct 
germ cell damage, analysis of the blood-testis barrier must be carried out. This 
chapter introduced the techniques used for BTB evaluation in later chapters. Two 
methods were used, immunofluorescent co-staining of blood-testis barrier proteins 
(junction protein and adaptor protein), and immunofluorescent detection of a biotin 
tracer, injected into freshly dissected testes as an evaluation of BTB function.  
 
The blood-testis barrier forms between days 15-19 in the rat (Vitale et al., 1973; 
Russell et al., 1989). Figure 4-6 supports the literature, and showed the presence of 
the tight junction proteins, occludin and ZO-1 present and co-localised at the site of 
the BTB in day 25 rats but absent in day 15 rats. Further investigations involving 
development of the BTB are discussed in chapter 6. 
 
To evaluate the BTB in adult testes, immunofluorescent co-staining was carried out 
for the tight junction pairs, occludin/ZO-1, and claudin-11/ZO-1, and the adherens 
junction pair, N-cadherin/β-catenin, to obtain an assessment of different structural 
components of the BTB. Occludin and ZO-1 are widely used to illustrate the 
integrity of the BTB in published studies (Wong et al., 2004; Wong et al., 2005; Yan 
and Cheng, 2005; Li et al., 2006; Xia et al., 2006; Wong et al., 2007; Kopera et al., 
2009). Clear and consistent co-localisation of occludin and ZO-1 was observed in 
control testis samples, although the absence of occludin was noted in some 
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seminiferous tubules. These tubules were noted to be at stage VIII of 
spermatogenesis, the stage at which the preleptotene spermatocytes traverse the 
BTB. This observation has been described in the literature (Li et al., 2006), although 
only in one study, which is surprising considering how often occludin is used as a 
marker for the BTB. Co-staining for claudin-11 and ZO-1 was less consistent than 
with occludin/ZO-1, however, both proteins could be seen to be localised to the site 
of the BTB in some tubules. On the other hand, some tubules showed only 
expression of one of the proteins. This could be due to the 3D nature of the structure 
of the BTB, with one protein localised below the other in the z-plane. It could also be 
due to the problems with the staining protocol, or alternatively a stage specific effect, 
as seen with occludin. Due to the more consistent immunofluorescent staining with 
occludin/ZO-1, this protocol was used in all investigations to evaluate the tight 
junctions in the BTB. 
 
The adherens junctions were assessed by co-staining for N-cadherin and β-catenin. 
N-cadherin was localised to the site of the blood-testis barrier as well as extending 
around the germ cells. Adherens junction proteins form interactions between Sertoli-
Sertoli cells and Sertoli-germ cells explaining this observation. Co-localisation of N-
cadherin and β-catenin was not observed. Instead β-catenin was localised to the 
nuclei of the preleptotene/leptotene spermatocytes, either side of the blood-testis 
barrier. Although the proteins do not co-localise, they are both found in the same 
area of the tubules, and could be interacting via other adaptor proteins. Co-staining of 
N-cadherin and β-catenin is still a useful tool in the assessment of the adherens 
junctions in the blood-testis barrier. 
 
The second technique used for evaluation of blood-testis barrier function was the 
biotin tracer technique. The biotin tracer, an ester of biotin that cannot penetrate cell 
membranes, was injected into freshly dissected testes, and then detected in the fixed 
tissue by immunofluorescence. If the BTB is functional, then the tracer should 
localise in the interstitum and only in the seminiferous tubules up to the site of the 
BTB. This localisation of the tracer was observed in most control seminiferous 
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tubules. There was, however, some variation in the localisation of the tracer in some 
tubules with some detection of biotin in areas of the adluminal compartment, 
although complete penetration of the tracer into the tubule was not observed in any 
control tissue. The staining patterns observed do not suggest a complete loss of 
integrity of the blood-testis barrier, although could be due to the tracer passing 
through the barrier during restructuring of the junction proteins. It could also be an 
effect of the experimental technique and found in areas of the testis close to the 
injection site, so a larger volume of tracer was present, or due to leaving the testis 
incubating with the injected tracer for slightly longer than other testes, or potentially 
due to hydrolysis of the biotin tracer before it was injected. Although some 
variability was observed with this technique, with analysis of control tissue samples, 
and large n numbers, reliable results were still obtained. 
 
The results presented in this chapter have introduced the concepts and techniques 
used in this investigation of the potential use of biomarkers for testicular damage, as 
well as providing a forewarning of the variation observed in control testicular tissue 
samples in the experimental approaches used in this thesis. 
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5 Leakage of Proteins from Seminiferous Tubules 
following the Administration of known Testicular 
Toxicants 
5.1 Introduction 
Following disruption of spermatogenesis, it is thought that germ cell proteins may 
leak from seminiferous tubules (STs) in the testes into interstitial fluid (IF) (Turner et 
al., 1996). These proteins have the potential to then diffuse into the bloodstream in 
the testis (Figure 5-1). A highly sensitive detection system could then be used to 





Figure 5-1 Germ cell derived proteins may leak from seminiferous tubules into interstitial 
fluid following disruption of spermatogenesis. 
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In order to investigate this hypothesis, it must first be established whether proteins do 
leak from seminiferous tubules into interstitial fluid following toxicological damage, 
and what the conditions leading to such leakage might be. Protein leakage from STs 
into IF could be caused by either germ cell damage or loss of integrity of the blood-
testis barrier. To investigate this, three model testicular toxicants were chosen; 
cadmium chloride, methoxyacetic acid and 1,3-dinitrobenzene, which specifically 
target different components of seminiferous tubules.  
 
5.1.1 Cadmium Chloride  
Cadmium chloride (CdCl2) is a well used tool for both in vivo and in vitro 
investigations involving the blood-testis barrier. It has been shown to cause 
disruption of tight junctions in vitro (Janecki et al., 1992) and in vivo (Hew et al., 
1993b), and has been shown to cause a stage-specific failure of spermiation (Hew et 
al., 1993a). However, the mechanism of action of cadmium chloride on the testes is 
not fully understood. Cadmium toxicity to humans is of increasing concern, and so 
more and more studies investigating the mechanism of such toxicity are emerging. A 
review of the current ideas about the mechanism of cadmium toxicity can be found in 
chapter 2. 
 
The widely studied nature of the effects of cadmium chloride makes it an ideal model 
toxicant to investigate disruption to the blood-testis barrier, and whether this leads to 
leakage of proteins from STs into IF. 
 
5.1.2 Methoxyacetic Acid 
Methoxyacetic acid (MAA) is another well-studied testicular toxicant. It has a stage-
specific effect causing the depletion of pachytene spermatocytes (Bartlett et al., 
1988). The damage is thought to be caused by a disruption of a signal required to 
maintain cell viability, because spermatocytes appear to undergo apoptosis (Bagchi 
and Waxman, 2008). The specific target of MAA makes it ideal for this study, to 
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investigate whether damage to the germ cells (specifically pachytene spermatocytes) 
causes proteins to leak from STs into IF. 
 
5.1.3 1,3-dinitrobenzene 
1,3-dinitrobenzene (DNB) or meta-dinitrobenzene is the third well-studied testicular 
toxicant used in these studies. It has been shown to have effects on Sertoli cells, 
causing vacuolation and retraction of Sertoli cell cytoplasm in the region of the 
primary spermatocytes (Blackburn et al., 1988), and also to have effects on 
spermatocytes and depletion of round spermatids, following prolonged dosing 
periods. The effects on spermatocytes are thought to be secondary to the Sertoli cell 
effects (Blackburn et al., 1988), and result in germ cell apoptosis (Muguruma et al., 
2005). The target specificity of DNB, and its well studied nature, makes it a useful 
toxicant for this study, to investigate whether damage to the Sertoli cells causes 
proteins to leak from STs into IF. 
 
5.1.4 General Aims 
The aim of this chapter was to use the three well defined testicular toxicants as tools 
to investigate whether proteins do leak from the seminiferous tubules into interstitial 
fluid following toxicological insult to the testes, and whether this leakage is due to 
loss of integrity of the blood-testis barrier or damage to germ cells. 
 
The approach to investigating this hypothesis involved treatment of adult male rats 
with the different testicular toxicants, followed by an evaluation of the damage 
caused using immunohistochemistry, an investigation into the leakage of proteins 
from STs into IF by Western blot and Coomassie gel analyses, and finally an 
assessment of the integrity of the blood-testis barrier, using immunofluorescent 
techniques. 
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5.2 Methods 
5.2.1 Treatments & Sample Numbers 
Cadmium chloride, methoxyacetic acid, and 1,3-dinitrobenzene treatments were 
carried out as described in section 3.3. Tissue was collected for fixation (with and 
without biotin tracer) for immunohistochemical and immunofluorescent 
investigations, frozen tissue was collected for PCR analysis, and IF samples were 
collected for Western blot and Coomassie gel analyses. 
 
Initial studies with cadmium chloride treatment examined the use of three doses, 
0.2mg/kg, 1mg/kg, and 3mg/kg cadmium chloride, selected from published literature 
to show a dose response effect (Hew et al., 1993b; Wong et al., 2004). Evaluation of 
the samples collected showed that 3mg/kg CdCl2 had a marked effect on the testes, 
but 0.2 and 1mg/kg did not appear to have any effect. A fourth dose, 1.75mg/kg, was 
chosen as an intermediate dose for future studies, in place of the 0.2mg/kg dose. 
Following selection and trials of these doses, two further studies were set up to 
collect the required tissue. The number of samples collected is shown in Table 5-1. 
There is some variation in the number of each type of sample/group because extra 
control fixed tissue from initial studies has been included, and some interstitial fluid 
samples had dried up in the freezer, due to the small volume collected, before gels 
and Western blots could be run. 
 
With the MAA studies, an initial investigation showed that 200mg/kg was not a high 
enough dose to cause significant damage to spermatocytes, so a second dose of 
650mg/kg was tested. Varying numbers of animals were used in these studies. A 
second repeat study was set up to include the biotin tracer analysis and collect further 
IF samples and frozen tissue. Six animals were used per dose group, collecting 4 
testes for each type of sample/group (Table 5-1). 
 
DNB doses, 25 and 50mg/kg, were selected based on previous studies in the 
laboratory, and published data (Blackburn et al., 1988), as doses expected to cause 
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mild and moderate effects, respectively. Two studies were run with 4 animals/group 
in the first study and 6 animals per dose group in the second, collecting 4 testes for 
each type of sample/group in the second study (Table 5-1). 
 
Table 5-1 Number of Samples collected from CdCl2, MAA and DNB studies. For fixed tissue 
(n) indicates number of fixed tissue samples injected with biotin tracer. 









0 10 (4) 4 7 
1 7 (4) 4 5 
1.75 8 (4) 4 8 
Cd 
3 7 (4) 4 8 
0 7 (4) 4 10 
200 8 (4) 4 8 MAA 
650 6 (4) 4 8 
0 8 (4) 4 8 
25 8 (4) 4 8 DNB 
50 8 (3) 4 8 
 
5.2.2 Treatment Effects – Observations 
Throughout sample collection during all studies, any differences observed between 
the dose groups (reaction to treatment, appearance of tissue) were noted. Differences 
were observed with the higher doses of cadmium chloride (1.75mg/kg and 3mg/kg) 
and the high dose of DNB (50mg/kg). Table 5-2 shows brief descriptions of the 
observed differences. It should be noted that the extreme effects seen with 50mg/kg 
DNB were only observed in the second, repeat, study, and a dose this high would not 
be used in any future DNB studies. It should also be noted that not all animals in 
each group exhibited the same observations, for example, testes from one animal in 
the 3mg/kg CdCl2 group looked completely normal. 
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Table 5-2 Observations during treatment administration and sample collection for all toxicant 
studies. 
Toxicant Dose (mg/kg) Observations 
0, 1 none 
Cd 
1.75, 3 
Animals appeared unwell immediately after 
dosing and were quiet and sedate. 24hrs 
later, animals appeared normal, testes 
purple/dark red appearance, testes more 
compact/solid but more IF/blood than 
control 
MAA 0, 200, 650 none 
0, 25 none 
DNB 
50 
24hrs after administration, one animal 
found dead, others looked unwell, with 
blueness of the extremities (cyanosis) 
 
5.2.3 Treatment Effects – Testis Weight and Interstitial Fluid Volume 
As described in sections 3.2 and 3.4.3, testis and interstitial fluid weights were 
recorded during IF collection. Bodyweights of all animals were also recorded at 
necropsy. Figure 5-2 shows graphs of average testis weight, and IF weight 
(expressed as a ratio of testis weight) for each dose group of each treatment. There 
was a slight trend for an increase in testis weight following cadmium chloride 
treatment and a statistically significant increase in IF weight following treatment 
with 1.75mg/kg and a trend for more IF with 3mg/kg CdCl2. No statistically 
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Figure 5-2 Testis Weights and Interstitial Fluid Weights expressed as ratio of testis weight 
(TW) for each dose group from a) Cadmium chloride study, b) MAA study and c) DNB study 
(mean with SEM). n=8 samples/group except 0mg/kg MAA where n=11. Statistical analysis, 
one-way ANOVA followed by Tukey post-test. * p<0.05 compared to control samples.  
 
5.2.4 Immunohistochemistry & Immunofluorescence 
Immunohistochemistry with the general antibody to seminiferous tubule proteins and 
an antibody to the germ cell protein DAZL, was carried out to investigate the damage 
caused by the toxicants to the testes. The DAB protocol described in section 3.5 was 
used. The presence of apoptotic cells was investigated by TUNEL 
immunohistochemistry (section 3.5.10).  
 
Double immunofluorescence staining was used to investigate the integrity of the 
blood-testis barrier by staining for occludin/ZO-1, claudin-11/ZO-1, and N-
cadherin/β-catenin, following the methods described in section 3.6. The biotin tracer 
(sections 3.3.6) was used for analysis of blood-testis barrier function, and detected by 
immunofluorescence as detailed in section 3.6.7. 
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5.2.5 Protein Analysis 
Proteins present in interstitial fluid samples were separated by 1D gel electrophoresis 
(section 3.8), and analysed by Coomassie-based dye staining (section 3.9) to look at 
total protein, or by Western blotting with the general seminiferous tubule antibody 
(STCM), using the method described in section 3.10. 
 
5.2.6 TaqMan® Q-PCR 
Snap-frozen tissue collected from the cadmium chloride, MAA, and DNB studies 
was used for RNA isolation. cDNA was made from the isolated RNA samples, and 
used in the TaqMan® reaction with primers and probes for the blood-testis barrier 
genes, occludin, claudin-11, JAM-A, ZO-1, N-cadherin, and β-catenin. GAPDH was 
analysed as a control gene, and results are expressed relative to GAPDH expression. 
Detailed methods are described in section 3.11. 
 
5.3 Results 
5.3.1 Cadmium Chloride 
5.3.1.1 Analysis of Damage caused by Cadmium Chloride Treatment 
Cadmium chloride is a model testicular toxicant and is reported to disrupt the blood-
testis barrier selectively at low doses. Four doses were selected, based on previous 
reports in the literature, to show a range of treatment effects, from mild to moderate.  
Figure 5-3 clearly shows the dose response effect seen with the different doses. 
Immunohistochemistry with the antibody to seminiferous tubule conditioned medium 
detected a range of ST proteins and can be used to show the treatment effects at each 
dose. Testis sections from animals treated with 0.2mg/kg cadmium chloride or 
1.0mg/kg cadmium chloride were comparable to control tissue, and suggest that there 
had been no effect of the treatment on the gross organisation of the STs. For this 
reason and in consideration of the 3Rs, the 0.2mg/kg dose was not included in repeat 
treatment studies. Testis sections from animals treated with either 1.75mg/kg or 
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3mg/kg cadmium chloride, and immunostained with the STCM antibody, showed 
disruption of the gross organisation of the STs, although the tubules themselves 
appeared intact. The effects seen with 3mg/kg cadmium chloride appeared more 
marked than those with the 1.75mg/kg dose. 
 
 
Figure 5-3 Testis sections from a) control (0.9% saline) rats and rats treated 24 hours earlier 
with b) 0.2mg/kg CdCl2, c) 1.0mg/kg CdCl2, d) 1.75mg/kg CdCl2 or e) 3.0mg/kg CdCl2, 
immunostained with an antibody to seminiferous tubule conditioned medium (brown) and 
counterstained with haematoxylin (blue). Scale bar represents 100µm. 
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5.3.1.2 Analysis of Protein Leakage 
The STCM antibody was also used to detect general changes in the proteins present 
in interstitial fluid collected from rats treated with 1.0, 1.75 and 3.0mg/kg CdCl2 
using Western blotting. Figure 5-4a shows a representative Western blot, with two 
samples from each dose group run with the STCM antibody. A total of four blots 
were run to ensure all samples collected were used in the quantification analysis (n=7 
for control, n=5 for 1mg/kg and n=8 for 1.75mg/kg and 3mg/kg). Quantification for 




Figure 5-4 a) Representative Western Blot with antibody to STCM, showing interstitial fluid 
samples from control rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2 and control 
homogenised seminiferous tubules (ST). Arrows indicate examples of protein bands 
quantified. b) Graphs showing quantification of 32kDa and 15kDa bands (mean with SEM), 
with values taken from samples run on four separate Western blots, expressed as a 
percentage of STs (n=7 for control, n=5 for 1mg/kg and n=8 for 1.75mg/kg and 3mg/kg). 
Statistical analysis, one-way ANOVA followed by Tukey post-test. *** p<0.001 compared to 
control samples. 
 
As shown previously (section 4.3.1) the STCM antibody detected a large number of 
proteins. These could be germ cell derived, Sertoli cell derived or peritubular cell 
derived. In order to investigate the hypothesis that proteins leak out of STs into IF 
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under toxicological insult, control STs were run on every Western blot as a 
comparison and in order to identify the presence of ST derived proteins in IF 
samples. 
 
Figure 5-4a shows a clear difference in the number of proteins present in IF from rats 
treated with 3mg/kg cadmium chloride, compared to IF from control rats. Two 
protein bands (32kDa, and 15kDa) were selected for quantification because they 
were present in the control ST sample, and because they appeared to show a dose 
response effect across IF samples. Despite observation of the band for the 32kDa 
protein only being present in the 3mg/kg CdCl2 IF sample on the Western blot, the 
graph in Figure 5-4b, suggests that there is no significant difference in the presence 
of this protein across the CdCl2 doses. This difference between observation and 
quantification, illustrates the importance of using a method for quantification and 
combining results from as many samples as possible run on different gels. 
 
The second protein band with a size of 15kDa showed a different result when 
quantified. The Western blot shown in Figure 5-4a suggested a dose response effect 
of CdCl2 in inducing leakage/presence of this protein in IF samples. The 
quantification graph in Figure 5-4b showed a significantly greater amount of this 
protein present in IF samples from animals treated with 3mg/kg CdCl2 compared to 
control IF.  This graph also suggested that there was more 15kDa protein present in 
IF from animals treated with 1.75mg/kg CdCl2 compared to control, although this 
difference was not statistically significant. The large 15kDa band seen on the blot in 
the control ST sample, suggested that this protein is leaking from the STs into IF 
following treatment with high doses (3mg/kg and to an extent 1.75mg/kg) of 
cadmium chloride. 
 
Although the Western blot with the STCM antibody shows some differences in the 
proteins present in IF collected from each dose group, there are likely to be many 
more proteins present in the samples that are not detected by antibodies in the 
STCM, some of which may also be present at different levels in the different dose 
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groups, and like the 15kDa protein, may also appear to leak from STs into IF with 
high dose treatment of cadmium chloride. In order to investigate this, 1D protein gels 
were run, and stained with Gelcode, a Coomassie dye based stain, in order to look at 
all the proteins present in the samples. 
 
Figure 5-5a shows a representative Coomassie stained gel, with IF samples from the 
four cadmium chloride dose groups. A comparison of this gel and the STCM 
Western blot (Figure 5-4), showed many more proteins being detected with the 
Coomassie stain. Again there were clear differences between IF samples from the 
different cadmium chloride dose groups and more proteins were observed in IF 
samples from the 1.75 and 3mg/kg dose groups, compared to IF collected from 
control animals. This suggests that the higher doses of cadmium chloride are causing 
an increase in the number of proteins present in IF, presumably due to leakage of 
proteins from the seminiferous tubules. A range of protein bands were quantified, 
using ImageQuant software (refer to section 3.9.1) and results for nine such bands in 
all samples run on a total of four gels are shown in Figure 5-4b. Bands were selected 
for quantification due to ease of quantification, and their presence in the control ST 
sample as this ensured that they could have leaked from STs into IF. 
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Figure 5-5 a) Representative Coomassie gel, showing interstitial fluid samples from control 
rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2 and control homogenised 
seminiferous tubules (ST). Arrows indicate examples of protein bands quantified. b) Graphs 
showing quantification of indicated bands (mean with SEM), with values taken from samples 
run on four separate gels, expressed as a percentage of STs (n=8 samples/dose group, 
except 1mg/kg CdCl2 where n=5). Statistical analysis, one-way ANOVA followed by Tukey 
post-test. * p<0.05, ** p<0.01, *** p<0.001, compared to control samples. 
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The graphs show that there were differences in IF protein levels across the CdCl2 
doses with some of the selected proteins (39kDa, 32kDa, 25kDa, 17kDa, 15kDa and 
12kDa), whereas for others (45kDa, 28kDa, and 27kDa) there did not appear to be 
much change across the dose groups. Four proteins were present in significantly 
higher amounts in IF samples from animals treated with 3mg/kg CdCl2, compared to 
control IF samples. These were 32kDa, 25kDa, 17kDa, and 15kDa in size, and these 
also showed an increase in IF protein levels with the 1.75mg/kg dose as well, 
although this was not statistically significant in all cases. The presence of these 
proteins in the control ST samples again suggests that these are ST proteins, which 
have leaked out into the IF following administration of high dose cadmium chloride.  
 
The final two proteins, 39kDa, and 12kDa, showed a different pattern across the 
CdCl2 dose groups, with a significantly higher (compared to control) amount present 
in IF from animals treated with 1.75mg/kg CdCl2. With both proteins there was, 
however, no statistically significant difference in concentration across the three dose 
groups. This suggests that there could be an increase in concentration of these 
proteins following any dose of cadmium chloride or there could be a dose response 
up to 1.75mg/kg, but perhaps the same amount (or more) is leaking out following 
treatment with 3mg/kg CdCl2 and then leaking out of the IF, possibly into the blood. 
This is probably unlikely as it does not appear to be happening with the other 
proteins quantified, and the two proteins in question are different sizes. 
 
5.3.1.3 Analysis of Blood-Testis Barrier Integrity 
To investigate whether the CdCl2-induced protein leakage was due to loss of 
integrity of the blood-testis barrier (BTB), the tight junctions, adherens junctions and 
overall function of the BTB were assessed using immunofluorescent techniques.  
 
Figure 5-6 shows co-localisation of the tight junction protein, occludin, and adaptor 
protein, ZO-1, at the site of the BTB in control tissue (panel a). Following treatment 
with 0.2mg/kg or 1.0mg/kg cadmium chloride, the tight junctions still appeared to be 
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intact, as shown by co-localisation of occludin and ZO-1 at the site of the BTB 
(panels b, c). In panels d and e, showing testis sections from animals treated with 
1.75mg/kg and 3.0mg/kg CdCl2 respectively, neither occludin nor ZO-1 could be 
identified at the site of the BTB. This suggests that the integrity of the BTB has been 
disturbed, as least in part via loss of occludin and ZO-1 from the tight junctions. 
 
A further tight junction protein, claudin-11 was also assessed to confirm whether 
other components of the BTB had been disturbed following high dose cadmium 
chloride treatment. Figure 5-7 shows claudin-11 and ZO-1 localised to the site of the 
BTB in control tissue and tissue from animals treated with 1.0mg/kg CdCl2. The 
variations seen were discussed in chapter 4. With testis sections from animals treated 
with 1.75mg/kg and 3.0mg/kg CdCl2, some green staining (ZO-1) was observed 
although it is hard to tell whether this represents background or true staining. Either 
way,   ZO-1 did not appear to be localised to the site of the BTB, as was seen with 
the control tissue. Claudin-11 was also no longer localised to the site of the BTB 
following treatment with 1.75mg/kg or 3.0mg/kg CdCl2. 
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Figure 5-6 Co-localisation of ZO-1 (green) and occludin (red) with Dapi nuclear counterstain, 
in testis sections from a) control (0.9% saline) rats and rats treated 24 hours earlier with b) 
0.2mg/kg CdCl2, c) 1.0mg/kg CdCl2, d) 1.75mg/kg CdCl2 or e) 3.0mg/kg CdCl2. Scale bar 
represents 50µm. 
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Figure 5-7 Co-localisation of ZO-1 (green) and claudin-11 (red) with Dapi nuclear 
counterstain in testis sections from a) control (0.9% saline) rats and rats treated 24 hours 




These results support the results found with occludin and ZO-1 (Figure 5-6), and 
together they suggest that the integrity of the tight junctions in the BTB has been 
disturbed following treatment with 1.75mg/kg or 3.0mg/kg CdCl2. Although, there 
are many other tight junction proteins present in the BTB, an assessment of the three 
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proteins investigated seems sufficient to allow reasonable conclusions to be drawn. 
Two adherens junction proteins, N-cadherin and β-catenin, were also investigated to 
assess whether further components, other than the tight junctions, are disrupted in the 
BTB. 
 
N-cadherin is an adherens junction protein, and can be clearly seen in red at the site 
of the BTB in control tissue in Figure 5-8a. β-catenin, an adherens junction adaptor 
protein can also be seen in Figure 5-8a localised around the nuclei of spermatocytes 
in the vicinity of the BTB (variation in staining patterns described in chapter 4). A 
similar staining pattern was seen in testis sections from animals treated with 
1.0mg/kg CdCl2. However, with testis sections from animals treated with 1.75mg/kg 
or 3.0mg/kg CdCl2, this staining pattern was disrupted (Figure 5-8c,d). Thus, 
although some immunostaining for N-cadherin and β-catenin was evident localised 
around the area of the BTB, no distinct staining pattern along the site of the BTB was 
evident as was evident in control tissue. These results agree with the tight junction 
proteins previously investigated, and suggest that the adherens junctions at the site of 
the BTB are disrupted following treatment with 1.75mg/kg or 3.0mg/kg CdCl2.  
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Figure 5-8 Co-localisation of β-catenin (green) and N-cadherin (red) with Dapi nuclear 
counterstain in testis sections from a) control (0.9% saline) rats and rats treated 24 hours 




A final immunofluorescent method to assess whether the BTB is functional was 
investigated, using injections of a biotin tracer and a fluorescent detection system. 
Figure 5-9, panel a, shows the biotin tracer localised to the interstitum, and 
surrounding spermatocytes on the interstitial side of the BTB (shown by the presence 
of occludin).  The BTB was fully functional in control tissue, because as the tracer is 
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not membrane permeable, it cannot penetrate into the tubule if the BTB is functional. 
In animals treated with 1.0mg/kg CdCl2, a similar staining pattern was seen, agreeing 
with the results seen with the specific junction proteins and showing that the BTB is 
functional in the testis. A similar pattern was again seen with tissue from animals 
treated with 1.75mg/kg CdCl2 (Figure 5-9c), which contrasts with results for specific 
proteins in the BTB discussed above. This disparity could be due to the section of the 
testis used for the immunostaining – damage and disruption of the testis could have 
occurred in certain areas away from where the tissue was sectioned. Also this is an 
intermediate dose and some tubules could have been affected whereas others could 
appear normal.  
 
With the 3.0mg/kg CdCl2 treatment, no occludin was detected, as shown above, and 
the biotin tracer had penetrated the seminiferous tubule (Figure 5-9d). This agrees 
with the other results above with this dose and the individual junction proteins 
investigated, and further supports the idea that the BTB has been disrupted both 
structurally and functionally following treatment with 3.0mg/kg CdCl2. 
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Figure 5-9 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain in testis sections from a) control (0.9% saline) rats and rats treated 24 hours 
earlier with b) 1.0mg/kg CdCl2, c) 1.75mg/kg CdCl2 or d) 3.0mg/kg CdCl2. Scale bar 
represents 50µm. 
 
Analysis of mRNA expression of the BTB genes, occludin, claudin-11, JAM-A, ZO-
1, N-cadherin, and β-catenin is shown in Figure 5-10. There was a significant 
decrease in the expression of the gene for the tight junction protein, occludin, relative 
to GAPDH expression, following treatment with 3mg/kg CdCl2, this agrees with 
results for occludin protein visualised with immunofluorescence. A significant 
reduction in expression of claudin-11, JAM-A and ZO-1, relative to GAPDH 
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expression was also observed following treatment with 1.75mg/kg CdCl2, supporting 
the immunofluorescent data as claudin-11 and ZO-1 proteins were all depleted 
following treatment with 1.75mg/kg CdCl2 (see above). These results are, however, 
surprising as the protein data suggests that there should also be a decrease in 
expression of these tight junction genes following treatment with 3mg/kg CdCl2, and 
this was not observed (Figure 5-10). 
 
No differences in mRNA expression were seen with either of the adherens junction 
genes investigated, although there were downward trends in the CdCl2 treated 
animals. Some variability in the data was noted, and results from one animal in the 
CdCl2 high dose group were excluded as the histological analysis of one of the testes 
showed that the treatment had not had an effect on the structure of the testis. No 
significant differences were noted in the expression of the other control genes, 
SPAG5 and 3βHSD (not shown). These results suggest that there is an effect on 
mRNA expression for all four tight junction proteins following treatment with either 
1.75 or 3mg/kg cadmium chloride, although a larger sample size should probably be 
used to achieve more accurate results. 
 
Figure 5-10 TaqMan® analysis of blood-testis barrier genes in testis samples collected from 
animals treated with cadmium chloride (mean with SEM). Expression relative to GAPDH 
expression. n=4 samples/dose group except 3mg/kg CdCl2 where n=3. Statistical analysis, 
one-way ANOVA followed by Tukey post-test. * p<0.05, *** p<0.001 compared to control 
samples. 
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5.3.2 Methoxyacetic Acid 
5.3.2.1 Analysis of Damage caused by MAA Treatment 
Methoxyacetic acid (MAA) is another model testicular toxicant. It is well studied and 
known to induce death of pachytene spermatocytes by apoptosis leading to infertility 
(Tirado et al., 2003). MAA was selected as a second toxicant treatment to further 
investigate the protein leakage hypothesis and to investigate whether specific damage 
to germ cells also leads to leakage of proteins from STs into IF. 
 
Two MAA doses were chosen based on previous reports in the literature, to show a 
range of treatment effects, from mild to moderate (Bartlett et al., 1988; Tirado et al., 
2003).  Figure 5-11 shows the damage caused by each dose of MAA treatment. 
Three immunohistochemistry markers were used. Panels a-c show the proteins 
detected by the general STCM antibody, panels d-f show the germ cell marker, 
DAZL, and panels g-i show the apoptosis marker TUNEL.  
 
The general antibody to ST proteins showed that the 650mg/kg dose of MAA caused 
notable damage to the seminiferous tubules. This was most clearly visualised by 
examination of sections stained for the DAZL protein. DAZL is a germ cell protein 
that localises to pachytene spermatocytes in control tissue (Figure 5-11d). Following 
treatment with 650mg/kg MAA, the DAZL staining pattern was more sparse towards 
the basal compartment indicating a loss of pachytene spermatocytes, as expected 
with this dose of MAA. Treatment with 200mg/kg MAA showed an intermediate 
effect with loss of some pachytene spermatocytes but not to the extent seen with the 
650mg/kg dose.  
Figure 5-11 Testis sections from control (0.9% saline) rats and rats treated 24 hours earlier with 200mg/kg MAA or 650mg/kg MAA, 
immunostained with a-c) an antibody to seminiferous tubule conditioned medium (brown), d-f) DAZL (brown) and g-i) TUNEL (brown), all 
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The final marker used to illustrate the damage caused by MAA treatment in Figure 
5-11 was TUNEL, a marker of apoptosis. Panels g-i show an increase in the number 
of apoptotic cells across the dose groups. Comparing this to the effect observed in 
panels d-f with an increasing loss of spermatocytes across the dose groups, it is likely 
that this loss of spermatocytes is caused by treatment induced apoptosis of the 
spermatocytes. 
 
5.3.2.2 Analysis of Protein Leakage 
The STCM antibody was also used to investigate protein leakage from STs into IF, 
following MAA treatment. Figure 5-12a shows a representative Western blot with 
two samples from each dose group run with the STCM antibody. A total of four blots 
were run to ensure all samples collected were used in the quantification analysis 
(n=10 for control, n=8 for treated). Quantification for two protein bands on the 
Western blots is shown in Figure 5-12b. 
 
From the Western blots, there did not appear to be any major differences between the 
STCM antibody-detected proteins present in control IF when compared to IF 
collected from animals treated with 200mg/kg or 650mg/kg MAA. Control STs were 
run alongside IF samples to assess whether ST proteins were leaking into IF 
following toxicant treatment, and to allow normalisation of bands during 
quantification of bands on different Western blots.  
 
Two proteins bands, at 27kDa and 15kDa, were quantified from this Western blot 
(Figure 5-12b). The graphs show no significant differences between the amount of 
these proteins present in control IF, compared to the amount present in IF from 
animals treated with 200mg/kg or 650mg/kg MAA and the values obtained probably 
represent background ‘noise’.  However, there did appear to be a trend with the 
15kDa protein for more present in IF from 650mg/kg MAA treated animals. As 
before, with the cadmium chloride studies, protein leakage was further investigated 
by running IF samples on Coomassie stained gels. 
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Figure 5-12 a) Representative Western blot with antibody to STCM, showing interstitial fluid 
samples from control rats and animals treated with 200 or 650mg/kg MAA and control 
homogenised seminiferous tubules (ST). Arrows indicate examples of protein bands 
quantified. b) Graphs showing quantification of 27kDa and 15kDa bands (mean with SEM), 
with values taken from samples run on four separate Western blots, expressed as a 
percentage of STs (n=10 for control, n=8 for treated). No significant differences following 
statistical analysis (one-way ANOVA followed by Tukey post-test). 
 
Figure 5-13 shows a representative gel with IF samples from control animals, and 
those treated with either 200mg/kg or 650mg/kg MAA, and control STs for 
comparison between gels, and identification of ST proteins, stained with Gelcode 
Coomassie stain. As expected, many more proteins were identified on this gel 
compared to the Western blot in Figure 5-12. However, inspection of the bands on 
the gel also suggested that there were no major differences in proteins present in IF 
from control animals and those treated with 200mg/kg or 650mg/kg MAA. Six 
protein bands were quantified and the results are shown in Figure 5-13. 
Quantification indicated no significant differences between the amount of each 
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Figure 5-13 a) Representative Coomassie gel, showing interstitial fluid samples from control 
rats and animals treated with 200 or 650mg/kg MAA and control homogenised seminiferous 
tubules (ST). Arrows indicate examples of protein bands quantified. b) Graphs showing 
quantification of indicated bands (mean with SEM), with values taken from samples run on 
four separate gels, expressed as a percentage of STs (n=10 for control, n=8 for treated). No 
significant differences following statistical analysis (one-way ANOVA followed by Tukey post-
test). 
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These interstitial fluid analyses suggest that proteins are not leaking out of STs into 
IF following degeneration and loss of pachytene spermatocytes following MAA 
treatment. Analysis of the integrity of the BTB was also carried out with MAA 
treated tissue to confirm whether the barrier was intact and therefore preventing 
proteins leaking out of the tubules.   
 
5.3.2.3 Analysis of Blood-Testis Barrier Integrity 
As with the cadmium chloride studies, integrity of the blood-testis barrier was 
investigated by immunofluorescent analysis of junction proteins and by using the 
biotin tracer. Figure 5-14 shows immunofluorescent co-localisation studies for the 
tight junction protein pairs, ZO-1 and occludin, and ZO-1 and claudin-11, and the 
adherens junction protein pair, β-catenin and N-cadherin. In panel a, ZO-1 and 
occludin can be seen to be co-localised at the site of the BTB in control tissue.  In b 
and c, ZO-1 and occludin can, again, be seen co-localised at the site of the BTB, 
suggesting that the integrity of the tight junctions in the BTB has not been 
compromised by treatment with either 200mg/kg or 650mg/kg MAA. Results with 
ZO-1 and claudin-11 (shown in panels d-f), suggest the same conclusion, although 
the problems with this immunofluorescent staining combination as described 
previously (chapter 4) should be noted. The adherens junction proteins, β-catenin and 
N-cadherin, shown in panels g-i are located at the site of the BTB in the control 
tissue, as well as in tissue taken from animals treated with either 200mg/kg or 
650mg/kg MAA. This agrees with the results seen with the tight junction proteins, 
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Figure 5-14 Testis sections from control (0.9% saline) rats and rats treated 24 hours earlier 
with 200mg/kg MAA or 650mg/kg MAA, showing co-immunofluorescence for a-c) ZO-1 
(green) and occludin (red), d-f) ZO-1 (green) and claudin-11 (red) and g-i) β-catenin (green) 
and N-cadherin (red), all counterstained with dapi (blue). Scale bar represents 50µm. 
 
The functionality of the BTB following MAA treatment was investigated using the 
biotin tracer. Figure 5-15 shows detection of the tracer, and the location of occludin 
and, therefore, the site of the BTB.  In panel a, control tissue, the biotin tracer can be 
detected in the interstitum, and up to the BTB, showing that the barrier is functional. 
The same can be seen with testes collected from animals treated with either 
200mg/kg or 650mg/kg MAA, showing that the BTB is fully functional in the tissue. 
This agrees with the results seen looking at the co-localisation of the individual 
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Figure 5-15 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain, in testis sections from a) control (0.9% saline) rats and rats treated 24 hours 
earlier with b) 200mg/kg MAA, or c) 650mg/kg MAA. Scale bar represents 50µm. 
 
 
Analysis of the genes for BTB proteins, occludin, claudin-11, JAM-A, ZO-1, N-
cadherin and β-catenin, by TaqMan® PCR is shown in Figure 5-16. No significant 
differences in the number of mRNA copies for all six genes, relative to GAPDH 
expression was observed across the MAA dose groups. This supports the protein 
results shown above, and suggests that there are no differences in expression of the 
BTB proteins or their genes following treatment with either dose of MAA, despite 
the 650mg/kg dose clearly having a major adverse effect on pachytene 
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Figure 5-16 TaqMan® analysis of blood-testis barrier genes in testis samples collected from 
animals treated with MAA (mean with SEM). Expression relative to GAPDH expression. n=4 
samples/dose group except 200mg/kg MAA for β-catenin where n=3. No significant 
differences following statistical analysis (one-way ANOVA followed by Tukey post-test).  
 
Two DNB doses were chosen based on previous reports in the literature, to show a 
range of treatment effects, from mild to moderate. Figure 5-17 shows the damage 
caused by each treatment dose. As with MAA, three immunohistochemistry markers 
were used to evaluate treatment effects. Panels a-c show the proteins detected by the 
general STCM antibody, panels d-f show the germ cell marker, DAZL, and panels  
g-i show the apoptosis marker TUNEL.  
 
1,3-dinitrobenzene (DNB) is another model testicular toxicant. It is known to 
specifically target Sertoli cells (Blackburn et al., 1988). DNB was selected as a third 
toxicant treatment to further investigate the protein leakage hypothesis and to 
investigate whether specific damage to Sertoli cells would lead to leakage of proteins 
from STs into IF. 




Figure 5-17 Testis sections from control (corn oil) rats and rats treated 24 hours earlier with 25mg/kg DNB or 50mg/kg DNB, immunostained with 
a-c) an antibody to seminiferous tubule conditioned medium (brown), d-f) DAZL (brown) or g-i) TUNEL (brown), all counterstained with 
haematoxylin (blue). Arrows indicate Sertoli cell vacuolation caused by DNB treatment. Scale bar represents 100µm. 
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The general antibody to ST proteins revealed evidence of damage to the organisation 
of the tubules following treatment with 50mg/kg DNB. However, the germ cell 
marker DAZL gave a better picture of the damage caused. A loss of spermatocytes 
was evident after treatment with either 25mg/kg DNB or 50mg/kg DNB (panels e,f). 
These images also showed damage via vacuolation of the Sertoli cells with both 
doses. Qualitative analysis of apoptotic cells (shown in panels g-i), identified by 
TUNEL staining, suggested an increase in the number of apoptotic cells after either 
DNB dose when compared to control. 
 
5.3.3.2 Analysis of Protein Leakage 
The leakage of proteins from STs into IF following DNB treatment was investigated 
using Western blots with the antibody to STCM, followed by further analysis with 
Coomassie stained gels. Figure 5-18 shows a representative Western blot with IF 
collected from animals treated with control, 25mg/kg or 50mg/kg DNB, run 
alongside control STs for protein band comparison, and probed with the general 
antibody to ST proteins. The blot shows that a similar number of proteins are 
detected in each IF sample, and at about the same level, except in the first 25mg/kg 
DNB sample where there appeared to be more of every protein detected. Because 
there appeared to be an increase in the amount of every protein, this suggests that 
perhaps slightly more total protein was loaded into this lane on the original gel. It is 
for this reason that all samples (n=8 samples/dose group) were run on Western blots, 
and selected protein bands were then quantified and expressed in the graphs in Figure 
5-18b. The graphs for the 27kDa protein and 15kDa protein showed no significant 
differences in the amount of protein detected in IF from animals in either control or 
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Figure 5-18 a) Representative Western blot with antibody to STCM, showing interstitial fluid 
samples from control rats and animals treated with 25 or 50mg/kg DNB and control 
homogenised seminiferous tubules (ST). Arrows indicate examples of protein bands 
quantified. b) Graphs showing quantification of 27kDa and 15kDa bands (mean with SEM), 
with values taken from samples run on four separate Western blots, expressed as a 
percentage of STs (n=8 samples/dose group). No significant differences following statistical 
analysis (one-way ANOVA followed by Tukey post-test). 
 
 
Coomassie stained gels were also used to investigate whether proteins leaked from 
STs into IF following DNB treatment. Figure 5-19 shows a representative gel. As 
with the other treatments, many more proteins were identified with Coomassie 
staining, compared to Western blotting with the STCM antibody, although these 
proteins were also unknown. Six protein bands were quantified from the gel (and a 
further three gels, containing all the other IF samples collected from each animal 
treated in the DNB studies), and the results are shown in Figure 5-19b. The 
combined graphs showed no significant differences in the amount of any of the six 
proteins across the DNB dose groups. Particular attention should be paid to the 
proteins of sizes 15kDa and 12kDa which showed a dose related increase in IF in 
cadmium chloride treated animals (Figure 5-5). 
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Figure 5-19 a) Representative Coomassie gel, showing interstitial fluid samples from control 
rats and animals treated with 25 or 50mg/kg DNB and control homogenised seminiferous 
tubules (ST). Arrows indicate examples of protein bands quantified. b) Graphs showing 
quantification of indicated bands (mean with SEM), with values taken from samples run on 
four separate gels, expressed as a percentage of STs (n=8 samples/dose group). No 
significant differences following statistical analysis (one-way ANOVA followed by Tukey post-
test). 
 
The results from the Coomassie gels and the Western blots with STCM antibody 
suggest that proteins are not leaking out of the seminiferous tubules into the 
interstitial fluid following damage to the Sertoli cells, and loss of spermatocytes 
caused by DNB treatment. Analysis of the integrity of the BTB was carried out to 
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confirm whether the barrier was still intact and functional following DNB treatment, 
and therefore preventing protein leakage out into the IF. 
 
5.3.3.3 Analysis of Blood-Testis Barrier Integrity 
The integrity of the BTB following DNB treatment was assessed by 
immunofluorescence studies of junction proteins, and by using the biotin tracer. 
Figure 5-20 panels a-c show the tight junction proteins ZO-1 and occludin. Both 
proteins can be seen to co-localise at the site of the BTB in control tissue, and in 
testes from animals treated with either 25mg/kg or 50mg/kg DNB, suggesting that 
the tight junctions have not been disrupted. A third tight junction protein, claudin-11 
was also investigated. The results, shown in panels d-f, also showing the tight 
junction accessory protein ZO-1, suggest that claudin-11 is present in tubules across 
the dose groups, although ZO-1 and claudin-11 do not appear to co-localise at the 
BTB in every tubule. The problems with immunofluorescent detection of this tight 
junction protein pair were discussed in chapter 4, and due to these problems, the 
results seen with claudin-11 and in testes from DNB treated animals also suggested 
that the tight junctions are still intact. The adherens junction protein pair, β-catenin 
and N-cadherin, were also investigated following DNB treatment. Figure 5-20g-i 
shows the localisation of both proteins at the site of the BTB, and suggests no 
differences in the state of the adherens junctions between control tissue, and that 
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Figure 5-20 Testis sections from control (corn oil) rats and rats treated 24 hours earlier with 
25mg/kg DNB or 50mg/kg DNB, co-immunofluorescence with a-c) ZO-1 (green) and occludin 
(red), d-f) ZO-1 (green) and claudin-11 (red) or g-i) β-catenin (green) and N-cadherin (red), 
all counterstained with dapi (blue). Scale bar represents 50µm. 
 
 
Finally, the function of the barrier following DNB treatment was investigated using 
the biotin tracer. Figure 5-21 shows immunofluorescence detection of the biotin 
tracer, and the site of the BTB via detection of occludin. In control tissue (panel a), 
the biotin tracer is localised to the interstitum and the tubules, up to the site of the 
BTB. With tissue from animals treated with 25mg/kg or 50mg/kg DNB, the same 
distribution of biotin tracer can be seen (panels b, c), with no penetration of the biotin 
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tracer into the centre of the tubules. This shows that the blood-testis barrier is 




Figure 5-21 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain, in testis sections from a) control (corn oil) rats and rats treated 24 hours earlier 
with b) 25mg/kg DNB, or c) 50mg/kg DNB. Scale bar represents 50µm. 
 
 
Analysis of the genes for the BTB proteins, occludin, claudin-11, JAM-A, ZO-1, N-
cadherin and β-catenin, by TaqMan® PCR is shown in Figure 5-22. The results 
showed no significant differences in expression of any of the genes investigated, 
relative to GAPDH expression, across the dose groups, suggesting that the DNB 
treatment has had no effect on expression of these genes in the 24 hours following 
administration of treatment. This agrees with the protein investigations above, where 
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Figure 5-22 TaqMan® analysis of blood-testis barrier genes in testis samples collected from 
animals treated with DNB (mean with SEM). Expression relative to GAPDH expression. n=4 
samples/dose group. No significant differences following statistical analysis (one-way 
ANOVA followed by Tukey post-test).  
 
5.4 Discussion 
It was hypothesised that germ cell proteins might leak from seminiferous tubules into 
interstitial fluid following toxicological insult. To investigate whether this protein 
leakage occurred and whether it was due to loss of integrity of the blood-testis barrier 
or was simply a consequence of germ cell damage, adult male rats were treated with 
one of three known testicular toxicants which target different aspects of the testis; 
cadmium chloride, methoxyacetic acid, 1,3-dinitrobenzene. 
 
The damage caused by cadmium chloride treatment was investigated by 
immunohistochemistry with the general seminiferous tubule protein antibody. Dose 
dependent damage was observed, with disruption of the gross organisation of the 
seminiferous tubules following treatment with the intermediate (1.75mg/kg CdCl2) 
and high (3mg/kg CdCl2) doses. Observations at the sample collection stage also 
suggested an effect with the two higher doses. The testes from most of the animals in 
the 1.75 and 3mg/kg dose groups were a dark purple colour and were more turgid 
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than the control and low dose animals. Increases in interstitial fluid weight were also 
observed with the two higher dose groups. A 0.2mg/kg cadmium chloride dose group 
was included in initial studies but following histological examination, no differences 
were seen with this dose compared to vehicle control treatment. For this reason and 
considering the 3Rs, this dose was not included in further studies. The 1mg/kg, 
1.75mg/kg and 3mg/kg groups were continued. 
 
Leakage of proteins from the seminiferous tubules into interstitial fluid following 
high dose cadmium chloride treatment was suggested from Western blots using the 
STCM antibody. More protein bands were detected in IF samples from animals 
treated with 1.75mg/kg or 3mg/kg CdCl2, and quantification of a 15kDa band 
suggested it was leaking from STs into IF. Quantification of a 32kDa protein band 
suggested that this protein was not leaking from STs into IF. This could be because 
this protein is naturally present in the interstitial fluid. 
 
Protein leakage was further investigated using Coomassie dye stained gels, to 
evaluate changes in total protein in the IF samples. A clear dose related increase in 
the number of proteins present in the IF samples was identified across all four dose 
groups which suggested leakage of proteins from STs into IF following cadmium 
chloride treatment. Quantification of the protein bands suggested that some proteins 
increased in concentration in IF following treatment with the higher doses of CdCl2, 
such as the 25kDa, and 15kDa bands. The concentration of some proteins in the IF 
samples did not appear to change with any dose of CdCl2, such as the 45kDa protein; 
this could be because the protein is naturally present in IF, or perhaps more than one 
protein of the same size is present in the IF samples, masking any dose related 
changes. Other proteins appeared to be present in higher concentrations in the 
1.75mg/kg dose group, compared to control, although no significant differences were 
observed between this dose group and the other two doses, suggesting that there 
could be a general effect on leakage of the proteins following treatment with any 
dose of cadmium chloride. Nevertheless, the Coomassie gels supported the Western 
blot results, and suggested that some proteins do leak out of seminiferous tubules 
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into interstitial fluid following treatment with high doses of cadmium chloride 
(1.75mg/kg, 3mg/kg).  
 
The integrity of the blood-testis barrier was assessed to investigate whether the 
protein leakage observed could be due to loss of integrity of the barrier.                 
Co-localisation studies of the tight junction proteins, ZO-1 and occludin, and ZO-1 
and claudin-11, suggested that the tight junctions were disrupted following treatment 
with 1.75mg/kg or 3mg/kg cadmium chloride. Little or no ZO-1, occludin and 
claudin-11 protein was identified in the seminiferous tubules following these doses, 
with the little immunofluorescent staining that was evident suggesting that any 
protein present was not localised to the site of the blood-testis barrier. In comparison, 
the tight junction proteins were clearly co-localised at the site of the blood-testis 
barrier in control tissue and in that from animals treated with 0.2mg/kg and 1mg/kg 
cadmium chloride. The integrity of the adherens junctions in the BTB were also 
analysed using immunofluorescent co-localisation of N-cadherin and β-catenin. 
Whilst the results were generally in line with what was found for the tight junction 
proteins, the findings were less clear than with the tight junction proteins. N-cadherin 
was clearly localised at the site of the BTB in the control testes and in those from the 
1mg/kg CdCl2 dose group. In both groups, β-catenin was localised around the 
spermatocytes either side of the blood-testis barrier. Following treatment with either 
1.75mg/kg or 3mg/kg CdCl2, there appeared to be a reduction in the amount of both 
proteins present in the seminiferous tubules, and some disorganisation in the 
localisation of the proteins. This supports the tight junction results and confirms that 
the blood-testis barrier has probably been disrupted following treatment with high 
doses of cadmium chloride. 
 
To definitively evaluate blood-testis barrier function, penetration of the biotin tracer 
was evaluated (Tarulli et al., 2008; Meng et al., 2005). The results showed 
localisation of the biotin tracer solely to the interstitum in control tissue and in testes 
from the 1mg/kg and 1.75mg/kg CdCl2 dose groups, but with 3mg/kg cadmium 
chloride, the biotin tracer penetrated the seminiferous tubules, showing loss of 
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function of the blood-testis barrier. The results observed with the 1.75mg/kg dose 
group suggest that some seminiferous tubules could be affected by this intermediate 
dose, whereas some were unaffected.  
 
Finally, the genes for some blood-testis barrier proteins were investigated using 
TaqMan®. The results were variable, and only a small number of samples were 
investigated. A significant decrease in expression of occludin was detected following 
treatment with 3mg/kg CdCl2, agreeing with the protein data, which suggested that 
occludin was reduced in seminiferous tubules in animals treated with this dose. There 
were no statistically significant differences observed with the genes for the adherens 
junction proteins, N-cadherin and β-catenin, although a downward trend was 
observed with increasing CdCl2 dose. A decrease in these proteins was suggested 
following the intermediate and high dose treatments but not a complete absence, 
which supports the trend in the mRNA expression data. With the other three tight 
junction genes, ZO-1, claudin-11 and JAM-A, a significant reduction in expression 
was noted following treatment with 1.75mg/kg cadmium chloride, compared to 
control. From the protein data, an effect on expression of these genes in the 3mg/kg 
dose group would have also been expected. The discrepancy could be due to the 
small number of samples used for the gene expression experiments, especially as one 
animal in the high dose group was excluded from the analysis due to the histology 
appearing normal, suggesting that the treatment had not worked. 
 
The studies with cadmium chloride suggest that high doses (1.75mg/kg and 3mg/kg) 
cause disruption to the organisation of the seminiferous tubules, leading to leakage of 
some proteins from the tubules into the interstitial fluid. This protein leakage appears 
to be coincident with a loss of integrity of the blood-testis barrier. 
 
The second testicular toxicant used was methoxyacetic acid. Two doses were 
selected to produce mild and moderate effects (200mg/kg and 650mg/kg). 
Immunohistochemical analysis of testis sections showed a dose dependent loss of 
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pachytene spermatocytes likely due to apoptosis of the cells. This supports published 
data on MAA toxicity (Bagchi and Waxman, 2008).  
 
To investigate protein leakage following MAA treatment, Western blotting with the 
STCM antibody was carried out. No major differences were observed in the number 
of protein bands present in interstitial fluid samples from the control or either MAA 
dose group. Quantification of two protein bands (27kDa and 15kDa) hinted that there 
may have been an increase in the concentrations of the proteins following treatment 
with 650mg/kg MAA but there were no statistically significant differences. Analysis 
of total protein in IF samples was carried out using Coomassie dye stained gels. 
Again, no differences in protein concentrations in the IF samples from control and 
MAA treated animals were observed on the gels. Quantification of six protein bands 
(including those that appeared to leak out of STs in high dose cadmium chloride 
treated rats) supported this observation, and suggested that proteins are not leaking 
out of the seminiferous tubules into the interstitial fluid following treatment with 
MAA. 
 
The integrity of the blood-testis barrier was evaluated using immunofluorescent co-
localisation of the tight junction proteins, ZO-1 and occludin, and ZO-1 and claudin-
11, and the adherens junction proteins, N-cadherin and β-catenin. The results showed 
the junctions in tissue collected from animals treated with either 200mg/kg MAA or 
650mg/kg MAA were comparable to controls, which suggested that the blood-testis 
barrier was fully functional. This was confirmed directly using the biotin tracer. This 
showed that with both doses of MAA, the tracer was localised to the interstitum, as 
with control tissue. Similarly, expression analysis of blood-testis barrier genes 
showed no significant differences in testes from controls and from animals treated 
with either 200mg/kg or 650mg/kg MAA.  
 
The third well-studied testicular toxicant used was 1,3-dinitrobenzene, due to its 
reported effects on Sertoli cells (Blackburn et al., 1988). Two doses were selected to 
cause mild and moderate effects (25mg/kg and 50mg/kg). Observations at sample 
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collection found one animal had died following treatment with the high dose, and 
other animals in the group looked unwell, suggesting that the treatment had caused 
severe adverse effects to the animals. Immunohistochemistry with the STCM 
antibody and DAZL antibody was used to assess the damage caused by the doses of 
DNB. The results showed that DNB caused Sertoli cell vacuolation and loss of 
spermatocytes with a more marked effect following treatment with 50mg/kg DNB, 
compared to 25mg/kg DNB, as expected from the published literature. 
Immunohistochemistry with TUNEL suggested that the loss of germ cells was due to 
apoptosis. 
 
Protein leakage from seminiferous tubules into interstitial fluid following DNB 
treatment was evaluated by Western blot analysis with the STCM antibody. The 
results suggested that there were no differences in the proteins detected in control 
interstitial fluid samples, and those from animals treated with either dose of DNB, 
although there appeared to be an error in the amount of protein loaded into one lane 
of one gel (Figure 5-18). Quantification of two protein bands (27kDa and 15kDa) 
suggested no statistically significant differences in protein concentration between IF 
samples from control or DNB treated groups. Analysis of total protein using 
Coomassie stained gels, supported the Western blot results. No differences in the 
protein bands between dose groups were observed on the gels, and quantification of 
six protein bands showed no statistically significant differences between the groups. 
 
Immunofluorescence was again used to investigate the co-localisation of the tight 
junction proteins, ZO-1 and occludin, and ZO-1 and claudin-11, and the adherens 
junction proteins, N-cadherin and β-catenin to investigate the integrity of the blood-
testis barrier. The results suggested that there were no differences in the localisation 
and presence of these proteins in tissue from animals treated with either 25mg/kg or 
50mg/kg DNB and control tissue. Analysis of blood-testis barrier function with the 
biotin tracer showed the tracer localised to the interstitum in testes from both 
treatment groups and controls. These results suggest that treatment with either 
25mg/kg or 50mg/kg DNB has not disrupted the blood-testis barrier. Further support 
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for this conclusion came from analysis of expression of the genes for occludin, 
claudin-11, JAM-A, ZO-1, N-cadherin and β-catenin, which showed no differences 
in expression between tissue collected from animals treated with DNB or vehicle.  
 
The results presented in this chapter suggest that damage to the pachytene 
spermatocytes caused by MAA treatment, and damage to the Sertoli cells, caused by 
DNB treatment, do not cause disruption of the blood-testis barrier, and do not lead to 
leakage of proteins from the seminiferous tubules into the interstitial fluid. Therefore, 
induction of germ cell damage/degeneration, whether directly (MAA) or via 
perturbation of Sertoli cells (DNB), is not sufficient on its own to cause leakage of 
germ cell specific proteins into IF. Treatment with high doses of cadmium chloride 
caused disruption to the gross organisation of the seminiferous tubules, including 
germ cell loss/degeneration and also induced loss of integrity of the blood-testis 
barrier. Leakage of proteins from the tubules into IF was observed following high 
dose cadmium chloride treatment. This suggests that loss of integrity of the blood-
testis barrier is a pre-requisite for protein leakage from the STs into IF.  
 
To follow up on this conclusion, treatments to specifically target the blood-testis 
barrier will be investigated in chapter 6. 
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6 Is Loss of Integrity of the Blood-Testis Barrier required 
for Protein Leakage from Seminiferous Tubules into 
Interstitial Fluid? 
6.1 Introduction 
The results presented in the previous chapter suggested that potential biomarker 
proteins will only leak out of seminiferous tubules (STs) into interstitial fluid (IF) 
following a loss of integrity of the blood-testis barrier (BTB).  This has implications 
for the potential use of biomarkers for testicular toxicity as it suggests that a sensitive 
biomarker for general testicular toxicant-induced damage may not be possible to 
identify. 
 
In order to confirm this hypothesis, three approaches were taken to specifically target 
the BTB and investigate whether this really is integral to the problem. 
 
6.1.1 Development of the Blood-Testis Barrier 
The first approach used to try and confirm the hypothesis involved study of the 
development of the blood-testis barrier. The testes begin to develop early during 
embryogenesis (around day 12.5-13.5 of gestation in the rat, (Magre and Jost, 1991)) 
and continue to develop into adulthood. Spermatogenesis begins at puberty, 
following the formation of the BTB. In the rat, the onset of spermatogenesis occurs 
around postnatal day 8 (Vitale et al., 1973) with the formation of the blood-testis 
barrier occurring around postnatal days 15-19 (Vitale et al., 1973; Russell et al., 
1989). This can be used to look at the leakage of proteins from STs into IF from a 
different point of view. In theory, germ cell proteins should be present in the 
interstitial fluid before the BTB is formed, but following BTB formation, they should 
not be identified in IF due to the presence of the barrier preventing them leaking out.  
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The development of the blood-testis barrier was studied at 4 ages; postnatal day 10, 




The second approach to further investigate the role of the BTB and protein leakage 
from STs involved administration of glycerol. Intra-testicular injection of glycerol 
was first shown to inhibit spermatogenesis in rats by Wiebe and Barr, 1984.  They 
noted a depletion of spermatogenic cells, within 2 weeks of treatment but no effect 
on steroidogenesis (Wiebe and Barr, 1984). Eng et al., 1994, investigated the 
mechanism by which glycerol may exert its effects and suggested that a single intra-
testicular injection of a low concentration of glycerol can cause permanent damage to 
the seminiferous tubules by altering the permeability of the BTB. The effect of 
glycerol treatment on the BTB was further characterised by Wiebe et al., 2000, who 
found that glycerol caused specific disruption to the organisation of the Sertoli cell 
cytoskeleton (actin filaments and microtubules) and the tight junction protein, 
occludin, however the mechanism or initial target of glycerol was not investigated. 
 
Intra-testicular injections of glycerol were used to specifically target the BTB to 
evaluate whether this leads to leakage of proteins from STs. 
 
6.1.3 Transforming Growth Factor-β3 
Treatment with transforming growth factor-β3 (TGF-β3) was the third approach used 
to investigate the role of the BTB in leakage of proteins from STs into IF.  Xia et al., 
2006, reported that overexpression of TGF-β3 in primary cultured Sertoli cells led to 
disruption of tight junctions and adherens junctions. They went on to suggest an in 
vivo model for studying BTB dynamics by intra-testicular injection of TGF-β3. They 
showed that local administration of TGF-β3 caused reversible disruption to the tight 
junctions and basal ectoplasmic specialisations at the BTB and to the apical 
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ectoplasmic specialisations between spermatids and Sertoli cells (Xia et al., 2006).  
Further analysis showed specific reductions in the levels of occludin, ZO-1, N-
cadherin and nectin-3 protein levels, but no change in JAM-A or β-catenin protein 
levels following administration of TGF-β3 (Xia et al., 2006). Xia et al., 2008, further 
validated this model system and suggested that TGF-β3 may be causing disruption to 
the BTB by clathrin-mediated endocytosis of the BTB proteins. 
 
Local administration of TGF-β3 was used as the third approach to pinpoint whether 
disruption to the BTB and more specifically to the tight junctions is required for 
leakage of proteins from STs. 
 
6.1.4 General Aims 
The aim of the studies in this chapter is to further investigate the results observed in 
chapter 5 and to evaluate whether loss of integrity of the blood-testis barrier is 
required for leakage of proteins from seminiferous tubules into interstitial fluid. 
Three approaches were taken. Firstly testis development was used as a physiological 
approach to investigate whether there are changes in the amounts of proteins present 
in IF before and after the BTB forms. Secondly, two experimental approaches to 
specifically target the BTB were used, intra-testicular injection of glycerol, and intra-
testicular injection of TGF-β3. 
 
As in chapter 5, the damage caused by the treatments was investigated by 
immunohistochemistry, assessment of the blood-testis barrier using 
immunofluorescent techniques, and the interstitial fluid protein content evaluated by 
Western blotting and Coomassie gel analysis. 
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6.2 Methods 
6.2.1 Development of the Blood-Testis Barrier 
Samples were collected from male Wistar rats at four different ages, postnatal days 
10, 15, 18 and 25, for comparison with control adult tissue. These ages were selected 
to encompass the period in which the blood-testis barrier develops. Testes were 
collected and snap-frozen for PCR (section 3.4.2.2), or injected with biotin tracer 
(section 3.3.6). Interstitial fluid samples were also collected. Please refer to section 
3.4 for sample collection details. Fixed tissue collected previously in the lab was 
used for immunohistochemical analyses.  For fixed tissue, interstitial fluid samples, 
and frozen tissue, at least two testes were used per age, depending on availability of 
tissue, and success of the sample collection. For biotin tracer injected tissue, one 
animal was used at each age. 
 
6.2.2 Glycerol Treatment 
Adult male rats were treated with glycerol by intra-testicular injection as described in 
section 3.3.4. An initial investigation collecting testicular tissue 24 hours after 
treatment was carried out but the treatment appeared to have no effect so a second 
study was set up to collect tissue 48 hours after administration of the treatment.  
 
Testes were collected for fixation, injection of biotin tracer, and interstitial fluid 
collection. The number of samples collected is detailed in Table 6-1. No obvious 
effects were observed during administration of the treatment or sample collection. 
 
Table 6-1 Number of Samples collected from glycerol study. For fixed tissue (n) indicates 
number of fixed tissue samples injected with biotin tracer. 
Number of Samples 
Treatment 
Fixed Tissue Interstitial Fluid 
15% glycerol (right testis) 8 (4) 4 
Saline (left testis) 8 (4) 4 
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6.2.3 TGF-β3 Treatment 
Adult male rats were treated with TGF-β3 by intra-testicular injection as described in 
section 3.3.5. An initial investigation collecting testicular tissue 24 hours after 
treatment was carried out but the treatment appeared to have no effect so a second 
study was set up to collect tissue 48 hours after administration of the treatment.  
 
Testes were collected for fixation, injection of biotin tracer, and interstitial fluid 
collection. The number of samples collected is detailed in Table 6-2. 
 
During administration of the TGF-β3 treatment, one animal appeared to have much 
smaller testes than the others. Following sample collection, and analysis of the fixed 
tissue, the testes from this animal were not fully developed, so were not analysed 
further. 
 
Table 6-2 Number of Samples collected from TGF-β3 study. For fixed tissue (n) indicates 
number of fixed tissue samples injected with biotin tracer. 
Number of Samples 
Treatment 
Fixed Tissue Interstitial Fluid 
200ng TGF-β3 (right testis) 6 (3) 3 
PBS (left testis) 6 (3) 3 
 
 
6.2.4 Immunohistochemistry and Immunofluorescence 
Fixed testes were sectioned as described in section 3.4.2.1.1. Immunohistochemistry 
was carried out with the STCM antibody and an antibody to DAZL. 
Immunofluorescence was carried out to analyse distribution of the biotin tracer, and 
co-localisation of ZO-1 and occludin, and N-cadherin and β-catenin. Detailed 
methods are described in chapter 3. 
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6.2.5 1D Gel Analysis and Western Blotting 
Proteins present in interstitial fluid samples were analysed by running samples on 1D 
gels, then staining with GelCode Coomassie based stain, or Western blotting with the 
STCM antibody or an antibody to DAZL (samples from the development study). 
Details of these methods are included in chapter 3. 
 
6.2.6 TaqMan® Q-PCR 
RNA was extracted from snap-frozen tissue from the development study. cDNA was 
made and used for TaqMan® Q-PCR analysis of the blood-testis barrier genes, 
occludin, claudin-11, JAM-A, ZO-1, N-cadherin, and β-catenin, and the control gene, 
GAPDH. Detailed methods are described in chapter 3, along with primer and probe 
sequences used for the TaqMan® reaction. 
 
6.3 Results 
6.3.1 Development of the Testis and Blood-Testis Barrier 
The first approach involved analysis of proteins in interstitial fluid samples before, 
during, and after blood-testis barrier formation. 
 
6.3.1.1 Blood-Testis Barrier Formation 
The formation of the blood-testis barrier (BTB) during the development of the testis 
was confirmed by immunofluorescence for the tight junction proteins, occludin and 
ZO-1, and the adherens junction proteins, N-cadherin and β-catenin, as well as 
functional analysis using the biotin tracer, and TaqMan® analysis of the BTB genes.  
Figure 6-1 shows the localisation of ZO-1 and occludin at 5 different ages. Co-
localisation of both proteins was evident at day 18, although some tubules appeared 
less developed than others. By day 25, all tubules showed co-localisation of ZO-1 
and occludin at the site of the BTB, comparable to the staining seen in adult tissue. 
Between day 18 and day 25, it appears that the tight junction proteins are moving out 
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from the centre of the tubules towards the basement membrane as the tubules 
develop, until they reach the final site of the BTB. At day 10 and day 15, no occludin 
protein was detected in the seminiferous tubules. Some ZO-1 staining was identified 
at both ages, in a network pattern around the germ cells. This suggests that ZO-1 has 
a role in early development of the testis, before its role in the BTB. These results 
suggest that the tight junctions in the BTB are beginning to form between days 15-
18, and are fully formed by day 25, in agreement with the literature. 
 
 
Figure 6-1 Co-localisation of ZO-1 (green) and occludin (red) with Dapi nuclear counterstain 
(blue), on testis sections from rats at a) day 10, b) day 15, c) day 18, d) day 25, and e) 
adulthood. Scale bar represents 50µm. 
 
The development of the adherens junctions was also investigated using 
immunofluorescent detection of N-cadherin and β-catenin. Figure 6-2 shows the 
presence of N-cadherin (red staining) throughout the development of the testis but 
with a change in localisation. At day 10 and 15, N-cadherin appeared to be centrally 
located in the tubules, in a network pattern around the developing germ cells. By day 
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18, the protein began to localise towards the basement membrane of the tubules, and 
at day 25, it was present at the site of the BTB, comparable to adult tissue. β-catenin 
exhibited a different pattern during development of the testis. There was no β-catenin 
present at day 10, although it appeared to be present at day 15 in the interstitum, and 
around some of the germ cells. At day 18, when the N-cadherin was localising to the 
site of the BTB, the pattern of β-catenin protein did not seem to change. At day 25, 
the same pattern was clearer with β-catenin localised to spermatocytes and interstitial 
components, comparable to the β-catenin staining seen in adult tissue.  
 
These results suggest that N-cadherin expression follows the same pattern seen with 
the tight junction proteins, ZO-1 and occludin, during development of the testis and 
formation of the BTB. On the other hand, β-catenin exhibited the same staining 
pattern throughout the development process, suggesting it has a different role. 
 
 
Figure 6-2 Co-localisation of β-catenin (green) and N-cadherin (red) with Dapi nuclear 
counterstain (blue), on testis sections from rats at a) day 10, b) day 15, c) day 18, d) day 25 
and e) adulthood. Scale bar represents 50µm. 
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The function of the BTB during development of the testis was investigated using the 
biotin tracer. The tracer should be located in the interstitum and around the germ 
cells up to the site of the BTB if the barrier is functional. Following loss of integrity 
of the BTB, the biotin tracer can penetrate the seminiferous tubules. Therefore, it was 
expected that the tracer would be found throughout the tubules prior to formation of 
the BTB. Figure 6-3 shows the biotin tracer at different ages of testis development. 
Occludin is also shown to indicate the presence of the BTB from day 18 onwards. 
With day 18 and day 25 tissue the biotin tracer was localised to the interstitum and 
surrounding the germ cells up to the site of the BTB, which is comparable to adult 
tissue and indicates that the BTB is functional from day 18. The same pattern was, 
however, also seen with day 10 and day 15 testes. There was a slight difference with 
the day 15 tissue in which some biotin staining was seen in the centre of the tubules. 
This is similar to some tubules in adult tissue, described in chapter 4, and does not 
look like penetration of the tracer throughout the tubules. This result is unexpected 
and suggests that some sort of barrier is in place before the full BTB is formed. 
Perhaps some other BTB proteins are present, or the basement membrane has a 
barrier function at this stage in testis formation to protect the developing germ cells. 
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Figure 6-3 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain (blue), on testis sections from rats at a) day 10, b) day 15, c) day 18, d) day 25, 
and e) adulthood. Scale bar represents 50µm. 
 
Analysis of the genes for the tight junction proteins, occludin, claudin-11, JAM-A, 
and ZO-1, and adherens junction proteins, N-cadherin and β-catenin are shown in 
Figure 6-4. The results showed generally steady expression of all six genes across the 
age range. It is important to note that a lot of variability was seen in the individual 
data for each sample, and only a small number of samples were used suggesting that 
these results may not be very reliable. The results suggested statistically significant 
increases in expression of occludin, claudin-11 and ZO-1 at day 25 in comparison to 
adult. Significantly increased occludin mRNA expression was also observed at day 
10 and day 18 compared to adult, whereas the protein data suggested that occludin 
protein was not present until day 18. No differences in mRNA expression of N-
cadherin and β-catenin (except an increase in β-catenin expression at day 10) were 
noted across the age range, which does perhaps agree with the protein data shown in 
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Figure 6-2, which all appear to be located in the tubules throughout testis 
development although their location in the tubules changes.  
 
 
Figure 6-4 TaqMan® analysis of blood-testis barrier genes in testis samples collected from 
day 10, day 15, day 18, day 25 and control adult rats (mean with SEM). Expression relative 
to GAPDH expression. n=4 samples/age except day 15 where n=2 and adult where n=12. 
Statistical analysis, one-way ANOVA followed by Tukey post-test. * p<0.05, ** p<0.01, *** 
p<0.001 compared to adult samples. 
 
6.3.1.2 Protein Analysis of Interstitial Fluid Samples 
Analysis of proteins present in interstitial fluid samples and isolated seminiferous 
tubules was carried out using Western blotting with an antibody raised to 
seminiferous tubule conditioned medium (STCM).  Before samples were analysed, 
immunohistochemistry was carried out on tissue sections from day 10, 15, 18, 25, 
and adult rats with the STCM antibody to see if the STCM antibodies recognised 
proteins expressed at these ages (the antibody detects a range of different sized 
proteins of an unknown nature in adult samples).  Figure 6-5 shows testis sections 
from day 10, 15, 18, 25 and adult rats immunostained with the STCM antibody.  The 
antibody detected proteins present in seminiferous tubules at each age, although not 
all the proteins detected in the adult tissue appeared to be present through the age 
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range. Nevertheless, the results suggest that the STCM antibody can still be used to 
investigate proteins present in IF and ST samples. 
 
 
Figure 6-5 Testis sections from rats at a) day 10, b) day 15, c) day 18, d) day 25, and e) 
adulthood, immunostained with an antibody to seminiferous tubule conditioned medium 
(brown) and counterstained with haematoxylin (blue). Scale bar represents 100µm. 
 
 
Interstitial fluid samples collected from rats across the age range, were run on a 
Western blot with the STCM antibody, to investigate the hypothesis that germ cell 
derived proteins will be present in IF samples before the BTB is formed but not 
afterwards. The blot is shown in Figure 6-6 with quantification of some protein 
bands of interest. The Western blot showed that different proteins are present in IF at 
different stages of testis development. Because the proteins the antibody detects are 
unknown, it is hard to select germ cell proteins from the blot for quantification 
analysis. Looking at tissue samples from such young testes also has the added 
problem that many germ cell proteins will not be present until later in development, 
or even until the adult stage.  Different patterns can be seen with the proteins chosen 
for quantification from the Western blot. The 45kDa protein showed a decrease in 
the amount present in IF at day 18, with a large amount present at day 10. With the 
39kDa and 28kDa proteins, there was variability across the age range. The 15kDa 
protein showed very little or absence at days 10, 15, and 18, with a small amount 
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present in IF at day 25 and a much larger amount in the adult IF. This result could be 
because the protein is not expressed until later germ cells emerge, rather than an 
increase in leakage of the protein from the STs across the age range. 
 
Seminiferous tubules were isolated from testes at the different ages to try and 
identify the origin of some of the proteins seen in the IF samples. Isolated STs were 
run on a Western blot with the STCM antibody. Figure 6-7 shows that the proteins 
present in the ST samples, identified with this antibody were fairly consistent across 
the age range, with more proteins present in the adult sample. One of the proteins 
quantified in the previous figure, 15kDa, was again quantified because a clear band 
was visible in the day 25 sample, as well as in the adult sample. This result suggests 
that this protein is expressed in the later stages of spermatogenesis, because it is 
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Figure 6-6 a) Western Blot with antibody to STCM, showing interstitial fluid samples from 
day 10, 15, 18, 25 and adult (A) rats and control homogenised seminiferous tubules (ST). 
Arrows indicate examples of protein bands quantified. b) Graphs showing quantification of 
indicated bands (mean with SEM), with values taken from samples run on one blot, 
expressed as a percentage of STs (n=2 samples/age).  
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Figure 6-7 a) Western Blot with antibody to STCM, showing seminiferous tubule samples 
from day 10, 15, 18, 25 and adult (A) rats. Arrow indicates protein band quantified. b) Graph 
showing quantification of 15kDa bands (mean with SEM) (n=1 sample/age).  
 
As with protein analysis in IF samples in chapter 5, IF samples from the different 
aged rats were run on Coomassie stained gels to evaluate total protein content rather 
than just those proteins detected with the STCM antibody.  The gel and 
quantification of some protein bands are shown in Figure 6-8. Many more proteins 
were detected with this method than with Western blotting with the STCM antibody, 
and some variation across the age range was evident. From the quantification, 
proteins of 191kDa and 39kDa, in size, showed similar patterns with an increase in 
the amount of protein in adult IF samples, suggesting that they could be expressed in 
the later stages of spermatogenesis, and could be expressed in Sertoli cells rather 
than germ cells. The 28kDa protein had a similar pattern, but with an increase at day 
25 as well as in adult samples, again, suggesting that it is likely to be a product of the 
Sertoli cells switched on as the testis developed. The proteins of 45kDa, and 27kDa 
in size, did not appear to change much across the age range suggesting that they are 
interstitial compartment proteins, or present in the basal tubule compartment, or 
secreted from the seminiferous tubules. Unlike in the Western blot in Figure 6-6, the 
15kDa appeared to be very variable in the amount present in IF samples across the 
age range. 
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Figure 6-8 a) Coomassie gel showing interstitial fluid samples from day 10, 15, 18, 25 and 
adult (A) rats and control homogenised seminiferous tubules (ST). Arrows indicate examples 
of protein bands quantified. b) Graphs showing quantification of indicated bands (mean with 
SEM), with values taken from samples run on one gel, expressed as a percentage of STs 
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6.3.1.3 Analysis of Germ Cell Specific Proteins in IF Samples 
The general approach to investigating proteins present in IF samples from animals 
during testis development to investigate the hypothesis that germ cell derived 
proteins should leak into IF before the BTB has formed could be unsuccessful 
because the different stages of germ cells are not present at such young ages, and 
spermatogenesis only begins at day 8 in the rat with formation of the BTB at day 15-
19. One germ cell protein that is expressed from day 10 is DAZL. DAZL protein, 
along with the germ cell proteins, calpastatin and VASA were investigated by 
immunohistochemistry and Western blotting (DAZL and VASA). Calpastatin is 
expressed in spermatids, and was only expressed in adult tissue (data not shown) so 
no differences in IF would be detected across the age range. VASA was expressed in 
spermatocytes from day 10, but was not identified in IF samples (data not shown).  
Immunohistochemistry with DAZL across the age range is shown in Figure 6-9, and 
DAZL is clearly present in germ cells from day 10. 
 
IF samples from the different aged rats were run on a Western blot with an antibody 
to DAZL. Results and the quantification of the band at about 25kDa are shown in 
Figure 6-10. Although DAZL protein is described as being 33kDa, the bands 
identified in the IF samples on the Western blot do appear to be DAZL protein. A 
band about 39kDa in size was identified in the control adult ST sample. Perhaps the 
protein is processed and shortened when leaking out of the seminiferous tubules, 
resulting in a protein about 25kDa in length. The blot suggested that there are no 
differences in the amount of DAZL present in IF samples taken from day 10, 15, 18, 
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Figure 6-9 Testis sections from rats at a) day 10, b) day 15, c) day 25, and d) adulthood, 
immunostained with an antibody to DAZL (brown) and counterstained with haematoxylin 
(blue). Scale bar represents 100µm. 
 
 
Figure 6-10 a) Western Blot with antibody to DAZL, showing interstitial fluid samples from 
day 10, 15, 18, 25 and adult (A) rats and control homogenised seminiferous tubules (ST). 
Arrow indicates protein bands quantified. b) Graphs showing quantification of 25kDa band, 
thought to be DAZL (mean with SEM), with values taken from samples run on one Western  
blot, expressed as a percentage of STs (39kDa band used for normalisation) (n=2 
samples/age).  
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6.3.2 Glycerol Treatment 
6.3.2.1 Analysis of Damage caused by Glycerol Treatment 
Testis sections from rats treated with glycerol were immunostained with the general 
antibody to seminiferous tubule proteins (STCM) to analyse any damage caused to 
the structure of the seminiferous tubules. A section from a control testis and three 
sections from the concurrent glycerol treated testis are shown in Figure 6-11. The 
panels show the range in affect across the section of the treated testis. Panel d is 
comparable to the control section shown in panel a, but damage can be seen to the 
tubules shown in panels b and c. In b, there seems to have been a loss of germ cells 
from the tubules, and in c, vacuolation and loss of organisation of the seminiferous 
epithelium. As shown by the variation of damage across the section, the effect of the 
glycerol was localised with much of the tissue section looking normal. It is assumed 
that the damage is localised to the area the glycerol was injected into, although it was 
hard to confirm the site of injection in the paraffin embedded tissue. 
 
Figure 6-11 Testis sections from a) control testis, and b,c,d) testis treated with glycerol, 
immunostained with an antibody to seminiferous tubule conditioned medium (brown) and 
counterstained with haematoxylin (blue). Scale bar represents 100µm. 
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Figure 6-12 Detection of ZO-1 (green) and occludin (red) with Dapi nuclear counterstain 
(blue), on testis sections from a,b) a control testis, c-h) testes injected with glycerol. Scale 
bar represents 50µm. 
 
Glycerol treatment was investigated due to its proposed effect on the blood-testis 
barrier. Co-localisation of the tight junction proteins, occludin and ZO-1 was 
assessed by immunofluorescence. Figure 6-12 a and b show sections from a control 
testis used in the glycerol study and illustrate the co-localisation of ZO-1 and 
occludin at the site of the BTB. Panels c-h show sections taken from testes treated 
with glycerol. The co-localisation of occludin and ZO-1 can be seen in tubules in 
panels d and f, which are comparable to the control testes. Panels c, e, g, and h show 
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localised effects of glycerol treatment which seems to be causing vacuolation (c), and 
a loss of occludin from the site of the BTB (c, e, g). In panels c, e, and h, it looks like 
the occludin protein has moved towards the lumen of the tubules and is located 
around the germ cells. In panel g, the treatment could also be affecting the 
distribution of ZO-1 as the protein now appears localised in Sertoli cells, 
perpendicular to the basement membrane rather than paralleling the basement 
membrane.  
 
The function of the BTB was investigated using the biotin tracer. Testis sections 
stained to show localisation of the tracer and occludin are shown in Figure 6-13. 
Control tissue in panel a shows the localisation of the BTB (occludin) and the biotin 
tracer localised to the interstitum and around the germ cells up to the site of the BTB. 
Figure 6-13 b and c, again illustrate the localised effect of the glycerol treatment. In 
panel b, occludin has been lost from the site of the BTB and the biotin tracer can be 
found throughout the tubules. In panel c, the treated testis section is comparable to 
the control tissue in panel a, with the tracer localised to the interstitum, and occludin 
present. 
 
These results suggest that treatment with glycerol does cause damage to the BTB 




Figure 6-13 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain (blue), on testis sections from a) a control testis, b,c) testes injected with 
glycerol. Scale bar represents 50µm. 
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6.3.2.2 Analysis of Protein Leakage 
Leakage of proteins from STs into IF, following glycerol treatment was investigated 
using Western blotting with the STCM antibody, and Coomassie stained gels. The 
Western blot is shown in Figure 6-14. From the Western blot, there were no obvious 
differences in proteins present in the IF samples from control and treated testes. 
Three bands were quantified, and the graphs for the 45kDa and 39kDa proteins agree 
with this observation, with no significant differences between control and treated 
samples. The 15kDa protein band was also quantified, and showed significantly more 
protein in IF samples collected from testes treated with glycerol. This suggested that 
the protein could be leaking out of the damaged tubules into the IF. 
 
The Coomassie stained gel with IF samples from control and glycerol treated rats is 
shown in Figure 6-15.  As with the Western blot, there did not appear to be any 
obvious differences in the protein bands in IF from control and treated testes on the 
Coomassie gel. Quantification of six proteins, however, showed different results 
from the Western blot. With proteins of 45kDa, 39kDa, 28kDa, 15kDa, and 12kDa in 
size, there was a trend for an increase in the samples from glycerol treated testes, but 
no significant differences. The final band quantified, 27kDa, suggested a slight 
decrease in concentration following glycerol treatment, although this was, again, not 
statistically significant. These results suggested a trend for some leakage of proteins 
from STs following glycerol treatment. The lack of statistical significance of these 
results could be due to the localised nature of the effect of the treatment. Figure 6-11, 
Figure 6-12, and Figure 6-13 all show that there are still some unaffected tubules 
present in the glycerol treated testis, and so protein leakage is likely to only occur 
from the small number of damaged tubules. 
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Figure 6-14 a) Western Blot with antibody to STCM, showing interstitial fluid samples from 
control (C) and glycerol treated (T) testes and control homogenised seminiferous tubules 
(ST). Arrows indicate examples of protein bands quantified. b) Graphs showing quantification 
of indicated bands (mean with SEM), with values taken from samples run on one Western 
blot, expressed as a percentage of STs (n=4 samples/dose group). Statistical analysis,         
t-test. * p<0.05 compared to control samples.  
 
Chapter 6     BTB Integrity and Protein Leakage 187 
 
Figure 6-15 a) Coomassie stained gel, showing interstitial fluid samples from control (C) and 
glycerol treated (T) testes and control homogenised seminiferous tubules (ST). Arrows 
indicate examples of protein bands quantified. b) Graphs showing quantification of indicated 
bands (mean with SEM), with values taken from samples run on one gel, expressed as a 
percentage of STs (n=4 samples/dose group). Statistical analysis, t-test, showed no 
significant differences.  
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6.3.3 TGF-β3 Treatment 
6.3.3.1 Analysis of Damage  
Testis sections from testes treated with TGF-β3, and control testes were 
immunostained with the general antibody to seminiferous tubule proteins (STCM), to 
analyse the damage caused by the treatment. Figure 6-16 shows a control testis 
section (a) and two pictures of a treated testis section (b,c). The results showed that 
some damage is present in tubules in the treated testis, but most of the tubules 
appeared normal. This suggested that the TGF-β3 treatment, like the glycerol 




Figure 6-16 Testis sections from a) control testis, and b,c) testis treated with TGF-β3, 
immunostained with an antibody to seminiferous tubule conditioned medium (brown) and 
counterstained with haematoxylin (blue). Scale bar represents 100µm. 
 
The state of the blood-testis barrier following treatment with TGF-β3 was 
investigated by immunofluorescence co-staining of ZO-1 and occludin, and using the 
biotin tracer. Figure 6-17 shows the co-localisation of occludin and ZO-1 in control 
tissue (a), and from a TGF-β3 treated testis (b,c). As shown before, ZO-1 and 
occludin clearly co-localised at the site of the BTB in control tissue (panel a). The 
tubules in panel c, taken from a TGF-β3 treated testis, are comparable to the control 
tissue, showing that the integrity of the BTB is still intact in some areas of the testis. 
Panel b shows another area of a TGF-β3 treated testis, where damage to the tubules 
was identified (Sertoli cell vacuolation), and where there was apparent loss of 
occludin protein from the site of the BTB. This supported the results in Figure 6-16 
which suggest that TGF-β3 treatment has had a localised effect on the testis. 
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Figure 6-17 Detection of ZO-1 (green) and occludin (red) with Dapi nuclear counterstain 
(blue), with testis sections from a) a control testis, b,c) testes injected with TGF-β3. Scale bar 
represents 50µm.  
 
The biotin tracer was used to analyse BTB function. Results are shown in Figure 
6-18. As shown before, in control tissue (a), the biotin tracer was restricted to the 
interstitial compartment and in STs up to the site of the BTB (shown by localisation 
of occludin) as the BTB is fully functional. Figure 6-18b and c, show STs from a 
TGF-β3 treated testis. In panel b, the tracer appears to have penetrated the tubules, 
but occludin still seems to be present. On comparison to some of the control tissue 
presented in chapter 4, this result could be one of the natural variations seen with the 
biotin tracer and probably does not represent loss of function of the BTB. In Panel c, 
two tubules appear to have occludin protein, but the third does not (indicated by *). 
This could be due to the stage of the tubule (occludin has been reported to be absent 
at stage VIII (Li et al., 2006)) or an effect of the TGF-β3 treatment. Either way, the 
biotin tracer has not penetrated this tubule, suggesting that components of the BTB 
are still present, forming a functional barrier. 
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Figure 6-18 Detection of biotin tracer (green) and occludin (red) with Dapi nuclear 
counterstain (blue), with testis sections from a) a control testis, b,c) testes injected with TGF-
β3. Scale bar represents 50µm. 
 
6.3.3.2 Analysis of Protein Leakage 
Protein leakage from STs into IF following TGF-β3 treatment was evaluated using 
Western blotting with the STCM antibody and Coomassie stained gels. Figure 6-19 
shows IF samples from control testes and testes treated with TGF-β3 run on a 
Western blot with the STCM antibody. From the Western blot, there appeared to be 
some differences in the proteins present in each sample but there were no clear 
differences between samples from control testes, and TGF-β3 treated testes. 
Quantification of two protein bands suggested a trend for a decrease in the amount of 
45kDa and 15kDa proteins in IF from TGF-β3 treated testes. This result was 
unexpected, as the TGF-β3 treatment did appear to have some effect on some of the 
tubules so a slight increase in proteins would have been expected in IF from treated 
testes rather than a decrease. There could have been problems loading the samples on 
the gel, as there does seem to be a lot more protein in the first control sample run on 
the blot compared to all of the other samples, and this could have affected the 
quantification. 
 
In order to confirm this effect, and look at a wider range of proteins, IF samples from 
control and treated testes were run on Coomassie stained gels. From the gel, shown 
in Figure 6-20, there appeared to be no consistent differences between the proteins 
present in IF from control and treated testes. Quantification of six protein bands 
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showed differing results. Analysis of the 45kDa and 39kDa bands suggested no 
differences in the amount of protein in control and treated samples. However, the 
other four proteins, 28kDa, 25kDa, 15kDa, and 12kDa, all showed a trend for an 
increase in the protein in IF samples from TGF-β3 treated testes. These results 
suggest that the treatment could be having some effect on the leakage of proteins 
from STs into IF, but due to the localised effect of the treatment in a small area of the 




Figure 6-19 a) Western Blot with antibody to STCM, showing interstitial fluid samples from 
control (C) and TGF-β3 treated (T) testes and control homogenised seminiferous tubules 
(ST). Arrows indicate examples of protein bands quantified. b) Graphs showing quantification 
of indicated bands (mean with SEM), with values taken from samples run on one Western 
blot, expressed as a percentage of STs (n=3 samples/dose group). Statistical analysis,        
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Figure 6-20 a) Coomassie stained gel, showing interstitial fluid samples from control (C) and 
TGF-β3 treated (T) testes and control homogenised seminiferous tubules (ST). Arrows 
indicate examples of protein bands quantified. b) Graphs showing quantification of indicated 
bands (mean with SEM), with values taken from samples run on one gel, expressed as a 
percentage of STs (n=3 samples/dose group). Statistical analysis, t-test, showed no 
significant differences.  
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6.4 Discussion 
The aim of this chapter was to further investigate the hypothesis generated at the end 
of chapter 5, suggesting that proteins leak from seminiferous tubules into interstitial 
fluid only following loss of integrity of the blood-testis barrier. Three approaches 
were taken to specifically address this. 
 
The first approach was a physiological approach looking at the development of the 
BTB and the presence of proteins in interstitial fluid before and after the barrier has 
formed. Immunofluorescent co-staining for occludin and ZO-1 showed the presence 
of occludin protein localised to the site of the BTB in the tubules at day 18 whereas it 
was completely absent from tubules at day 10 and day 15. This agrees with the 
reported development of the BTB, as the barrier has been shown to form between 
days 15-19 in the rat (Vitale et al., 1973; Russell et al., 1989). ZO-1 was also present 
at the BTB from day 18, but some ZO-1 was also present at day 10 and day 15 in a 
network pattern around the germ cells. This difference in localisation could suggest a 
role for ZO-1 in germ cell-Sertoli cells interactions. It may also be due to the 
different ZO-1 isoforms. The ZO-1α+ isoform was reported to be predominantly 
expressed during puberty, while ZO-1α- is predominantly expressed in adulthood 
(Pelletier et al., 1997). The differing localisation of the protein as the testes develop 
could be due to a change in the expression of the different ZO-1 isoforms.  
 
Immunofluorescent co-staining for the adherens junction proteins, N-cadherin and β-
catenin as well as the biotin tracer technique were also used to assess development of 
the BTB. N-cadherin appeared to be present at all of the ages investigated, with a 
network pattern around the germ cells at day 10 and 15, and moving out to the site of 
the BTB at day 18 and comparable to adult by day 25. β-catenin appeared to be 
present at day 15 onwards, localised around the germ cells. The localisation of β-
catenin at day 25 is comparable to the adult, where it is clearly found localised to the 
spermatocytes. These results suggest roles for N-cadherin and β-catenin in early 
testis development, but localisation to the site of the BTB at around day 18, 
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supporting the results seen with ZO-1 and occludin, and the reported age for barrier 
formation in the literature. 
 
The biotin tracer technique was used to assess the functional development of the 
BTB. The results were unexpected as the biotin tracer appeared to be localised to the 
interstitum at day 10, 15, 18 and 25. Following tracer studies reported in the 
literature, using peroxidase and lanthanum techniques (Vitale et al., 1973), and the 
BTB protein localisation results, the biotin tracer was expected to localise to the 
interstitum only following BTB formation at day 18. The observations could indicate 
a barrier role for the basement membrane during early testis development. 
 
Expression of the genes for the BTB proteins, occludin, claudin-11, JAM-A, ZO-1, 
N-cadherin, and β-catenin, was also investigated across the age range. The results 
were variable, probably due to the small sample numbers, although at these stages in 
development there could also be large natural variability between different animals. 
A statistically significant increase in claudin-11 and ZO-1 mRNA expression was 
observed at day 25, in comparison with adult. mRNA expression of N-cadherin and 
JAM-A did not appear to change over the age range. mRNA expression of occludin 
was variable, and β-catenin expression was increased at day 10 in comparison to 
adult. The mRNA expression data does not fit in with the protein data, and the 
variability does not allow conclusions to be drawn.  
 
Analysis of proteins in interstitial fluid samples collected from animals at the 
different ages was performed using Western blotting with the STCM antibody, and 
Coomassie stained gels. Immunohistochemistry was first carried out with the STCM 
antibody to evaluate whether it detected proteins present in the testis of younger 
animals. A range of proteins were detected across the age range, although not all the 
proteins present in the adult testis appeared to be present in the younger testes. 
 
Western blotting with the STCM antibody to investigate proteins present in IF 
samples at the different ages showed different proteins present at different stages of 
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development. Quantification of the protein bands showed variability across the age 
range for the 45kDa, 39kDa and 28kDa proteins. The 15kDa band illustrated a 
limitation of this approach, as it was found in higher amounts in IF from adults but 
little or no protein was present at the earlier ages. This indicated that the 15kDa 
protein and potentially many more were not expressed in the seminiferous tubules 
until later in development/adulthood. Isolated seminiferous tubules from the age 
range were also analysed by Western blotting with the STCM antibody. The results 
were similar, with many more proteins present in STs from adult rats compared to 
STs from younger rats. Again this was supported by quantification of the 15kDa 
band, which seemed to appear in STs from day 25. The same effect was also noted 
when the IF samples were run on Coomassie stained gels. Quantification of six 
protein bands showed variability in the amounts of proteins present in IF, and 
suggested some proteins expressed late in development (day 25) and adulthood are 
likely to be Sertoli cell derived proteins, such as the 39kDa and 28kDa. The results 
for the 15kDa band did not show the same result as the Western blots, with the 
highest concentration of the protein observed in day 18 samples. However this could 
be due to problems loading the gel, or the small number of samples assessed. 
 
Due to the problems with IF protein analysis due to some proteins being expressed at 
later stages of development/in later stage germ cells, three specific germ cell proteins 
were investigated. Calpastatin was shown to be expressed in spermatids, and 
therefore could not be used to show changes in concentration in IF samples before 
and after BTB formation. DAZL protein is, however, expressed in the pachytene 
spermatocytes in adults, and can be detected in early spermatocytes from day 10, as 
shown with immunohistochemistry. This made DAZL an ideal protein to investigate 
in IF samples from the different aged rats. Western blotting for DAZL, showed a 
protein band present in all samples about 25kDa in size. Quantification of this band 
suggested an increased amount present in adult IF samples but the data was variable. 
It is unclear whether this band is DAZL protein, because it was expected to be 33kDa 
in size. The bands observed could be proteins containing some of the epitopes 
recognised by the antibody rather than actually DAZL protein and detection of 
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DAZL protein could show a different effect. VASA, also expressed in 
spermatocytes, was also investigated but was not detected in IF samples across the 
age range. 
 
The physiological approach, to look at the proteins present in the interstitial fluid 
before and after formation of the BTB proved inconclusive. Protein analysis was 
difficult due to many of the proteins of interest not being expressed until the later 
stages of development. 
 
The second approach taken to investigate loss of integrity of the blood-testis barrier 
and leakage of proteins from STs into IF was intra-testicular injection of glycerol 
which has been reported to cause disruption of occludin in the BTB (Wiebe et al., 
2000). Analysis of the effects of glycerol treatment on the seminiferous tubules by 
immunohistochemistry with the STCM antibody suggested that the glycerol 
treatment had a localised effect on the tubules causing disruption to the organisation 
of the tubules including germ cell loss, and Sertoli cell vacuolation in some areas of 
the testis sections analysed. Other areas of the sections appeared comparable to the 
concurrent control testis. These results suggested that the effect is localised to the site 
of injection, although it was hard to confirm the site of injection in the paraffin 
embedded tissue. Analysis of further tissue sections throughout the testis could have 
been carried out to confirm this. The results agreed with the effects of 10% glycerol 
treatment reported by Igdoura and Wiebe, 1994, who described suppression of 
spermatogenesis one week following administration of glycerol, with a gradual loss 
of all types of germ cells by 8 weeks due to premature disengagement and sloughing 
of germ cells (in 75% of tubules, while 23% appeared normal, and less than 1% were 
acellular).  This study also suggests that a longer time period may be required for the 
glycerol treatment to exert its effect throughout the testis, and perhaps the testicular 
samples should have been collected after a longer time period than 48 hours.  
 
The effect of glycerol treatment on the BTB was investigated by 
immunofluorescence co-staining for ZO-1 and occludin, and using the biotin tracer 
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technique. The localisation of the tight junction proteins, ZO-1 and occludin was 
shown to be variable across different tubules from treated testes. As shown with the 
immunohistochemistry, some tubules were comparable to control tissue, with ZO-1 
and occludin localised to the site of the BTB. In other tubules, ZO-1 appeared to 
remain localised to the BTB, while there was a loss of occludin from this site. In 
some of these tubules, occludin appeared to have re-localised away from the BTB 
and to surround germ cells. An effect on ZO-1 was also suggested in some tubules 
with apparent localisation perpendicular to the basement membrane rather than 
paralleling the basement membrane. The results seen with the biotin tracer were also 
variable, with some tubules from glycerol treated testes comparable to control with 
the tracer localised to the interstitum and up to the site of the BTB, and penetration of 
the tracer observed in other tubules from treated testes suggesting a loss of function 
of the BTB. The results suggested that glycerol is having a localised effect on the 
integrity of the BTB, and appeared to cause disruption by a loss of occludin protein 
from the site of the BTB. 
 
Protein leakage from STs into IF following glycerol treatment was evaluated by 
Western blot and Coomassie stained gel analysis of IF samples. Western blotting 
with the STCM antibody showed a statistically significant increase in the 
concentration of the 15kDa protein in IF following glycerol treatment, but no 
statistically significant differences were observed with the 45kDa and 39kDa protein 
bands also quantified. These results suggested that leakage of some proteins, such as 
the 15kDa protein, may be occurring following glycerol treatment. Analysis of IF 
proteins from vehicle control and glycerol treated testes, by Coomassie dye staining 
showed a trend for an increase in concentration of five proteins analysed (45kDa, 
39kDa, 28kDa, 15kDa, and 12kDa) in IF from glycerol treated testes compared to 
vehicle control treatment. This suggested that proteins are leaking from STs into IF 
following glycerol treatment, but due to the localised effect of the treatment on the 
seminiferous tubules, protein leakage is likely to be occurring from only some of the 
tubules, which could be why the results of the proteins analysed were not statistically 
significant. Following observations in the literature (Igdoura and Wiebe, 1994), 
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analysis of proteins in IF following glycerol treatment after a longer period of time 
might show a greater amount of protein leaking from the STs. Furthermore, only a 
small number of samples were analysed in this study (4 animals), and increasing the 
number of samples could provide more concrete evidence.  
 
The results for the glycerol treatment suggested that glycerol has a localised effect on 
the testes causing a loss of germ cells, and a loss of occludin protein from the BTB. 
Analysis of proteins present in IF samples suggested a trend for an increase in the 
amount of some proteins present in IF from glycerol treated testes, suggesting that 
proteins are leaking from tubules affected by the glycerol treatment. 
 
The third approach taken to investigate the role of the blood-testis barrier in leakage 
of proteins from STs into IF was intra-testicular injection of TGF-β3, which had been 
validated by Xia et al., 2008, as a model for BTB disruption. Analysis of the effects 
of the TGF-β3 treatment on the testes was carried out by immnuohistochemical 
staining for the STCM antibody. As with the glycerol treatment, the results showed 
some tubules appeared comparable to the control tissue, but a small number of 
tubules (from observation) appeared to be damaged. This suggested that the TGF-β3 
was having a localised effect at the sites of injection, although it was hard to identify 
the injection sites following embedding in paraffin wax. To investigate this further, 
more tissue sections could have been cut from each of the wax blocks and a number 
of sections across the testis analysed.  
 
The blood-testis barrier was evaluated in the control and TGF-β3 treated testes by 
immunofluorescence co-staining for occludin and ZO-1, and using the biotin tracer 
technique. The results showed some tubules in the TGF-β3 treated testes to be 
comparable to control, with co-localisation of occludin and ZO-1 at the site of the 
BTB. In some tubules in the treated testes, there appeared to be some loss of occludin 
from the site of the BTB. This further supported the idea that TGF-β3 had a localised 
effect, and suggested that it has affected occludin protein. This agrees with results 
reported by Xia et al., 2006, who noted a reduction in occludin following TGF-β3 
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treatment, however, they also reported a reduction in ZO-1 protein as well, and there 
did not appear to be any loss of ZO-1 in these experiments.  With the biotin tracer 
analysis of BTB function, some tubules in the TGF-β3 treated testes had a fully 
functional BTB, shown by localisation of the biotin tracer to the interstitum and up to 
the site of the BTB. Penetration of the biotin tracer into some tubules was observed, 
although this appeared to be between the Sertoli cells, rather than the complete 
penetration seen following BTB disruption with cadmium chloride treatment (chapter 
5). The result observed is comparable to effects seen in some control tissue (chapter 
4), suggesting that it is due to the natural variations seen with the tracer. These 
results suggested that the BTB was still functional following TGF-β3 treatment. As 
only occludin has been shown to be absent from TGF-β3 treated testes, it could be 
that other BTB proteins (including ZO-1) could still be present and maintain the 
integrity of the BTB. 
 
The leakage of proteins from STs into IF following TGF-β3 treatment was 
investigated using Western blotting with the STCM antibody and Coomassie stained 
gels. No obvious differences were observed between the protein bands on the 
Western blot with the STCM antibody in the IF samples from TGF-β3 treated testes 
compared to control. Quantification of the 45kDa band and 15kDa band showed a 
trend for a reduced amount of protein present in IF following TGF-β3 treatment. 
These results were unexpected. If the TGF-β3 treatment has only had an effect on 
specific components of the BTB (such as occludin) and BTB integrity is being 
maintained by other proteins (as suggested by the biotin tracer results), proteins 
would not be expected to leak from the STs into IF, based on the results discussed in 
chapter 5. However, the amount of protein in IF following treatment would be 
expected to be comparable to control, rather than a reduction in protein concentration 
after treatment. The changes observed could be due to inaccurate loading of samples 
onto the gel, or inadequate mixing of samples prior to loading. Only a small number 
of samples were used for this analysis and inclusion of a greater number of samples 
could provide more reliable results.  
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Quantification of the bands from the Coomassie stained gel showed variable results. 
There were no differences observed between the amounts of 45kDa, or 39kDa 
proteins present in IF from TGF-β3 treated testes compared to control. However, 
trends for an increase in the concentrations of the other four proteins quantified 
(28kDa, 25kDa, 15kDa and 12kDa) in IF following TGF-β3 treatment were noted. 
The results for the 15kDa band are particularly interesting as they disagree with the 
result seen for the 15kDa band on the Western blot, although the amount of 15kDa 
protein detected in IF on the Coomassie gel (compared to STs) is much higher than 
that on the Western blot. This could, however, be due to different 15kDa proteins 
being detected in the two different systems, or potentially more than one protein of 
15kDa in size being detected on the Coomassie gel. The results from the Coomassie 
gel suggested that there could be some protein leaking from the STs into IF 
following TGF-β3 treatment, although due to the localised effect of the TGF-β3, the 
effect on the proteins was not statistically significant.  
 
The aim of this chapter was to further investigate the role of BTB integrity in leakage 
of proteins from seminiferous tubules into interstitial fluid samples. The results 
presented suggest that the physiological approach to further investigate the protein 
leakage hypothesis proved inconclusive due to many of the proteins of interest not 
being expressed until in later stage germ cells and so were not present while the 
blood-testis barrier was developing. Specific targeting to occludin in the BTB by 
glycerol treatment suggested some localised loss of integrity of the BTB and a trend 
for leakage of proteins from STs into IF following treatment. Targeting the BTB by 
TGF-β3 treatment caused some localised damage but loss of integrity of the BTB 
was not observed, although there was a localised loss of occludin protein. Analysis of 
IF protein content showed variable results with a suggestion of some leakage of 
proteins from STs into IF following TGF-β3 treatment. The results observed with 
these treatments support the hypothesis that proteins only leak from STs into IF 
following a loss of integrity of the blood-testis barrier. Further experiments with 
these treatments, perhaps leaving the damage to develop for a longer period of time 
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could be carried out to try and obtain wider disruption of the BTB throughout the 
testis, and thus more significant protein leakage data. 
 
 
Chapter 7     Protein Biomarkers 202 
7 Detection of Testicular Damage using Protein 
Biomarkers 
7.1 Introduction 
Throughout this thesis, the hypothesis that germ cell derived proteins may leak from 
seminiferous tubules into interstitial fluid following toxicant-induced testicular 
damage has been investigated. If proteins do leak from the STs into IF, following 
toxicological insult, they may leak from the interstitial fluid into the blood and may 
be detected in blood samples. This would provide a simple way of determining 
testicular toxicity following treatment without having to look at testicular tissue. This 
could allow ‘early warning’ detection of testicular damage as biomarker levels in the 
blood could be monitored throughout a toxicology study, allowing detection before 
the histopathological analysis at the end of the study. Assessing the tissue at the end 
of the study also only shows the state of the tissue at one point in time. A biomarker 
would allow a profile of the damage across a period of time to be obtained. Table 7-1 
details the criteria for a biomarker for testicular toxicity. This table also highlights a 
second hypothesis, to be investigated in this chapter, in that smaller molecular weight 
proteins are thought to be more likely to leak out of STs into IF. 
 
Based on these criteria (Table 7-1), potential protein biomarkers of testicular toxicity 
were selected from a list of testis specific genes, generated from a bioinformatic 
screen carried out at GSK. A list of gene expression data was generated by 
Affymetrix Genechip® analysis of rat testicular tissue (RNA was isolated from 
homogenised whole testes from control rats), with expression of selected genes 
validated by TaqMan® analysis (GSK internal report). A literature search was carried 
out to further characterise the genes of interest identified in the Genechip® analysis 
and confirm testis specificity (GSK internal report). Three proteins were selected 
from the resulting list; fatty acid binding protein 9 (FABP9) (also known as TLBP or 
PERF15), a disintegrin and metalloprotease domain 3 (ADAM3) (also known as 
cyritestin), and Calpastatin (tCAST), primariliy based on the availability of 
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commercial antibodies (for ease of protein detection), and the molecular weight (to 
investigate the hypothesis that smaller molecular weight proteins are thought to be 
more likely to leak out of STs into IF). 
 
Table 7-1 Criteria for a protein biomarker for testicular toxicity. 
Criteria Reason 
Low molecular weight 
Suspect low molecular weight proteins are 
more likely to leak out of STs 
Abundant 
Enough protein must be present to reach the 
blood system 
Testis specific 
Protein cannot be present in other tissues or 
testicular damage will not be detected 
Commercially available 
antibodies to protein 
For ease of protein detection and consistency 
of results 
Not usually found in 
IF/plasma/serum 
Protein cannot naturally leak out of tubules 
Stable 
Once protein leaks from STs, it must be stable 
enough to leak into the IF/blood for detection 
 
 
FABP9 is a small transport protein (15kDa) present in the rat perforatorium at the 
inner acrosomal and outer face of the nuclear envelope of the sperm head, and can be 
identified in pachytene spermatocytes and spermatids (Oko and Morales, 1994). It is 
thought to mediate structural rearrangement and stability of the acrosome (Oko and 
Morales, 1994), as well as having a role in germ cell apoptosis in the developing 
testis (Kido and Namiki, 2000). ADAM3 is germ cell specific, found in round and 
elongate spermatids (Linder et al., 1995). It is a transmembrane protein in the 
acrosomal membrane, and is processed to its active form during sperm transport in 
the epididymis (Linder et al., 1995). Calpastatin is an inhibitor of calpain, a calcium 
dependent cysteine protease. The testis specific form (tCAST) has a different N-
terminal domain to somatic calpastatin, which causes it to localise to the cytosol (Li 
et al., 2000). Testis calpastatin is a membrane associated protein present in 
spermatids, and is thought to have a role in the acrosome reaction and gamete fusion 
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(Li and Goldberg, 2000). ADAM3 (110kDa precursor) and calpastatin (76kDa 
predicted) are larger than FABP9 (15kDa) and so could be used to show that only 
small proteins leak from the seminiferous tubules following toxicant induced damage 
to spermatogenesis. 
 
Two well-studied germ cell proteins were also investigated as potential biomarkers 
for testicular toxicity. The selected proteins were VASA and DAZL. VASA is a 
member of the DEAD-box family of genes, which encodes an ATP-dependent RNA 
helicase and is expressed specifically in germ cells and involved in regulation of cell 
proliferation (Tanaka et al., 2000). DAZL (deleted in azoospermia like) is an RNA 
binding protein expressed in multiple cellular compartments (nucleus and cytoplasm) 
during development of male germ cells (Reijo et al., 2000). Again both proteins are 
different sizes, VASA is a larger protein at 76kDa, and DAZL is a smaller protein, 
33kDa in size.  
 
All five proteins were investigated by looking at the localisation of the proteins using 
immunohistochemistry. The ability to detect the proteins in IF samples, and to 





Samples collected throughout the studies detailed previously in this thesis were used 
for evaluating potential protein biomarkers. Fixed testes, interstitial fluid, and snap-
frozen testis samples from the cadmium chloride, MAA, and DNB studies were used 
for the main investigations. Fixed tissue, and interstitial fluid samples from the 
glycerol and TGF-β3 studies, and fixed tissue, snap-frozen tissue, and isolated 
seminiferous tubules from the development study were used for additional 
investigations.  
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Detailed descriptions of treatments and sample collection methods are presented in 
chapter 3. Information regarding the design and purpose of the main studies is 




Immunohistochemistry with antibodies to the proteins of interest (DAZL, VASA, 
ADAM3, Calpastatin, FABP9), was carried out to investigate the localisation of the 
proteins in the testis. The DAB protocol described in section 3.5 was used. 
 
7.2.3 Western Blotting 
Western blotting was used to investigate whether the proteins of interest are present 
in interstitial fluid and ST samples. Antibodies to DAZL, VASA, ADAM3, 
Calpastatin and FABP9 were used, following the methods described in sections 3.8 
and 3.10. Where necessary, blocking peptides were purchased and run alongside 
samples on Western blots to try and confirm the identity of the protein bands 
observed. 
 
7.2.4 TaqMan® Q-PCR 
Snap-frozen tissue collected from the cadmium chloride, MAA, DNB, and 
development studies was used for RNA isolation. cDNA was made from the isolated 
RNA samples, and used in the TaqMan® reaction with primers and probes for the 
FABP9 gene. Detailed methods are described in section 3.11. 
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7.3 Results 
7.3.1 DAZL 
Immunohistochemistry to show DAZL was used in chapter 5, as a good marker of 
toxicant induced damage. Figure 7-1 shows testis sections taken from animals treated 
with one of the three doses of the main testicular toxicants used in this thesis 
(cadmium chloride, MAA, DNB).  DAZL was clearly present in the pachytene 
spermatocytes and residual bodies towards the lumen, as seen in the control tissue. 
With low dose toxicant treatment, a reduction in DAZL staining was suggested 
following MAA and DNB treatment, which caused a loss of pachytene 
spermatocytes. With low dose CdCl2 treatment (1mg/kg) no changes were identified, 
and there did not appear to be any damage to the tubules. Following high dose 
toxicant treatment, there was a reduction in DAZL staining with all three toxicants. 
This reduction in DAZL staining, from observation, looked to be more marked 
following high dose treatment compared to low dose treatment with MAA and DNB. 
This property and the germ cell specificity of DAZL, along with its small size make 
it a good potential biomarker candidate. 
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Figure 7-1 Testis sections from control rats from each toxicant study (a, d, g) and rats 
treated 24 hours earlier with a low dose of toxicant (1mg/kg CdCl2 (b), 200mg/kg MAA (e) or 
25mg/kg DNB (h)) or a high dose of toxicant (3mg/kg CdCl2 (c), 650mg/kg MAA (f) or 
50mg/kg DNB (i)), immunostained to show DAZL (brown) and counterstained with 
haematoxylin (blue). Scale bar represents 100µm. 
 
 
For DAZL to be used as a biomarker for testicular toxicity, it must leak out of STs 
into IF, following toxicological insult to the testes. IF samples from the three toxicant 
studies were run on Western blots and probed with the DAZL antibody. Figure 7-2 
shows IF samples from the cadmium chloride study. Three different sized bands can 
be identified on the Western blot. The first, seen in all samples at a size of 64kDa is 
albumin, likely to be detected due to the large amount of this protein in IF samples, 
and its ‘sticky’ nature. A band around 39kDa in size can be seen in the ST sample, 
and bands about 25kDa in size can be identified in the IF samples. These bands are 
thought to be DAZL, because they are around the expected size of DAZL (33kDa) 
and the detection system is picking up these bands specifically. The size discrepancy 
between the bands in the IF samples and the ST sample could be due to the protein 
being processed and shortened when leaking out of the germ cells/seminiferous 
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tubules, resulting in a protein about 25kDa in length. Further explanations could be 
due to species differences in the protein size or the gel system used to separate the 
proteins. Alternatively the protein bands observed on the Western blot could be 
proteins containing some of the epitopes recognised by the antibody which are 
naturally present in interstitial fluid, and not DAZL protein. The minimal amount of 
protein present in any of the samples, perhaps, supports this explanation. These 
bands were quantified and the results shown in Figure 7-2b. The graph shows no 
significant differences in the amount of DAZL protein present in IF samples from 
animals treated with the four different CdCl2 doses. This, and the minimal amount of 
protein detected, suggests that DAZL is not leaking out of STs into IF, following 
cadmium chloride induced damage, as a larger amount of protein would be present in 
the IF samples from the 3mg/kg dose group if this were the case (protein leakage 




Figure 7-2 Representative Western Blot probed with DAZL antibody, showing interstitial fluid 
samples from control rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2 and control 
homogenised seminiferous tubules (ST). Arrows indicate DAZL protein bands. (b) Graphs 
showing quantification of 25kDa band (mean with SEM), thought to be DAZL with values 
taken from samples run on two separate Western blots (n=4 samples/dose group), 
expressed as a percentage of STs (39kDa band used for normalisation). Statistical analysis, 




Chapter 7     Protein Biomarkers 209 
IF samples from the MAA and DNB studies were also run on Western blots and 
probed with DAZL antibody. The results are shown in Figure 7-3. Again, bands at 
about 25kDa were detected in IF samples, and a band of about 39kDa in STs were 
detected. Quantification of the bands on both Western blots, suggest no significant 
differences in the amount of DAZL protein in IF samples across the MAA dose 
range, nor across the DNB dose range. This result further suggests that DAZL 
protein is not leaking out of STs into IF following toxicant induced damage to the 
germ cells, so DAZL could not be used as a biomarker. The lack of protein leakage 
with MAA and DNB treatment is not unexpected, following on from the results 
presented in chapter 5, which suggested that loss of integrity of the BTB is necessary 
for leakage of proteins, and these treatments specifically target spermatocytes and 
Sertoli cells, respectively. However, the samples were available, and it is important 
to further explore the protein profiles of these IF samples, to provide further evidence 
that loss of integrity of the BTB is needed for proteins to leak from STs into IF. 
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Figure 7-3 Representative Western Blots probed with  DAZL antibody, showing (a) 
interstitial fluid samples from control rats and animals treated with 200 or 650mg/kg MAA 
and control homogenised seminiferous tubules (ST), and (c) interstitial fluid samples from 
control rats and animals treated with 25 or 50mg/kg DNB and control homogenised 
seminiferous tubules (ST). Arrows indicate DAZL protein bands. Graphs showing 
quantification of 25kDa band (mean with SEM), thought to be DAZL with values taken from 
samples run on two separate Western blots (n=4 samples/dose group), expressed as a 
percentage of STs (39kDa band used for normalisation), for (b) MAA samples, and (d) DNB 





The second widely used germ cell protein investigated was VASA. 
Immunohistochemistry with VASA to show its localisation in tissue from control, 
low dose and high dose groups from each of the main toxicant studies is shown in 
Figure 7-4.  The control tissue shows that VASA is expressed in more germ cells 
than DAZL, namely in all spermatocytes and spermatids. Again there was no 
Chapter 7     Protein Biomarkers 211 
difference between control tissue and that from animals treated with low dose 
cadmium chloride (1mg/kg). There was, however, a loss of some VASA protein with 
low doses of MAA and DNB, due to their depletion of spermatocytes. With high 
doses of all three treatments, there was a more marked loss of VASA protein 
compared to the low dose. Again, this makes VASA a potential candidate biomarker, 
although it is a larger protein, at 76kDa in size, and small molecular weight proteins 
are thought to be more likely to leak out of STs into IF. 
 
 
Figure 7-4 Testis sections from control rats from each toxicant study (a, d, g) and rats 
treated 24 hours earlier with a low dose of toxicant (1mg/kg CdCl2 (b), 200mg/kg MAA (e) or 
25mg/kg DNB (h)) or a high dose of toxicant (3mg/kg CdCl2 (c), 650mg/kg MAA (f) or 
50mg/kg DNB (i)), immunostained to show VASA (brown) and counterstained with 
haematoxylin (blue). Scale bar represents 100µm. 
 
 
To investigate whether leakage of VASA does occur following cadmium chloride 
treatment, IF samples collected during the studies were run on a Western blot and 
probed with VASA antibody. A representative Western blot is shown in Figure 7-5. 
A band of about 76kDa in size was identified in the ST sample and in some IF 
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samples. A band with a slightly smaller molecular weight was also identified in some 
lanes, thought to be albumin due to its size of 64kDa. From the blot, VASA appeared 
to be present in IF samples collected from animals treated with high dose (3mg/kg) 
cadmium chloride, and in control STs. Quantification of the 76kDa bands from the 
four separate Western blots required to run all the IF samples collected during the 
studies is shown in Figure 7-5b. There was significantly more VASA protein 
identified in IF from animals treated with 3mg/kg CdCl2, suggesting that VASA was 
leaking out of the STs into IF following high dose cadmium chloride treatment. From 
the graph, there is also a hint that there was more VASA protein present in IF 
samples from animals treated with 1.75mg/kg CdCl2, compared to control and low 
dose, suggesting that there may be a small amount of VASA leaking out with the 
damage caused by the mid-dose treatment. This dose response is ideal for a 
biomarker, as it suggests the amount of protein leaking out is proportional to the 
amount of damage present, so the extent of the damage could be predicted based on 
the amount of biomarker detected.  
 
 
Figure 7-5 a) Representative Western Blot probed with VASA antibody, showing interstitial 
fluid samples from control rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2 and 
control homogenised seminiferous tubules (ST). Arrow indicates VASA protein. b) Graph 
showing quantification of 76kDa band (mean with SEM), thought to be VASA with values 
taken from samples run on four separate Western blots (n=7 samples for control, n=5 for 
1mg/kg group, n=8 for 1.75 and 3mg/kg groups), expressed as a percentage of the ST 
sample. Statistical analysis, one-way ANOVA followed by Tukey post-test. *** p<0.001 
compared to control samples (0mg/kg). 
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Figure 7-6 Representative Western blots probed with VASA antibody, showing (a) interstitial 
fluid samples from control rats and animals treated with 200 or 650mg/kg MAA and control 
homogenised seminiferous tubules (ST), and (c) interstitial fluid samples from control rats 
and animals treated with 25 or 50mg/kg DNB and control homogenised seminiferous tubules 
(ST). Arrows indicate VASA protein bands. Graphs showing quantification of 76kDa band 
(mean with SEM), thought to be VASA with values taken from samples run on two separate 
Western blots (n=4 samples/dose group), expressed as a percentage of STs, for (b) MAA 
samples, and (d) DNB samples. Statistical analysis, one-way ANOVA followed by Tukey 
post-test showed no significant differences 
 
 
Interstitial fluid samples collected from the MAA and DNB studies were also run on 
Western blots and probed with VASA antibody, to further investigate the theory that 
proteins only leak out of STs into IF, following loss of integrity of the BTB. The 
Western blots are shown in Figure 7-6. As before, a band about 76kDa in size was 
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seen in ST samples, suggesting VASA had been successfully detected on the blots. 
The protein did not appear to be present in IF samples from animals treated with 
vehicle control, or with any dose of MAA or DNB. This conclusion was supported 
by the quantification, where no significant differences in the amounts of VASA 
protein can be identified between control and treated samples, and the values 
detected are likely to be background noise especially when compared with the high 




The first of the potential biomarker candidate proteins selected from the 
bioinformatic screen was ADAM3. The localisation of ADAM3 was investigated 
using immunohistochemistry on testis sections from control animals and from 
animals treated with 3mg/kg cadmium chloride (Figure 7-7). ADAM3 was expressed 
in round spermatids in the control tissue. Less ADAM3 protein was evident 
following high dose cadmium chloride treatment, due to the extensive damage to the 
organisation of the tubules following treatment.  
 
 
Figure 7-7 Testis sections from a) control (0.9% saline) rat and b) rat treated 24 hours 
earlier with 3.0mg/kg CdCl2, immunostained with an antibody to ADAM3 (brown) and 
counterstained with haematoxylin (blue). Scale bar represents 100µm.  
 
The presence of ADAM3 protein in IF samples from control and high dose cadmium 
chloride treated animals and seminiferous tubules was investigated using Western 
blotting. Figure 7-8 shows a Western blot probed with ADAM3 antibody. One 
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protein band was identified in all IF samples, about 64kDa in size. This size 
corresponds to the size of albumin, a high concentration of which is present in IF 
samples, and does seem to trap antibodies/proteins on Western blots. Two further 
bands (about 42 and 28kDa) were also identified in the ST sample. ADAM3, 
however, is expected to be 110kDa in size (precursor protein), so these protein bands 
do not appear to be ADAM3, even though the ADAM3 antibody had been used to 
probe the membrane. Due to a relatively high concentration of antibody being 
necessary for this Western blot (and the immunohistochemistry) and the unknown 
nature of the bands detected on the Western blot, ADAM3 was not investigated 
further as a potential biomarker candidate protein. 
 
Figure 7-8 Western Blot probed with ADAM3 antibody, showing interstitial fluid samples 
from control rats (C) and animals treated with 3.0mg/kg CdCl2 (T) and control homogenised 
seminiferous tubules (ST).  
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7.3.4 Calpastatin 
The second potential biomarker protein to be investigated was calpastatin. The 
location of the protein was evaluated using immunohistochemistry (Figure 7-9).  
Calpastatin was expressed in spermatids as seen in the control tissue. Treatment with 
low doses of all three toxicants did not appear to have any effect on the localisation 
of calpastatin or the expression of the protein. Although low doses of MAA and 
DNB have been shown to have an effect on the tubules, both causing a loss of 
pachytene spermatocytes, as tissue was collected only 24 hours after treatment, these 
treatments had no effect on the spermatids. Following high dose treatment of all 
three toxicants, less calpastatin staining was evident, presumably due to the more 
marked adverse effect the high dose treatments had on spermatogenesis. 
 
 
Figure 7-9 Testis sections from control rats from each toxicant study (a, d, g) and from rats 
treated 24 hours earlier with a low dose of toxicant (1mg/kg CdCl2 (b), 200mg/kg MAA (e) or 
25mg/kg DNB (h)) or a high dose of toxicant (3mg/kg CdCl2 (c), 650mg/kg MAA (f) or 
50mg/kg DNB (i)), immunostained to show calpastatin (brown) and counterstained with 
haematoxylin (blue). Scale bar represents 100µm. 
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A Western blot trial was carried out with IF from control and 3mg/kg CdCl2 treated 
animals to determine the required concentration of calpastatin antibody (Figure 
7-10). Calpastatin protein should be 76kDa in size, although the antibody used 
should detect bands at 70kDa and 52kDa. The full length protein can also be detected 
at 110kDa, according to the manufacturers’ information. On the Western blot, a 
prominent band at around 170kDa was seen in both IF samples. Further fainter bands 
were evident at about 150kDa, 64kDa (albumin), and 39kDa and 14kDa in the 
sample from the treated animal. In the ST sample, bands at about 150kDa, 39kDa 
and 25kDa were detected. As none of these protein bands correspond to the expected 
size of calpastatin, and the lack of availability of a blocking peptide to investigate 
whether the high molecular weight band seen is calpastatin, the protein was not 
investigated further as a potential biomarker candidate. 
 
Figure 7-10 Western blot probed with calpastatin antibody, showing interstitial fluid samples 
from a control rat (C) and an animal treated with 3.0mg/kg CdCl2 (T) and control 
homogenised seminiferous tubules (ST). 
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7.3.5 Fatty Acid Binding Protein 9  
7.3.5.1 FABP9 Protein Analysis 
The final biomarker candidate protein was FABP9. Its localisation is shown in Figure 
7-11, although the staining is not very distinct. It appeared to be expressed in 
spermatocytes and spermatids. Following low dose toxicant treatment, the expression 
and localisation of the protein did not appear to change. After treatment with high 
doses of toxicants, the overall level of staining still seemed comparable to the control 
tissue, even though damage to the tubules and loss of spermatocytes were evident. 
  
 
Figure 7-11 Testis sections from control rats from each toxicant study (a, d, g) and from rats 
treated 24 hours earlier with a low dose of toxicant (1mg/kg CdCl2 (b), 200mg/kg MAA (e) or 
25mg/kg DNB (h)) or a high dose of toxicant (3mg/kg CdCl2 (c), 650mg/kg MAA (f) or 
50mg/kg DNB (i)), immunostained to show FABP9 (brown) and counterstained with 
haematoxylin (blue). Scale bar represents 100µm. 
 
The presence of FABP9 in interstitial fluid samples was investigated by Western 
blotting with an antibody to FABP9. Figure 7-12 shows IF samples collected from 
animals treated with the various doses of cadmium chloride. A protein band of about 
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15kDa in size was detected in some IF samples and in the ST sample. This 
corresponds with the expected size of FABP9 and so suggests that FABP9 protein is 
being detected in this Western blot. A large band was present in the ST sample, 
showing that FABP9 protein is present in STs, as expected following the 
immunohistochemistry results. Bands were also detected in IF samples collected 
from animals treated with 1.75mg/kg and 3mg/kg CdCl2, and a faint band was 
evident in IF samples from animals treated with 1mg/kg CdCl2.  No bands were seen 
in IF samples from control animals. This suggests that FABP9 protein is leaking out 
of STs into IF following cadmium chloride treatment. Quantification of the bands 
from all samples run from the cadmium chloride studies showed a highly significant 
increase (greater than 40 fold) in the amount of FABP9 in IF from animals treated 
with 3mg/kg CdCl2. The graph also suggests an increase in FABP9 in IF from 





Figure 7-12 Representative Western blot probed with FABP9 antibody, showing interstitial 
fluid samples from control rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2 and 
control homogenised seminiferous tubules (ST) (a). Arrow indicates FABP9 protein. (b) 
Graph showing quantification of 15kDa band (mean with SEM), thought to be FABP9 with 
values taken from samples run on four separate Western blots (n=7 samples for control, n=5 
for 1mg/kg group, n=8 for 1.75 and 3mg/kg groups), expressed as a percentage of STs. 
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Figure 7-13  Representative Western Blots probed with  FABP9 antibody, showing (a) 
interstitial fluid samples from control rats and animals treated with 200 or 650mg/kg MAA 
and control homogenised seminiferous tubules (ST), and (c) interstitial fluid samples from 
control rats and animals treated with 25 or 50mg/kg DNB and control homogenised 
seminiferous tubules (ST). Arrows indicate FABP9 protein bands. Graphs showing 
quantification of the 15kDa band (mean with SEM), thought to be FABP9 with values taken 
from samples run on three separate Western blots (n= 6 samples/dose group), expressed as 
a percentage of STs, for (b) MAA samples, and (d) DNB samples. Statistical analysis, one-
way ANOVA followed by Tukey post-test showed no significant differences 
 
 
Western blots with the FABP9 antibody were also run with IF samples collected 
from MAA and DNB studies (Figure 7-13). Bands were clearly seen at about 15kDa 
in size. The most prominent band on both Western blots was in the ST sample. Faint 
bands were detected with some of the IF samples from both MAA and DNB studies. 
Quantification of the intensity of the protein bands across two Western blots for each 
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treatment showed a trend for a slight increase in the amount of FABP9 in the IF 
samples across the dose range for both toxicants, although this was not significantly 
different from controls with any dose of either MAA or DNB treatment. The 
magnitude of the change is put in perspective by comparison with the levels of 
FABP9 detected after cadmium chloride treatment (Figure 7-12). 
 
 
Figure 7-14 Western Blot probed with FABP9 antibody, showing interstitial fluid samples 
from control rats and animals treated with 1, 1.75 or 3.0mg/kg CdCl2, control homogenised 
seminiferous tubules (ST), and recombinant mouse FABP9 protein (rmFABP9).  
 
 
In order to confirm that the protein bands seen in the Western blots with the FABP9 
antibody were actually FABP9, recombinant FABP9 protein was purchased. The 
recombinant protein was run on a Western blot with the FABP9 antibody and 
alongside IF samples from cadmium chloride treated animals and seminiferous 
tubules (Figure 7-14).  Protein bands were detected in the IF sample from the 3mg/kg 
CdCl2 and ST sample as well as the recombinant protein. The recombinant protein 
appeared to be slightly larger in size than the bands in the IF and ST sample, but this 
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is likely due to the way the protein was purified and the extra molecular weight could 
be due to the remains of the histidine tag. The larger band, at about 39kDa, also 
detected in the lane with the recombinant protein, could be the protein with the full 
tag for purification still attached.  This blot suggests that the protein detected by the 
antibody in the IF and ST samples is FABP9. A further Western blot could be run, 
using the recombinant protein to block the FABP9 antibody, and look for the absence 
of the bands, but there was not enough recombinant protein available to do this. 
 
7.3.5.2 FABP9 Gene Expression 
 
Differences in FABP9 gene expression were also investigated in testis samples 
collected from the cadmium chloride, MAA, and DNB studies by TaqMan® PCR 
(Figure 7-15). The results showed no differences in expression of the FABP9 gene 
across the dose groups for all three toxicants, even though an effect on the protein 
was suggested with the higher doses in Figure 7-11.  However, the protein expression 
of FABP9 has only been analysed qualitatively using immunohistochemistry and the 
staining observed is not very distinct. It could be that there is no change in the total 
amount of FABP9 protein in the testis following any treatment, or perhaps the gene 
expression studies were insensitive to any changes in gene expression. 
  
 
Figure 7-15 TaqMan® analysis of FABP9 gene in testis samples collected from animals 
treated with (a) cadmium chloride, (b) MAA, (c) DNB (mean with SEM). Expression relative 
to GAPDH expression. n=4 samples/dose group, except 3mg/kg CdCl2 where n=3. Statistical 
analysis, one-way ANOVA followed by Tukey post-test showed no significant differences. 
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7.3.5.3 Further FABP9 Investigations 
From the results seen with the three toxicant treatments, cadmium chloride, MAA 
and DNB, FABP9 seems to be a good indicator of protein leakage, as well as a 
potential biomarker candidate. Investigations with FABP9 were, therefore, carried 
out with samples from the glycerol, TGF-β3, and testis development studies. 
 
Immunohistochemistry with the FABP9 antibody was carried out with control and 
treated tissue from the glycerol and TGF-β3 studies (Figure 7-16). Again, the 
staining was not distinct, but FABP9 was detected in spermatids in the control tissue, 
and similarly in the areas of the treated testes that did not seem to be affected by 
treatment (Figure 7-16c, f). In the areas that were affected by treatment, there 
appeared to be less staining for FABP9 (Figure 7-16b, e). 
 
 
Figure 7-16 Testis sections from control rats (a, d) and rats treated 48 hours earlier with 
15% glycerol (b,c) or 200ng TGF-β3 (e,f) immunostained to show FABP9 (brown) and 
counterstained with haematoxylin (blue). Scale bar represents 100µm. 
 
Interstitial fluid samples collected from control testes and testes injected with either 
glycerol or TGF-β3 were run on Western blots with the FABP9 antibody (Figure 
7-17).  A large bright band was detected in the ST sample on both blots, showing that 
the Western blot had worked. Faint bands were evident in most IF samples from both 
the glycerol and TGF-β3 studies. Quantification of the bands showed a significantly 
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higher concentration of FABP9 in IF from testes injected with glycerol, compared to 
control testes, suggesting leakage from STs. No significant difference was observed 
between the control IF and IF from TGF-β3 treated testes. 
 
 
Figure 7-17 Western blots probed with  FABP9 antibody, showing (a) interstitial fluid 
samples from control rats (C) and animals treated with 15% glycerol (T) and control 
homogenised seminiferous tubules (ST), and (c) interstitial fluid samples from control rats 
(C) and animals treated with 200ng TGF-β3 (T) and control homogenised seminiferous 
tubules (ST). Arrows indicate FABP9 protein bands. Graphs showing quantification of 15kDa 
band (mean with SEM), thought to be FABP9 expressed as a percentage of STs, with values 
taken from samples run on one Western blots for (b) glycerol samples (n=4 samples/dose 
group), and (d) TGF-β3 samples (n=3 samples/dose group). Statistical analysis, t-test. ** 
p<0.01 compared to control samples. 
 
 
Testis sections collected as part of the testis development study were also stained to 
show FABP9 protein by immunohistochemistry (Figure 7-18). The results clearly 
showed that FABP9 is not present in the developing testis until day 25, where it 
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localised to spermatocytes. As shown previously in adult control tissue, FABP9 is 
also present in developing spermatids, but this stage is not present at day 25. 
 
 
Figure 7-18 Testis sections from rats at a) day 10, b) day 15, c) day 18, d) day 25 and e) 
adult, immunostained to show FABP9 (brown) and counterstained with haematoxylin (blue). 





Figure 7-19 Western blot probed with FABP9 antibody (a), showing seminiferous tubule 
samples from day 10, 15, 18, 25 and adult (A) rats. Arrow indicates FABP9 protein band 
quantified. (b) Graph showing quantification of 15kDa band, thought to be FABP9 (mean with 
SEM) (n=1 sample/age). 
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A Western blot showing isolated seminiferous tubules from the different stages of 
testis development with the antibody to FABP9 is shown in Figure 7-19. The blot 
supports the immunohistochemistry results and shows the presence of FABP9 in STs 
at day 25 and in adult testis tissue, with a small amount present at day 18. 
 
mRNA samples isolated from testes at the different stages of development were run 
with TaqMan® PCR to look at expression of the FABP9 gene (Figure 7-20). The 
results showed significantly more FABP9 expression at day 18, compared to day 10 
and day 15. A significant increase in expression was also noted at day 25 (with 
similar levels to adult tissue) compared to days 10, 15, and 18. This supports the 




Figure 7-20 TaqMan® analysis of FABP9 gene in testis samples collected from days 10, 15, 
18, 25 and control adult rats. Expression relative to GAPDH expression. n=4 samples/age 
except day 15 where n=2 and adult where n=12. Statistical analysis, one-way ANOVA 
followed by Tukey post-test. ** p<0.01, *** p<0.001 compared to day 10 and day 15 samples 
(and day 18 samples versus day 25 and adult).  
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7.4 Discussion 
Biomarkers for testicular toxicity would be useful for assessment of damage in 
regulatory toxicology studies in the pharmaceutical industry.  They would allow 
detection of testicular damage at various time points throughout the study rather than 
just at the end. This would give a profile of the damage over the study period, and 
also a chance to detect damage much earlier in a study. This could lead to a reduction 
in the number of such studies needed as a compound causing testicular damage could 
be screened out at an earlier stage than might be the case with current methods of 
testicular damage detection.  
 
Five potential candidate proteins were investigated for their suitability as biomarkers 
for testicular toxicity.  DAZL, a well-studied germ cell marker, is small in size at 
33kDa, and is specifically expressed in spermatocytes. Immunohistochemical 
analysis suggested a dose dependent decrease in DAZL protein following MAA and 
DNB treatment. This dose-dependence would be ideal for a biomarker, as the 
concentration of biomarker detected would correlate to the extent of testicular 
damage. However, Western blotting with a DAZL antibody to investigate the 
presence of the protein in IF samples following toxicant treatment, suggested that 
DAZL does not leak out of STs into IF following high dose CdCl2 treatment or after 
MAA or DNB treatment, although there was some discrepancy in the size of the 
bands identified on the Western blots compared to the predicted size. If DAZL 
protein does not leak out of STs into IF following BTB damage, it could not be used 
as a biomarker. 
 
VASA is another well-studied germ cell protein. It is larger than DAZL at 76kDa in 
size and therefore was expected to be less likely to leak out of the STs. 
Immunohistochemical analysis of VASA protein showed that it was present in 
spermatocytes and spermatids, and that there was an apparent dose-related reduction 
in the amount of protein present in the testis following treatment with MAA, DNB 
and CdCl2. Western blot analysis of VASA protein in IF samples collected from the 
three toxicant studies, showed the presence of VASA protein in ST samples, and IF 
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from animals treated with 3mg/kg CdCl2, with a small amount present in IF from 
animals treated with 1.75mg/kg CdCl2. This suggests that VASA protein is leaking 
out of STs into IF following mid and high dose cadmium chloride treatment in a dose 
dependent manner. This supports the results presented in chapter 5, where it was 
found that proteins only leak from STs into IF following CdCl2 induced damage to 
the BTB, and not following spermatocyte loss with MAA treatment or Sertoli cell 
damage with DNB treatment. The apparent leakage of VASA disagrees with the 
hypothesis that small molecular weight proteins are more likely to leak out of STs 
into IF, as VASA protein is a relatively large protein. 
 
DAZL and VASA are both germ cell derived proteins, however, only VASA 
appeared to leak from the seminiferous tubules into the IF following high dose 
cadmium chloride treatment. This difference could be due to the differences in 
localisation or function of the proteins. A further explanation for the difference could 
be related to the size discrepancy with the protein bands observed on the Western 
blots with the DAZL antibody and the predicted molecular weight of DAZL. The 
proteins observed could contain some of the epitopes recognised by the DAZL 
antibody but not actually be DAZL protein. If this were the case, perhaps the effects 
observed are not related to DAZL protein. 
 
ADAM3 is a larger molecular weight protein (110kDa precursor protein) found in 
spermatids. Initial investigations with ADAM3 suggested that the antibody was not 
very sensitive, as high concentrations were required for successful 
immunohistochemistry.  Western blot analysis of IF samples from control and high 
dose cadmium chloride treated animals did not appear to detect ADAM3 in IF 
samples and detected bands of unexpected size in the ST sample. For these reasons, 
ADAM3 was not investigated further as a potential biomarker. 
 
Calpastatin is another relatively large protein, 76kDa in size, expressed in 
spermatids. A reduction in calpastatin protein was suggested by 
immunohistochemistry following high dose treatment of all three testicular toxicants, 
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although the lack of effect following low dose treatments does not make calpastatin 
an ideal biomarker candidate. Initial Western blot investigations with IF from a 
control animal and an animal treated with 3mg/kg CdCl2, and control STs, showed a 
range of different sized protein bands detected by the calpastatin antibody.  None of 
these bands corresponded to the protein bands suggested by the antibody 
manufacturer. The Western blot was repeated using a different electrophoresis 
system for initial separation of protein bands (tris-glycine gel system) to investigate 
whether the original gel system used was affecting the way the proteins ran. The 
same protein bands were detected with the second system (results not presented), 
validating the original system used but providing no further explanation for the 
unexpected sizes of the protein bands. A calpastatin blocking peptide was not 
available to investigate whether the bands seen are really calpastatin protein. To 
further investigate this, an antibody to somatic calpastatin could be used to probe a 
Western blot and see whether bands of the same size are detected by probing for the 
conserved region of the somatic and testis calpastatins. An appropriate antibody was 
not available so calpastatin was not investigated further as a potential biomarker 
candidate. 
 
The final potential biomarker candidate investigated was FABP9, a small protein 
(15kDa) found in spermatocytes and spermatids. The presence of FABP9 protein in 
IF samples following CdCl2, MAA and DNB treatment was investigated by Western 
blotting. FABP9 protein was detected in IF samples from animals treated with mid 
and high dose CdCl2 in a dose dependent manner. No significant differences were 
found with FABP9 in IF from all doses of the MAA and DNB studies. This suggests 
FABP9 is leaking out of STs into IF following cadmium chloride treatment and 
supporting the results described in chapter 5. The identity of the protein seen on the 
Western blots was confirmed using a recombinant FABP9 protein. TaqMan® PCR 
showed no change in FABP9 gene expression. However, the protein analyses 
considered the quantification of FABP9 protein leaking into the IF, rather than the 
total amount of FABP9 protein present in the testis, so this gene expression data does 
not oppose the protein data.  FABP9 is a promising biomarker protein, due to its 
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small size, leakage from STs into IF following BTB damage and strong detection by 
Western blotting. Investigations with tissue from the glycerol, TGF-β3 and 
development studies and FABP9 were also carried out.  
 
Immunohistochemistry to show FABP9 in tissue collected from glycerol and TGF-β3 
treated testes, suggested a reduction in FABP9 expression in the localised areas of 
treatment induced damage. Western blot analysis of FABP9 in IF samples collected 
following these treatments, showed significantly more FABP9 protein in IF from 
glycerol treated testes, compared to control, even though the treatment had only a 
localised effect on the testis. This suggests that FABP9 could be a sensitive marker, 
as changes in amount of protein in IF following slight damage can be detected. No 
changes were detected in the concentration of FABP9 in IF from TGF-β3 treated or 
control testes. This could be due to the very small, localised amount of damage 
caused by the TGF-β3 treatment, and therefore no protein leakage from STs into IF. 
These results support those described in chapter 6.  
 
Testis sections from day 10, 15, 18, and 25 were immunostained to show FABP9. 
The results clearly show that FABP9 is present in the spermatocytes at day 25, but no 
FABP9 is present at or before day 18, presumably because spermatocytes of the right 
stage of development are not present at these ages. FABP9 is thought to have a role 
in the wave of apoptosis at this stage in development (Kido and Namiki, 2000), 
which supports the presence of FABP9 at day 25. Isolated seminiferous tubules run 
on a Western blot with the FABP9 antibody also support this result, where FABP9 
was detected in small amounts at day 18, with an increase at day 25 to about half the 
concentration of FABP9 present in adult STs. TaqMan® analysis showed that the 
FABP9 gene was expressed in significantly higher amounts at day 18, compared to 
days 10 and 15, and expression increased to the same level as in adults at day 25. 
This supports the protein data.  
 
Following these investigations, it is concluded that FABP9 and VASA are both 
promising biomarker candidates for detection of damage to the BTB. If these were to 
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be developed for use in regulatory toxicology studies, a sensitive assay would need 
to be developed. Interstitial fluid samples have been used for protein analysis in these 
investigations, but the protein biomarker would need to be detectable in blood 
samples for use in toxicology studies, where the biomarker will be much more dilute. 
Although the FABP9 antibody appears to be quite sensitive for detection of 
differences in IF protein levels, it probably would not be sensitive enough for 
detection of low levels in blood samples. ELISAs could be investigated for analysis 
of VASA and FABP9 in blood samples, or more sensitive detection methods such as 
FACTT (fluorescent amplification catalysed by T7 polymerase technique) (Zhang et 
al., 2006) could be evaluated. 
 
Following the results presented in chapters 5 and 6, these proteins would, however, 
only be of use in detection of damage that involved disruption of the blood-testis 
barrier, rather than general disruption to spermatogenesis. Therefore, such a marker 
would probably only be useful if you were specifically looking for damage to the 
blood-testis barrier, and would not be useful in drug toxicology testing, where the 
site and mechanisms of toxicity are unlikely to be known. 
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8 Applications and Refinements for Detection of 
Testicular Toxicity 
8.1 Introduction 
The investigations into proteins present in interstitial fluid (IF) using Western 
blotting and Coomassie stained gels throughout this thesis all illustrate one limitation 
of this approach; the large amount of albumin protein in the samples, which could be 
masking other proteins. A study was carried out to investigate three commercially 
available kits designed for removal of albumin from samples, and their ability to 
remove albumin from IF and blood samples collected during the cadmium chloride 
studies, as well as whether the other proteins in the samples were affected during the 
process. 
 
Three kits were chosen due to their differing mechanisms of action. The BioRad 
AurumTM Affi-Gel® Blue Mini Kits and Columns utilise the Cibacron Blue F3GA 
dye mechanism for albumin removal. The kit is designed for the removal of albumin 
from serum or plasma samples using single use spin down columns. The second kit, 
ProteoExtract® Albumin Removal Kit from Calbiochem, uses a novel albumin 
specific resin in affinity gravity flow columns. It claims to provide a fast, 
reproducible and highly specific method to remove albumin from samples  such as 
plasma, serum, or cerebrospinal fluid, and to have efficiency with samples from a 
range of species (human, rabbit, rat, mouse, pig).  The final kit chosen was the 
Qiagen QproteomeTM Murine Albumin Depletion Kit. This kit again uses affinity 
columns but with monoclonal antibodies that bind albumins, in the form of single use 
spin down columns. This kit is specifically designed to deplete albumin in mouse or 
rat plasma and serum samples. 
 
IF and peripheral vein blood plasma samples from animals treated with 1.75mg/kg 
CdCl2, and control animals (and for one kit from animals treated with 0.2mg/kg 
CdCl2), were run through the kits and ‘before’ and ‘after’ samples were then run on 
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Coomassie stained gels to assess the reduction of albumin, and whether any other 
proteins had been removed in the process. IF samples were used because they have 
been the main sample used for the study of proteins in this thesis. Peripheral vein 
blood was also collected from early cadmium studies for use in investigating whether 
proteins leak into the blood from IF, but were not investigated in the scope of this 
idea. Samples from animals treated with 1.75mg/kg CdCl2 were included, because 
protein leakage from STs to IF has previously been observed with this dose, allowing 
an evaluation of the effect of the kits on proteins of interest. Samples from the 
3mg/kg dose group were not available. 
 
Removal of albumin from samples would be a useful refinement to the analysis of 
proteins in IF and blood samples, but this approach will not be refined completely, 
and the investigations in this thesis suggest that this is not a suitable way to detect 
testicular damage. A different approach was investigated, which although will not 
provide an early warning detection system for testicular toxicity, may improve the 
detection of testicular damage at the end of a study. 
 
Automated immunohistochemistry was carried out on testis sections from animals 
treated with CdCl2, MAA or DNB, staining for the germ cell protein DAZL, as this 
had been shown earlier to be a good, clean marker for germ cells. Stained sections 
were analysed using Image Analysis software, and the percentage area of DAZL 
staining calculated for each section, as a means of quantifying germ cell area. 
 
8.2 Methods 
8.2.1 Albumin Removal Study 
A small study was set up to look at the removal of albumin from interstitial fluid 
samples and peripheral blood plasma samples from control and cadmium chloride 
treated rats.  
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8.2.1.1 Bio-Rad Kit – AurumTM Affi-Gel® Blue Mini Kit 
Samples were run through the kit (Bio-Rad, Herts, UK) according to the 
manufacturers’ instructions. 20mM Tris buffer, pH8.3 was chosen as a suitable low-
salt application buffer. The columns were placed in test tubes to allow the resin to 
settle, then the residual buffer was drained by gravity flow. The columns were 
washed twice with Tris buffer, and the resin bed dried by centrifugation. 75µL of 
each sample was diluted with 225µL Tris buffer. Dried columns were placed in clean 
collection tubes. 300µL of sample was loaded onto the top of the column and 
allowed to drain through by gravity-flow. Columns were then centrifuged at 
10,000xg for 20 seconds before washing the resin with 400µL Tris buffer, followed 
by a final centrifuge at 10,000xg for 20 seconds. The albumin depleted sample in the 
collection tube was stored at -20oC. 
 
8.2.1.2 Calbiochem Kit – ProteoExtract® Albumin Removal Kit 
Samples were run through the kit (Calbiochem, Merck Biosciences, Nottingham, 
UK) according to the manufacturers’ instructions. Samples were diluted 10 fold with 
the supplied ProteoExtract® Albumin Binding Buffer (35µL sample with 315µL 
buffer). Storage buffer was removed from the columns and 1mL Albumin Binding 
buffer was added to equilibrate the columns. Columns were then placed in clean 
collection tubes, the diluted samples added and allowed to pass through the column 
by gravity-flow. 600µL buffer was added to wash the columns and allowed to pass 
through by gravity-flow. This step was repeated to thoroughly wash the column. The 
resulting albumin depleted samples in the collection tubes were stored at -20oC. 
 
8.2.1.3 Qiagen Kit – QproteomeTM Albumin/IgG Depletion Kit 
Samples were run through the kit (Qiagen, West Sussex, UK) according to the 
manufacturers’ instructions. PBS was used as the dilution buffer. Samples (25µL) 
were diluted with 75µL PBS. Qproteome Depletion Spin Columns were briefly 
centrifuged to remove resin from the cap, caps and bottom closures were removed, 
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and storage buffer was drained out by gravity-flow. Columns were equilibrated with 
2x 0.5mL aliquots of PBS, each aliquot being allowed to run out by gravity-flow. 
The bottoms of the columns were sealed with a luer plug, and the diluted sample 
added. Columns were shaken to form a homogenous suspension and incubated on an 
end-over-end shaker at room temperature. Luer plugs were removed and columns 
transferred to clean collection tubes. The flow-through was collected by 
centrifugation at 500xg for 10 seconds. Columns were washed with 2x 100µL 
aliquots of PBS, collecting the flow-through by centrifugation at 500xg for 10s each 
time. The resulting combined flow-throughs containing the albumin depleted 
samples were stored at -20oC. 
 
8.2.1.4 Protein Assay 
Albumin depleted samples from all three kits were assayed for protein content using 
the Bio-Rad DC assay (section 3.7). Samples were diluted as necessary in the 
appropriate buffer used for the albumin depletion. BSA standards were also prepared 
in each buffer, and separate standard curves made for samples from each kit to 
ensure accuracy of results. 
 
8.2.1.5 Analysis of Albumin-depleted Samples using 1D Gels 
Albumin depleted samples were run alongside corresponding original samples on 1D 
gels, and stained for total protein (sections 3.8 and 3.9). Protein bands were analysed 
using ImageQuant software (section 3.9.1). The amount of each protein present in the 
albumin depleted sample was expressed as a percentage of the amount of protein in 
the original sample (100% indicates no loss of protein in sample after running 
through albumin depletion kit, less than 100% indicates some loss of the protein, and 
greater than 100% indicates a gain of protein). In order to obtain more accurate 
results, each sample was run on three separate gels, and the average percentage 
change for each sample calculated. 
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8.2.2 Automated Immunohistochemistry 
Fixed tissue was processed and sectioned as described in section 3.4.2.1. As with the 
bench protocol for DAZL immunohistochemistry, the slides were first dewaxed and 
rehydrated (section 3.5.1), before carrying out antigen retrieval in citrate pH6 buffer 
(section 3.5.2). The slides were then loaded onto the Bond System (Vision 
Biosystems, Leica, Bucks, UK), and run with the Bond Polymer Refine detection kit, 
which includes a peroxidase block, post-primary polymers and DAB chromagen. 
DAZL, primary antibody was diluted to 1:1000 in antibody diluent supplied with the 
kit, and loaded onto the machine. The program was set to exclude the haematoxylin 
counterstain step for ease of image analysis, and the machine was left to run 
overnight. When the program finishes, the Bond machine washes the slides with 
water every 5 minutes to ensure they do not dry out. Slides were removed from the 
machine, dehydrated and fixed with coverslips using Pertex (section 3.5.8). 
 
8.2.3 Image Analysis 
Image analysis was carried out using a Nikon Eclipse E800 microscope with camera 
attached, and Image-Pro 6.2 software. Sections were first tiled using the camera to 
create a picture of the whole section on the computer screen (Figure 8-1a). The total 
area of the section was calculated by drawing round the section. The threshold for 
staining to be included in the analysis was set by selecting two or three of the darkest 
coloured pixels. The software then selected all pixels above the threshold in the 
tissue section, allowing the total area of most intense DAZL staining to be calculated 
(Figure 8-1b). The percentage of DAZL staining was calculated for each section and 
graphed using GraphPad Prism. Statistical analysis was carried out using a one way 
ANOVA, followed by Tukey’s post-test. 
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Figure 8-1 Testis section stained for DAZL using automated immunohistochemistry, 
photographed using Image Analysis software (a). The area of the section was calculated (b- 
green line) and the area of staining then calculated (b – red). 
 
8.3 Results 
8.3.1 Albumin Removal from Samples 
Coomassie gels showing IF and blood samples before and after running through the 
albumin removal kits are shown in Figure 8-2. Albumin protein can be seen as the 
band at 64kDa. There appears to be a decrease in the amount of albumin in most of 
the samples run in all the kits (except samples IF4 and IF7 which don’t seem to have 
changed much). This suggests success of the albumin depletion kits. However, not all 
the albumin was depleted. This perhaps would not be necessary as the decrease in 
size of albumin protein band does make it easier to see other protein bands of a 
similar size on the Coomassie gels. The percentage change in the amount of albumin 
in samples before, compared to after, running through the kit was calculated for each 
sample. Samples were run on three separate gels and the average percentage change 
calculated. The results are shown in Figure 8-3. 
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Figure 8-2 Coomassie stained gels showing samples before (lanes labelled B) and after 
(lanes labelled A) they were run through albumin removal kits from Qiagen (a), Calbiochem 
(b) and BioRad (c, d). IF – interstitial fluid, PV – peripheral vein blood. Different samples 
were used for each kit. Arrows indicate protein bands quantified (shown in Figure 8-3 and 
Figure 8-4). 
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Figure 8-3 Graph showing percentage change in albumin (64kDa band) after samples were 
run through albumin removal kits compared to before for all samples (mean with SEM). N=3 
for each sample. Dashed line at 100% indicates where the same amount of albumin was 
present before and after albumin depletion.  
 
This quantification showed a decrease in albumin in all samples following running 
through the albumin depletion kits except for sample IF7, in which the amount of 
albumin did not change. Figure 8-3 shows that there was considerable variation in 
the amount of albumin that was removed from different samples, and all of the kits 
were slightly better at removing albumin from the blood plasma samples than from 
the IF samples. This could be for two reasons. Firstly, there was a larger amount of 
albumin in the initial blood samples than in the IF samples (seen on the gels in 
Figure 8-2), and therefore more chance for the kits to remove more albumin. 
Secondly, the kits are designed to remove albumin from blood plasma samples rather 
than from interstitial fluid samples, as blood samples are a more widely used as a test 
material. Perhaps this observation is therefore also more relevant.  
 
The Coomassie stained gels (Figure 8-2) and graph (Figure 8-3) do not show any of 
the three kits tested to be consistently better than the others at removing albumin 
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from samples. Samples run through the BioRad kit had both the best and the worst 
change in albumin before and after running through the kit (PV5 compared to IF7). 
There was also a large difference between the best and worst sample change with the 
Calbiochem kit (PV3 compared to IF4). This suggests that perhaps the Qiagen kit is 
the better kit as it provided a more consistent amount of albumin depletion.  
 
Another consideration when using albumin removal methods is whether the method 
moves proteins of interest from the samples along with the albumin. The re
percentage change after albumin removal of four proteins identified in all the 
samples (arrows, Figure 8-2) was calculated. From the gels, it is hard to tell whether 
the amounts of the proteins have increased or decreased following albumin depletion. 
Again the mean percentage change was calculated after running the samples on three 
separate gels, and the results are shown in Figure 8-4. It is important to note that 
because 1D gel electrophoresis was used to investigate the proteins present in 
samples, that the protein bands on the gels could contain more than one different 
protein of the same molecular weight. However, because the analysis involves a 
comparison of samples before and after albumin retrieval, the same proteins should 
be identified in the same bands.  
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Figure 8-4 Graphs showing the percentage change after running samples through albumin 
removal kits for proteins of interest (indicated in Figure 8-2) (mean with SEM). N=3 for each 
sample. Dashed line at 100% indicates that the same amount of protein was present before 
and after albumin depletion.  
 
The graphs in Figure 8-4 show a range of effects on the different proteins in the 
different samples. Some, such as the 39kDa protein in sample IF3, have increased in 
concentration following albumin removal. This could be because the same amount of 
total protein of each sample was loaded onto the gels, so as there is less albumin 
present in the sample, the concentration of the other proteins will increase, and more 
could have been loaded onto the gel in the ‘after’ sample. This, again, shows success 
of the albumin depletion and would improve detection of proteins of interest in the 
samples. To have any application, the amount of the proteins should not decrease 
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following albumin depletion, and in the majority of the IF samples, there appears to 
be the same amount or more of each of the proteins investigated with all three 
albumin removal kits. However, many of the blood plasma samples showed a 
decrease in the amount of the four proteins investigated, suggesting that some non-
specific binding/depletion has occurred. This agrees with the results seen with 
albumin, which suggests that the kits are better at removing albumin from blood 
plasma samples, compared to IF samples, and are also better at binding non-specific 
proteins, which could be due to the kits being more tailored to blood samples than IF 
samples. However, the minimal number of wash/elution steps were carried out for 
each kit, and further steps could have been carried out with the kits which might have 
increased the percentage recovery of these proteins. From the loss of proteins of 
interest approach, there does not appear to be any advantage to any of the kits tested. 
If albumin removal were important for a study, albumin removal would need to be 
optimised for the samples collected. 
 
8.3.2 Image Analysis: An Alternative Method for Detection of Testicular 
Damage 
 
A different approach to assess testicular toxicity was investigated using automated 
immunohistochemistry and image analysis. DAZL staining was used as it is a germ 
cell marker and in previous chapters (chapter 5) was shown to be a good marker for 
damage to the testes caused by MAA and DNB treatments. The DAZL antibody also 
gave strong staining with low background which is essential for the semi-automated 
analysis to be feasible. Three or four sections were used for each dose of each 
treatment and the percentage of DAZL staining was calculated using Image-Pro 
software.  
 
The results with testis sections from animals treated with various doses of cadmium 
chloride are shown in Figure 8-5. Significantly less staining was seen with testis 
sections from animals treated with 3mg/kg cadmium chloride compared to control or 
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lower dose groups. Considering the extensive damage to the seminiferous tubules, 
caused by 3mg/kg CdCl2, this result was not surprising. However, a decrease in the 
amount of DAZL staining was not detected with the 1.75mg/kg CdCl2 dose group, 
even though this dose has previously been shown to cause some damage to the 
seminiferous tubules (chapter 5). This could be due to the small numbers of sections 
investigated, or the subjective nature of the technique, where it is hard to ensure the 
same threshold of staining has been selected in each section. The 1.75mg/kg dose of 
CdCl2 may also not have an effect on the number of DAZL positive germ cells 
present. 
 
The results seen with sections from MAA treated animals are shown in Figure 8-6. A 
significant decrease in the percentage of DAZL staining can be seen with sections 
from animals treated with 650mg/kg MAA. This agrees with the treatment effects 
observed in chapter 5, and the nature of MAA, which causes selective depletion of 
pachytene spermatocytes.  
 
In Figure 8-7, the results with tissue sections taken from animals treated with DNB 
are shown. There was a trend for less DAZL staining following treatment with 
25mg/kg DNB compared to control tissue and a significant decrease in DAZL 
following treatment with 50mg/kg DNB. DNB treatment affects the Sertoli cells with 
a secondary loss of spermatocytes, so a decrease in DAZL staining would be 
expected following the high dose. 
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Figure 8-5 Graph showing percentage of DAZL staining in testis tissue sections from 
animals treated with 0, 0.2, 1, 1.75 or 3mg/kg cadmium chloride. (log transform results +1). 
n=3 samples/dose group, statistical analysis one-way ANOVA followed by Tukey post-test. 




Figure 8-6 Graph showing percentage of DAZL staining in testis tissue sections from 
animals treated with 0, 200 or 650mg/kg MAA. (log transform results +1). n=4 samples/dose 
group, statistical analysis one-way ANOVA followed by Tukey post-test. ** represents p<0.01 
compared to control samples.  
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Figure 8-7 Graph showing percentage of DAZL staining in testis tissue sections from 
animals treated with 0, 25 or 50mg/kg DNB. (log transform results +1). n=4 samples/dose 
group, statistical analysis one-way ANOVA followed by Tukey post-test. ** represents p<0.01 
compared to control samples. 
 
8.4 Discussion 
One of the problems with analysis of proteins in interstitial fluid samples throughout 
this thesis was the large amount of albumin present in the samples which limited the 
total amount of protein that could be loaded onto gels and, therefore, limited the 
sensitivity to detect low abundance proteins on the gels. Three commercially 
available kits for removal of albumin were investigated as a potential refinement for 
the analysis of such samples in future investigations. The kits all involved application 
of the sample to single use columns, but had different mechanisms of albumin 
removal (Table 8-1).  
 
The AurumTM Affi-Gel® Blue Mini Kit from BioRad utilises the Cibacron Blue 
F3GA dye mechanism for albumin removal. The kit was fairly easy to use, although 
the instructions state “do not overdry resin bed and frit” during one of the 
centrifugation steps, and it was hard to tell whether the columns had been overdried. 
The method was relatively quick to carry out, although buffer had to be prepared to 
run through the kit. A range of buffers are suggested in the instructions and if this kit 
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were to be used again, the buffer would need to be optimised for the samples. This, 
kit also required the largest sample volume (125µL is suggested), and it was hard to 
choose interstitial fluid samples with enough volume to run through the kit. This 
however, was not a problem for the blood plasma samples, and IF samples could 
have been diluted further if necessary. The albumin depletion of the samples run 
through this kit was very variable (ranging from 0.2 to 87.6% albumin depleted) and 
from the analysis of the four proteins of interest, there does seem to be some loss of 
other proteins during the process, possibly through non-specific binding. The lack of 
specificity of Cibacron dye based albumin removal has been previously described 
(Steel et al., 2003; Gianazza and Arnaud, 1982; Subramanian, 1984) and a published 
study comparing five commercially available albumin and IgG depletion kits 
(including the Calbiochem ProteoExtract kit, and the BioRad Aurum Serum Protein 
Minikit) also showed that the BioRad kit had the greatest non-specific binding, and 
the lowest reproducibility of the kits tested (Bjorhall et al., 2005).  This publication 
investigated non-specific binding by analysing the proteins present in depleted serum 
samples, plus the elution of bound proteins from depletion columns, and running all 
samples diluted 1:100 on 1D-gels so that the percentage of proteins present in the 
depleted serum compared to original serum sample could be calculated. Perhaps it 
would have been better to have loaded the same volume of sample on the gels run in 
this study rather than the same amount of protein to show whether there was a 
reduction in the amount of protein of interest following albumin removal.  
 
The second kit, ProteoExtract® Albumin Removal Kit from Calbiochem, uses a novel 
albumin specific resin in affinity gravity flow columns. The kit was quick and easy to 
use, with buffer supplied in the kit, and a simple gravity flow protocol. A small 
sample volume of 20-60µL can be used, which is more suitable for depletion of 
important or small samples. Albumin depletion was variable for the samples run 
through this kit (from 11.6 to 83.5% albumin depleted), with more albumin being 
depleted from plasma samples than from IF samples. There was also some loss of 
proteins of interest in the plasma samples following albumin depletion with this kit. 
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The final kit chosen was the Qiagen QproteomeTM Murine Albumin Depletion Kit, 
which uses affinity columns with monoclonal antibodies that bind albumins. This kit 
was also quick and easy to use, although used spin down columns. PBS was used as 
the dilution buffer, which is regularly used in the laboratory so extra time was not 
required for buffer preparation. The protocol required only a small sample volume 
(25µL) and also had the option for additional wash steps to increase the recovery of 
proteins following albumin depletion. The kit is also specific for rat and mouse 
samples so should be better at depleting albumin from the samples than the other kits 
tested. Again, there was some variability between albumin depletion across the 
samples (from 19.4 to 79.5% albumin depleted) but it provided the most consistent 
reduction in albumin across the samples tested compared to the other two kits. 
Analysis of the four proteins of interest suggested some loss of proteins in the plasma 
samples following albumin depletion. However, columns with antibodies to albumin 
have been previously reported to have the least non-specific binding (Bjorhall et al., 
2005). The methods used in this study would need to be improved as described above 
in order to support this hypothesis. 
 
Overall, this brief albumin depletion study shows some variability in the amount of 
albumin removed from samples with all kits, although they all seem to have removed 
a greater percentage of albumin from the plasma samples than from the IF samples. 
From these analyses, the Calbiochem and Qiagen kits appear to be better at depletion 
of albumin without reducing the amount of other proteins in the samples, compared 
to the BioRad kit (Table 8-1). This agrees with published results and the BioRad kit 
instructions suggesting that the Cibacron dye method does allow some non-specific 
binding. Removal of albumin would be advantageous if the protein profile of 
different samples needed to be compared, especially if proteins of interest are around 
the same size as albumin (64kDa). Each of the kits used in this study would need to 
be optimised (number of wash steps, dilution buffer, sample volume) for use with the 
specific samples required. Further methods of albumin depletion could also be 
investigated, such as the TCA/acetone precipitation method (Chen et al., 2005). 
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Cibacron blue dye on 
bead, cross linked 
agarose gel, spin down 
columns 
Affinity columns (novel  
albumin-specific resin), 








75-125µL (75µL) 20-60µL (35µL) 25µL 
Buffer 
20mM Tris buffer, 
pH8.3 
Albumin binding buffer 
supplied with kit 
PBS 
Number of wash 
steps 
1 2 3 + 2 optional 
Time Fast Fast Fast 
Ease of use Easy to use although 
had to make up buffer 
Easy to use – buffer 
supplied with kit 
Easy to use 
Effectiveness        
(% albumin depleted) 
0.2-87.6% 11.6-83.5% 19.4-79.5% 
Problems Hard to tell whether 






Following results previously described in this thesis, suggesting that proteins only 
leak from STs into IF following damage to the BTB, and therefore suggesting that a 
general biomarker for early detection of testicular toxicity cannot be found, an 
alternative method for detection of testicular toxicity was investigated, namely 
automated immunohistochemistry and image analysis. Although this would not 
provide an early warning detection system for testicular toxicity, it may improve the 
detection of testicular damage at the end of a toxicology study. 
 
One germ cell protein, DAZL, was investigated with a limited number of testis 
sections from the CdCl2, MAA and DNB studies carried out previously. The 
automated immunohistochemistry method was quicker than the usual ‘hands on’ 
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approach and should produce more consistent results. Staining with an antibody to 
DAZL was successful, and the results from the image analysis showed that a 
significant reduction in the percentage of DAZL staining in each tissue section could 
be detected in the high dose groups of all three toxicant treatments. The limitations to 
this investigative study were the number of sections used (3 or 4/dose group) and if 
more had been used, a difference may have been detected in the lower dose groups. 
On the other hand, observation of a significant decrease in the high dose groups with 
such a small number of samples also suggests that the technique is sensitive to 
testicular damage. 
 
This method could be useful in routine toxicology testing, as it provides a relatively 
simple quantification of something that is normally only descriptive. It could also 
allow for quick detection of some testicular damage, which could then be further 
investigated without a pathologist having to look closely at lots of tissue sections. 
This has cost implications as it could be set up as a high-throughput screen carried 
out by a less qualified person.   
 
A limitation of the investigative study described here, is that only one marker was 
used so only one area of testicular/germ cell damage was assessed. Further markers 
targeting different stages of germ cells, such as VASA or FABP9, or different areas 
of the testis, such as Sertoli cell or Leydig cell markers, could also be investigated 
and a panel of markers set up for a high-throughput screen, which would be more 
sensitive at detecting damage as well as providing more information about the 
damage caused. Different markers could be selected depending on the potential 
target of the drug compound being investigated. Of course, this would involve more 
tissue sections and more immunohistochemistry runs, but the system used for this 
investigation was relatively fast and easy to carry out so a screening system could 
easily be set up. 
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9 General Discussion 
9.1 Objective and Approach 
The objective of this project was to investigate whether sensitive biomarkers can be 
identified and measured as a means of providing an ‘early warning’ of testicular 
damage in non-clinical toxicology studies. Biomarkers would aid the detection of 
testicular toxicity in such studies by providing information about testicular damage 
before necropsy at the end of a study, and providing an indication of how any 
testicular damage may progress throughout the study, compared to the current 
method of detection of testicular toxicity which is based mainly on histopathology at 
the end of the study. Inhibin B, ABP, LDH-C4, and creatine, amongst other 
molecules, have previously been investigated as biomarkers for testicular toxicity 
(Section 2.5.2.7). However, all of these proved to have limitations and have not been 
accepted for widespread use in the pharmaceutical industry or for monitoring adverse 
effects in the clinic.  
 
The approaches taken to investigate the potential use of biomarkers to detect 
testicular toxicity were based on results described by Turner et al., 1996, who 
showed preliminary evidence that disruption of spermatogenesis by heat treatment, 
increased the number and amounts of seminiferous tubule-derived proteins in 
testicular interstitial fluid, and suggested that such proteins therefore have potential 
to be markers of disruption to spermatogenesis. This promoted the hypothesis that 
germ cell derived proteins may leak from the seminiferous tubules into the interstitial 
fluid, and then into the bloodstream, following toxicological insult to the testis, 
which could be due to either germ cell damage or loss of integrity of the blood-testis 
barrier. To investigate this hypothesis, the approach was to establish whether proteins 
do leak from STs following testicular toxicity, and investigate the conditions leading 
to such leakage. This involved the administration of three well-studied testicular 
toxicants to adult male rats, which specifically target different components of 
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seminiferous tubules, followed by an evaluation of the damage caused and analysis 
of proteins present in the interstitial fluid. 
 
For these studies three related techniques were used to investigate potential protein 
biomarkers. First, an antibody to seminiferous tubule conditioned medium (STCM 
antibody), prepared by a previous PhD student (Turner, 1996) was used to 
investigate a range of seminiferous tubule derived proteins in tissue and interstitial 
fluid samples collected from the toxicant studies. Second, 1D gels stained with 
GelCode, a Coomassie dye based stain, were used to investigate the total protein 
composition in interstitial fluid samples. Third, specific proteins were selected from 
an Affymetrix Genechip® screen carried out at GSK, based on the criteria for a 
specific protein biomarker for testicular toxicity. These proteins were investigated in 
samples collected from the toxicant studies, and allowed investigation of a second 
hypothesis, namely that smaller molecular weight proteins were thought to be more 
likely to leak out of seminiferous tubules into IF. 
 
9.2 Protein Leakage 
The model testicular toxicants, cadmium chloride (which disrupts the blood-testis 
barrier and spermatogenesis), methoxyacetic acid (which causes degeneration of 
pachytene spermatocytes) and 1,3-dinitrobenzene (which causes Sertoli cell 
vacuolation) were administered to adult male rats at doses chosen to produce mild 
and moderate toxicological effects on the testis. To investigate whether proteins 
leaked from STs into IF following toxicant treatment, the proteins present in IF 
samples from control and treated animals were compared by Western blotting with 
the STCM antibody and Coomassie gel analysis. Testicular damage was assessed by 
immunohistochemistry with the STCM antibody and an evaluation of the blood-testis 
barrier utilised immunofluorescent analysis of tight and adherens junction proteins, 
together with functional analysis using the biotin tracer technique. 
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The results from the toxicant studies showed that proteins did not leak from the STs 
into IF following treatment with any dose of either MAA or DNB, even though the 
pachytene spermatocytes were depleted, or Sertoli cell vacuolation occurred 
following the respective treatment. Neither of these treatments were shown to have 
an effect on the integrity of the BTB either. Leakage of some ST proteins was 
observed following treatment with high doses of cadmium chloride.  A loss of 
integrity of the BTB was also observed following treatment with high doses of 
cadmium chloride. These results suggested that a loss of integrity of the blood-testis 
barrier is required for leakage of proteins from STs into IF. 
 
To further investigate these results, three further approaches were taken to 
specifically target the BTB to elucidate whether loss of BTB integrity really is the 
factor leading to leakage of proteins from STs into IF following cadmium chloride 
treatment. A physiological approach was taken involving study of the development 
of the blood-testis barrier in young rats. The BTB forms between postnatal days 15-
19 in the rat (Vitale et al., 1973; Russell et al., 1989), so it was hypothesised that 
germ cell derived proteins may be present in IF before the BTB is formed but not 
after, due to the presence of the barrier preventing them from leaking out. Four ages 
were investigated across the BTB development period (postnatal days 10, 15, 18, 25) 
and the BTB was shown to be present at day 25, forming at day 18, and absent at 
days 10 and 15, in agreement with the literature. Analysis of the proteins present in 
IF collected from rats at each age, however, highlighted a limitation of this approach, 
that many (germ cell) proteins of interest are not expressed until later in the 
development process/in later stage germ cells, and therefore cannot be used to 
investigate this hypothesis. One germ cell protein, DAZL, that was shown to be 
expressed in spermatocytes from day 10, was investigated by Western blotting in IF 
samples from the different aged rats. The results suggested no differences in the 
amount of DAZL present in IF samples across the age range. However, whether the 
protein band analysed on the blots was actually DAZL protein was not clear. The 
development studies, therefore, proved inconclusive in investigating proteins in IF 
before and after the BTB had formed.  
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The two further approaches to elucidate the role for loss of integrity of the BTB in 
leakage of proteins from STs into IF, involved specifically targeting junction proteins 
in the BTB. Intra-testicular administration of glycerol was shown by Wiebe et al., 
2000, to cause disruption of occludin in the BTB, and intra-testicular administration 
of TGF-β3 was validated as a model for BTB disruption by Xia et al., 2008. Adult 
male rats were administered either glycerol or TGF-β3, and tissue/IF samples 
collected 48 hours later to investigate whether specific disruption of the BTB led to 
leakage of proteins from STs into IF. Treatment with glycerol caused a localised 
disruption to the organisation of the STs (Sertoli cell vacuolation and germ cell 
disruption), with loss of occludin protein from the site of the BTB in some STs. This 
disruption was thought to be localised to the site of injection although this could not 
be confirmed. Analysis of the proteins present in IF samples following glycerol 
treatment suggested a trend for an increase in the amount of some proteins compared 
to IF from control testes, suggesting that some proteins are leaking from tubules 
affected by the glycerol treatment. Further investigations could be carried out to 
provide more concrete evidence for this result, by using an increased number of 
samples, or leaving a longer period of time between administration of glycerol 
treatment and collection/analysis of samples, based on observations in the literature 
where effects on spermatogenesis were observed 1 week following administration of 
glycerol treatment (Igdoura and Wiebe, 1994). 
 
Treatment with TGF-β3 also caused some localised damage to a small number of 
seminiferous tubules. Disruption of occludin from the site of the BTB was observed 
in some STs, although investigations with the biotin tracer suggested that the BTB 
was functional following TGF-β3 treatment. Analysis of the proteins present in IF 
samples following TGF-β3 treatment suggested some proteins could be leaking from 
STs into IF, however, the results were variable and analysis of a larger number of 
samples would be required to obtain more reliable results. Nevertheless, the results 
suggested that only minor leakage of germ cell proteins occurred. 
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The investigations to elucidate a role for loss of integrity of the BTB and leakage of 
proteins from STs into IF by specifically targeting the junctions in the BTB with 
glycerol or TGF-β3 treatment supported the hypothesis that proteins only leak from 
STs into IF following loss of integrity of the BTB. However, further experiments 
with these treatments could be carried out, possibly leaving the damage to develop 
for longer before collecting samples, to try and obtain wider disruption of the BTB 
throughout the testis, and more significant protein leakage data. To further 
investigate the effect of BTB disruption on protein leakage, additional treatments to 
specifically target the BTB, such as intra-testicular injection of TNF-α (Li et al., 
2006), or administration of an occludin peptide (Chung et al., 2001), could also be 
investigated, although these may prove to be limited for the same reasons as the 
glycerol and TGF-β3 studies (i.e. only localised damage). 
 
9.3 Protein Biomarkers  
While investigating whether proteins do leak from seminiferous tubules into 
interstitial fluid, five potential biomarker protein candidates were selected and 
evaluated alongside the treatment studies. The proteins investigated were selected 
from a list of testis specific proteins based on results from a testicular gene analysis 
screen carried out at GSK, and well-studied germ cell proteins, based on the criteria 
described in Table 7-1. The selected proteins allowed the investigation of the 
hypothesis that smaller molecular weight proteins are more likely to leak out of STs 
than large molecular weight proteins. Samples collected from the toxicant studies 
were used to evaluate the potential for each biomarker candidate protein. 
 
DAZL and VASA are both well-studied germ cell proteins. DAZL was specifically 
expressed in spermatocytes, and immunohistochemistry suggested a dose-dependent 
decrease in DAZL protein following MAA and DNB treatments. However, analysis 
of DAZL protein in interstitial fluid samples suggested that DAZL does not leak out 
of STs into IF following high dose CdCl2 treatment or MAA or DNB treatment. 
There was some discrepancy in the protein bands observed when Western blotting 
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with the DAZL antibody compared to the predicted size of the protein, so further 
investigations, such as trying a different antibody, different Western blot system, or 
analysis of the protein band identified, could be carried out to clarify the discrepancy. 
However, if DAZL does not leak out of STs into IF following BTB damage, it could 
not be used as a biomarker. Results obtained with the VASA protein proved more 
positive. Again a dose-dependent reduction in VASA protein expression in 
seminiferous tubules was suggested following treatment with CdCl2, MAA and 
DNB, by immunohistochemical analysis. Evaluation of VASA in IF samples, by 
Western blotting, suggested that VASA protein was leaking from STs into IF 
following mid and high dose cadmium chloride treatment in a dose dependent 
manner. No leakage of VASA was observed following MAA or DNB treatment, 
further supporting the hypothesis discussed in section 9.2. Surprisingly, VASA is a 
relatively large protein (76kDa) and perhaps would have been thought to be less 
likely to leak from STs than DAZL (33kDa). 
 
ADAM3 and calpastatin were selected from the GSK screen. Both proteins were 
detected in testis sections by immunohistochemistry and both were shown to be 
localised to spermatids. Analysis of the proteins in IF samples by Western blotting 
proved unsuccessful with antibodies to both proteins and no conclusions could be 
drawn. Alternative antibodies for each protein could be sourced in order to try further 
investigations by Western blotting. 
 
The final biomarker candidate investigated was FABP9, a small protein expressed in 
spermatocytes and spermatids. The presence of FABP9 was investigated in IF 
samples from the toxicant studies by Western blotting and FABP9 protein was 
detected in IF samples from animals treated with mid and high dose CdCl2 in a dose 
dependent manner. No significant increases in the amount of FABP9 in IF following 
treatment with either dose of MAA or DNB were observed, again supporting the 
results discussed in section 9.2. Further investigations with FABP9 were carried out 
using tissue collected from the glycerol, TGF-β3 and testis development studies. A 
significant increase in FABP9 protein was detected in IF samples from glycerol 
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treated testes compared to control, even though the glycerol treatment had only a 
localised effect on the testis. This result suggests that FABP9 could be a sensitive 
marker and detect slight disruption to the BTB. No differences were observed in IF 
samples following TGF-β3 treatment, however, this could be due to the very small 
amount of damage observed.  Results from the development study showed that 
FABP9 is present only from around day 18, again illustrating the limitation of the 
physiological approach to investigating the role for the BTB in leakage of proteins 
from STs.  
 
The protein biomarker investigations suggested that VASA and FABP9 are 
promising biomarker candidates for detection of damage to the BTB. If they were to 
be developed for use in regulatory toxicology studies, a sensitive assay would need 
to be developed, and the potential for detecting changes in the levels of the 
biomarker in blood samples evaluated. However, these proteins would only be of use 
in the detection of testicular damage that involved disruption to the blood-testis 
barrier, rather than general disruption to spermatogenesis. Therefore, such a marker 
is unlikely to aid detection of testicular toxicity in regulatory toxicology studies.  
 
9.4 Refinements for Detection of Testicular Toxicity 
The results obtained in the studies discussed so far suggest that the later initial aims 
of the project (to identify protein biomarkers that have the potential to signal an 
adverse change to spermatogenesis after toxic insult and develop a highly-sensitive 
assay for detection of low-levels of the biomarker) cannot be accomplished. 
However, improvements to the current detection methods for testicular toxicity and 
the methods used in these investigations can be discussed. 
 
One problem with the protein analysis throughout this thesis was the large amount of 
albumin present in the IF samples which limited the amount of protein that could be 
loaded onto the gels, and therefore the sensitivity to detect low abundance proteins; 
this would prove to be an even bigger limitation when trying to detect germ cell 
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proteins in blood plasma. Three commercially available kits were investigated as a 
potential refinement for analysis of such samples in future studies. The brief 
investigation using the kits suggested that it was possible to deplete the amount of 
albumin present in plasma and interstitial fluid samples, although the results were 
variable with each kit/sample. If an albumin removal kit were to be used in future 
studies, it would need to be specifically optimised for the samples involved. 
 
An alternative method to aid detection of testicular toxicity was also investigated. 
Automated immunohistochemistry and image analysis could improve the detection 
of testicular damage at the end of a regulatory toxicology study, even though they 
would not be able to provide an early warning detection system. Automated 
immunohistochemistry with DAZL antibody was carried out using testis sections 
obtained during the toxicant studies. This method was quicker than the ‘hands on’ 
immunohistochemistry methods, and should produce more consistent results. A 
significant decrease in the percentage of DAZL staining on each testis section was 
observed following high dose treatment with MAA, DNB and cadmium chloride. A 
dose-response was not observed, which could be due to the limited number of 
samples evaluated. A larger sample size should be used to assess the potential for this 
technique in detection of mild toxicant induced effects. 
 
This method could be used in routine toxicology tests as it provides a quantitative 
result for something that is normally descriptive, and could be used as a screen for 
testicular damage, with any positive results followed up by a pathologist. However, 
only one marker, DAZL, was used in this study, and therefore only one area of the 
testis (spermatocytes) assessed. A panel of markers could be investigated that target 
different stages of germ cells, such as VASA or FABP9, or different areas of the 
testis, such as Leydig cells or Sertoli cells, and then set up as a high-throughput 
screen for detecting testicular damage.  
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9.5 Summary 
The development of sensitive biomarkers for testicular toxicity would be a useful 
addition to the current endpoints used for assessment of testicular toxicity. A variety 
of markers have been investigated in the past although none have been accepted for 
widespread use. This project aimed to investigate the potential for biomarkers for 
testicular toxicity based on the idea that germ cell derived proteins may leak from 
seminiferous tubules into interstitial fluid following toxicological insult. The results 
obtained suggest that such a biomarker, for general testicular damage, cannot be 
found, although markers for disruption of the blood-testis barrier (VASA and 
FABP9) could be further investigated if a biomarker for such damage would be of 
value. Therefore, further attention could be focussed on improving current methods 
of detection of testicular toxicity, such as histopathology, potentially by developing 
an automated immunohistochemical screening system to assess different areas of the 
testis to provide quick results that could be followed up in more detail. 
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